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Abstract 
 
Background: Diabetes complications are multi-factorial. Several of these risk factors can be 
modified so to improve the health condition of the patient and at the same prevent the 
occurrence of other complications.   
 
Study aim and objectives: The aim of the study was to identify the determinants of type 2 
diabetes complications management in Jenin and Tubas districts. The objectives were to 
identify the health care system and the patients' own factors role in determining diabetes’ 
complications. 
 
Methodology: A cross sectional study was conducted  on 800 patients’ medical files with type 
2 diabetes that were randomly selected from 16 PHC centers at MOH, UNRWA and PMRS. 
Also, all physicians dealing with patients type 2 working at the same centers (n= 139) filled in 
a questionnaire at the fourth quarter of 2009 to ascertain their knowledge, use of diabetes 
management guidelines and health care system aspects for diabetes management. In addition, 
information about services provided at these clinics were collected.  
 
Results: Analysis of patients' data showed that the mean age of the patients was 58,8 ± 11,4 
(mean ± S.D). A 64% of diabetic patients in this study were males. Half of the patients were 
not working, and more than third were illiterates. A 65.5% of the study population showed 
positive family history of diabetes.  
 
The data showed that 33,1% of study population tested their fasting blood sugar (FBS) once in 
the last month and 17,6% did HbA1c test before three months. Also, 81,6% these patients had 
a lipid profiling once in the last year, 70,5% had kidney function testing, 15% did a 
microalbumin test in the last year, of study population, 45,6% consulted an ophthalmologist in 
the last year and 43,6% did an electrocardiogram (ECG) at least once as a baseline. The 
prevalence of diabetic complications among these patients were as follows: neuropathy 38.4%, 
retinopathy 26.8%, and nephropathy was 20.5%.  
 
 v
In the univariate analysis for patients' data, a significant difference was found between diabetic 
retinopathy with age, educational level, diabetes family history and previous coronary artery 
disease (P <0.05).  A significant association was found between nephropathy with age, gender, 
kidney function tests, urine for microalbumin, diabetes family history, previous hypertension 
(P <0.05). Neuropathy was significantly associated with age, gender, FBS, HbA1c and ECG, 
family history of diabetes, hypertension and obesity (P <0.05). 
 
The multiple logistic regression models showed that age, low educational level, lipid profile 
testing and history of coronary artery disease were shown to be risk factors for Retinopathy. 
Also, age, gender, FBS, HbA1c, ECG monitoring and history of hypertension and diabetes 
were shown as risk factors for neuropathy. While, age, gender, KFT, urine for microalbumin 
monitoring, history of dislepedimia and coronary artery disease determined the occurrence of 
nephropathy among these diabetic patients. 
 
Comparing the patients' files with the data reported by the physicians, more than two thirds of 
physicians stated that they recommend HbAlc testing, but only (17.6%) of the patients medical 
files confirmed this recommendation. More than 86% of providers stated that they recommend 
eye examinations to these patients. Only 45.6% of patients medical files showed that their 
physicians ever sent them for eye examinations.  
In our study, only 3.6% of physicians reported having an endocrinologist at their clinic, 27.3% 
have ophthalmologist, 34.5% of these clinics have a nutritionist.  
Conclusion: This is the first study in Palestine which identified the determinants of type 2 
diabetes management complications. Age, gender, educational level, patients’ personal follow 
up, compliance of physicians with diabetes management guidelines and health care system 
structure are the major factors that affect type 2 diabetes complications management.  This 
recommended the need for an awareness program. The health care system needs a better 
modification according to the patients' needs. An advocacy for the national guidelines is an 
urgent need.  
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  ﻣﻠﺨﺺ اﻟﺮﺳﺎﻟﺔ
  
  اﻟﺘﺄﺛﻴﺮ ﻋﻠﻴﻬﺎ و هﺬﻩ ﻳﻤﻜﻦةرﻮ اﻟﻌﺪﻳﺪ ﻣﻦ ﻋﻮاﻣﻞ اﻟﺨﻄ . ﺑﺴﺒﺐ ﻋﺪة ﻋﻮاﻣﻞ ﻣﻀﺎﻋﻔﺎت ﻣﺮض اﻟﺴﻜﺮي ﺗﻨﺘﺞ :راﺳﺔ اﻟﺪﺧﻠﻔﻴﺔ
 . ﻣﻨﻊ ﺣﺪوث ﻣﻀﺎﻋﻔﺎت أﺧﺮى اﻟﻮﻗﺖ ﻧﻔﺲﻓﻲﻟﺘﺤﺴﻴﻦ اﻟﺤﺎﻟﺔ اﻟﺼﺤﻴﺔ ﻟﻠﻤﺮﻳﺾ و ﻬﺎﺗﻌﺪﻳﻠ
   
  اﻟﺜﺎﻧﻲاﻟﺴﻜﺮي ﻣﻦ اﻟﻨﻮع ﻣﻀﺎﻋﻔﺎت ﻣﺮض  اﻟﻌﻮاﻣﻞ اﻟﻤﺆﺛﺮة ﻓﻲ ادارة هﺬﻩ اﻟﺪراﺳﺔ إﻟﻰ اﻟﺘﻌﺮف ﻋﻠﻰﺖهﺪﻓ : اﻟﺪراﺳﺔأهﺪاف
 ﺗﺄﺛﻴﺮ اﻟﺨﺼﺎﺋﺺ اﻟﺸﺨﺼﻴﺔ  ﻧﻈﺎم اﻟﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ و دوراﻟﺘﻌﺮف ﻋﻠﻰﺑﺎﻻﺿﺎﻓﺔ اﻟﻰ  ,  ﺟﻨﻴﻦ وﻃﻮﺑﺎسﺤﺎﻓﻈﺘﻲﻓﻲ ﻣ
 .ﻣﻀﺎﻋﻔﺎت ﻣﺮض اﻟﺴﻜﺮي'ﻠﻤﺮﺿﻰ ﻓﻲ ﺗﺤﺪﻳﺪ ﻟ
   
ﻮاﺋﻴﺎ  اﻟﺘﻲ ﺗﻢ اﺧﺘﻴﺎرهﺎ ﻋﺸاﻟﺜﺎﻧﻲ ﻣﻦ اﻟﻨﻮع  ﻃﺒﻲ ﻟﻤﺮﺿﻰ ﺳﻜﺮي ﻣﻠﻒ008دراﺳﺔ ﻣﻘﻄﻌﻴﺔ ﻋﻠﻰ   أﺟﺮﻳﺖ: اﻟﺪراﺳﺔﻣﻨﻬﺠﻴﺔ
 ﻓﺈن  آﺬﻟﻚ ،.  واﻹﻏﺎﺛﺔ اﻟﻄﺒﻴﺔوآﺎﻟﺔ اﻟﻐﻮث ﻟﺘﺸﻐﻴﻞ اﻟﻼﺟﺌﻴﻦ ﻣﺮآﺰا ﻟﻠﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ اﻷوﻟﻴﺔ ﻓﻲ وزارة اﻟﺼﺤﺔ و61ﻣﻦ 
 = ﻋﺪدهﻢ ) و اﻟﻘﻄﺎع اﻟﺨﺎص ﻓﻲ اﻟﻤﺮاآﺰ ﻧﻔﺴﻬﺎاﻟﺜﺎﻧﻲ و ﻳﻌﻤﻠﻮن ﻣﻦ اﻟﻨﻮع  اﻟﺴﻜﺮيﻣﺮﺿﻰ  ﻳﺘﻌﺎﻣﻠﻮن ﻣﻊاﻟﺬﻳﻦﺟﻤﻴﻊ اﻷﻃﺒﺎء
إدارة ﻣﺮض اﻟﺴﻜﺮي ﻟﺪﻟﻴﻞ   اﻷﻃﺒﺎء واﺳﺘﺨﺪامﺔ ﻟﻠﺘﺄآﺪ ﻣﻦ ﻣﻌﺮﻓ, 9002 اﻟﺮاﺑﻊ ﻣﻦ ﻋﺎم  اﺳﺘﺒﻴﺎن ﻓﻲ اﻟﺮﺑﻊ ﻗﺎﻣﻮا ﺑﺘﻌﺒﺄة(931
ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ ، ﺗﻢ ﺟﻤﻊ ﻣﻌﻠﻮﻣﺎت ﺣﻮل . ﻹدارة ﻣﺮض اﻟﺴﻜﺮيﺑﺎﻟﻨﺴﺒﺔ اﻟﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ  ﻟﻤﻌﺮﻓﺔ ﺧﺼﺎﺋﺺ ﻧﻈﺎم و
 . اﻟﺨﺪﻣﺎت اﻟﻤﻘﺪﻣﺔ ﻓﻲ هﺬﻩ اﻟﻌﻴﺎدات
  
 ﻣﻦ  و(. 4.11=اﻧﺤﺮاف ﻣﻌﻴﺎري )ﻋﺎﻣﺎ 8،85ﺘﻮﺳﻂ ﻋﻤﺮ اﻟﻤﺮﺿﻰ هﻮ   أن ﻣ ﻧﺘﺎﺋﺞ اﻟﺪراﺳﺔ أﻇﻬﺮت: اﻟﺮﺋﻴﺴﻴﺔاﻟﻨﺘﺎﺋﺞ
 ﻓﻲ ﺣﻴﻦ . ٪ ﻣﻦ ﻣﺮﺿﻰ اﻟﺴﻜﺮي ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ آﺎﻧﻮا ﻣﻦ اﻟﺬآﻮر46ﻧﺘﺎﺋﺠﻨﺎ ﻋﻦ اﻟﺼﻮرة اﻟﻌﺎﻣﺔ ﻟﻠﻤﺮﺿﻰ ﺗﺒﻴﻦ أن ﻧﺴﺒﺔ 
 ﻳﻤﻠﻜﻮن اﻟﻤﺮﺿﻰ    ٪ ﻣﻦ 5.56 وآﺎﻧﺖ ﻧﺴﺒﺔ ,ﺜﻠﺚاﻟ أآﺜﺮ ﻣﻦ  ﻓﻴﻤﺎ آﺎﻧﺖ ﻧﺴﺒﺔ اﻻﻣﻴﻴﻦﻧﺼﻒ اﻟﻤﺮﺿﻰ ﻻ ﻳﻌﻤﻠﻮن ، آﺎن
  .ﺗﺎرﻳﺦ ﻋﺎﺋﻠﻲ اﻳﺠﺎﺑﻲ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻤﺮض اﻟﺴﻜﺮي
   
ﺧﻼل ﺴﻜﺮ ﻓﻲ اﻟﺪم اﺛﻨﺎء اﻟﺼﻴﺎم ﻣﺮة واﺣﺪة  ﻗﺪ أﺟﺮي ﻟﻬﻢ ﻓﺤﺺ اﻟ ٪ ﻣﻦ اﻟﺬﻳﻦ ﺷﻤﻠﺘﻬﻢ اﻟﺪراﺳﺔ1،33وأﻇﻬﺮت اﻟﺒﻴﺎﻧﺎت أن 
ﻣﻦ  %6.18. ﻣﻦ اﻟﻤﺮﺿﻰ  ٪ 6،71 ل آﻤﺎ ﺗﻢ اﺟﺮاء اﺧﺘﺒﺎر اﻟﺴﻜﺮ اﻟﺘﺮاآﻤﻲ ﺧﻼل اﻟﺜﻼث ﺷﻬﻮر اﻟﻤﺎﺿﻴﺔ . اﻟﺸﻬﺮ اﻟﻤﺎﺿﻲ
ﻣﻦ  ٪ 5،07 ﻓﺤﺺ وﻇﺎﺋﻒ  اﻟﻜﻠﻰ أﺟﺮي ل ﻣﺮة واﺣﺪة ﻓﻲ اﻟﻌﺎم اﻟﻤﺎﺿﻲ ، ﻓﻲ اﻟﺪماﻟﺪهﻮن اﻟﻤﺮﺿﻰ ﻗﺎﻣﻮا ﺑﺎﺟﺮاء ﻓﺤﺺ 
 ﻓﻲ اﻟﻌﺎم اﻟﻤﺎﺿﻲ  ﻣﻦ اﻟﻤﺮﺿﻰ ﻗﺎﻣﻮ ﺑﺎﺟﺮاء ﻓﺤﺺ اﻟﻤﺎﻳﻜﺮوأﻟﺒﻮﻣﻴﻦ ﻓﻲ اﻟﺒﻮل ٪51، و ﻣﺠﻤﻞ اﻟﻤﺮﺿﻰ ﺧﻼل اﻟﻌﺎم اﻟﻤﺎﺿﻲ
ﻗﺎﻣﻮا ﺑﻌﻤﻞ  ٪ 6،34 ﻃﺒﻴﺐ ﻋﻴﻮن ﻓﻲ اﻟﻌﺎم اﻟﻤﺎﺿﻲ و  ﻗﺎﻣﻮا ﺑﺰﻳﺎرة ٪6،54 اﻟﺬﻳﻦ ﺷﻤﻠﺘﻬﻢ اﻟﺪراﺳﺔ ، ﺿﻰ ﻣﺠﻤﻞ اﻟﻤﺮ ﻣﻦ.
 . ﻣﻦ ﺑﺪاﻳﺔ اﻟﻤﺮض ﻋﻠﻰ اﻷﻗﻞ ﻣﺮة واﺣﺪةﺗﺨﻄﻴﻂ ﻗﻠﺐ 
  
  ٪ ، اﻋﺘﻼل اﻟﺸﺒﻜﻴﺔ4.83اﻻﻋﺘﻼل اﻟﻌﺼﺒﻲ :  اﻟﺴﻜﺮي ﺑﻴﻦ هﺆﻻء اﻟﻤﺮﺿﻰ ﻋﻠﻰ اﻟﻨﺤﻮ اﻟﺘﺎﻟﻲ  ﻣﻀﺎﻋﻔﺎت ﻣﺮضاﻧﺘﺸﺎرﻧﺴﺒﺔ 
 .  ٪5.02 اﻟﻜﻠﻰ آﺎن اﻋﺘﻼل ٪ ، و8.62
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 ﻣﻊ ﺗﻘﺪم اﻟﻌﻤﺮ ،  اﻟﻤﺮﺿﻰ وﺟﻮد ﻋﻼﻗﺔ اﻳﺠﺎﺑﻴﺔ و ذات دﻻﻟﺔ اﺣﺼﺎﺋﻴﺔ ﺑﻴﻦ ﻣﺸﺎآﻞ اﻟﻌﻴﻮن ﻟﺒﻴﺎﻧﺎت  اﻟﺘﺤﻠﻴﻞ وﺣﻴﺪ اﻟﻤﺘﻐﻴﺮأﻇﻬﺮ
ﺣﻴﺚ آﺎﻧﺖ ﻗﻴﻤﺔ اﻟﺪاﻟﺔ اﻻﺣﺼﺎﺋﻴﺔ أﻗﻞ ﻣﻦ  ﻣﺮض اﻟﺸﺮﻳﺎن اﻟﺘﺎﺟﻲ ﻟﻤﺮض اﻟﺴﻜﺮي و اﻟﺘﺎرﻳﺦ اﻟﻌﺎﺋﻠﻲ  اﻟﻤﺴﺘﻮى اﻟﺘﻌﻠﻴﻤﻲ،
ﻓﺤﺺ اﺧﺘﺒﺎرات وﻇﺎﺋﻒ اﻟﻜﻠﻰ ، ,اﻟﺠﻨﺲ  ,  ﺑﻴﻦ اﻋﺘﻼل اﻟﻜﻠﻴﺔ ﻣﻊ اﻟﺴﻦﺔ اﺣﺼﺎﺋﻴﺔ ذو دﻻﻟ ارﺗﺒﺎط ﻣﻬﻢوﺟﺪ أﻳﻀﺎوﻗﺪ . %5
 ﺣﻴﺚ آﺎﻧﺖ ﻗﻴﻤﺔ اﻟﺪاﻟﺔ اﻻﺣﺼﺎﺋﻴﺔ أﻗﻞ ﻣﻦ ﻟﺴﻜﺮي وارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم اﻌﺎﺋﻠﺔ ﺑﻤﺮضاﻟﺒﻮل، ﺗﺎرﻳﺦ اﻟاﻟﻤﺎﻳﻜﺮوأﻟﺒﻮﻣﻴﻦ ﻓﻲ 
, اﺧﺘﺒﺎر اﻟﺴﻜﺮ اﻟﺘﺮاآﻤﻲﻟﺼﻴﺎم، ﺴﻜﺮ ﻓﻲ اﻟﺪم اﺛﻨﺎء اﻓﺤﺺ اﻟ, اﻟﺠﻨﺲ,  اﻟﺴﻦ ﻣﻊاﻻﻋﺘﻼل اﻟﻌﺼﺒﻲ ﻳﺮﺗﺒﻂ ﺑﺸﻜﻞ آﺒﻴﺮ. %5
 .%5ﺣﻴﺚ آﺎﻧﺖ ﻗﻴﻤﺔ اﻟﺪاﻟﺔ اﻻﺣﺼﺎﺋﻴﺔ أﻗﻞ ﻣﻦ ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم واﻟﺴﻤﻨﺔ , اﻟﺘﺎرﻳﺦ اﻟﻌﺎﺋﻠﻲ ﻟﻤﺮض اﻟﺴﻜﺮي, ﺗﺨﻄﻴﻂ اﻟﻘﻠﺐ
  
 اﻟﺸﺮﻳﺎن اضﻣﺮ أن وﻮﺪهﻓﺤﺺ اﻟن اﻟﻌﻤﺮ ، اﻟﻤﺴﺘﻮى اﻟﺘﻌﻠﻴﻤﻲ اﻟﻤﺘﺪﻧﻲ ، أد ﺪﻤﺘﻌ اﻟﻠﻮﺟﻴﺴﺘﻲ اﻟﻧﻤﺎذج اﻻﻧﺤﺪارآﻤﺎ أﻇﻬﺮت  
 ﻓﺤﺺ اﻟﺴﻜﺮ ,ﺴﻜﺮ ﻓﻲ اﻟﺪم اﺛﻨﺎء اﻟﺼﻴﺎمﻓﺤﺺ اﻟ  ﻣﺮاﻗﺒﺔ،، اﻟﻌﻤﺮ، اﻟﺠﻨﺲﺑﻴﻨﻤﺎ.  ﻻﻋﺘﻼل اﻟﺸﺒﻜﻴﺔةرﻮﺧﻄ ﻋﻮاﻣﻞﻲ هاﻟﺘﺎﺟﻲ 
 ﻟﻼﻋﺘﻼل اﻟﻌﺼﺒﻲ اﻟﻨﺎﺗﺞ ﻋﻦ  ﺑﺎﻟﻨﺴﺒﺔﺧﻄﻮرةﻋﻮاﻣﻞ هﻲ ﻀﻐﻂ اﻟﺪم واﻟﺴﻜﺮي ﺗﺎرﻳﺦ ﻋﺎﺋﻠﻲ ﻟ ﺗﺨﻄﻴﻂ اﻟﻘﻠﺐ ، و,اﻟﺘﺮاآﻤﻲ
ارﺗﻔﺎع ﻧﺴﺒﺔ اﻟﺪهﻮن ,  ﻓﺤﺺ اﻟﻤﺎﻳﻜﺮوأﻟﺒﻮﻣﻴﻦ ﻓﻲ اﻟﺒﻮل،ﻰﻓﺤﻮﺻﺎت وﻇﺎﺋﻒ اﻟﻜﻠ، ﻓﻲ ﺣﻴﻦ، اﻟﻌﻤﺮ، اﻟﺠﻨﺲ. ﻣﺮض اﻟﺴﻜﺮي
 . ﻣﺮاض اﻟﻜﻠﻰ ﺑﻴﻦ ﻣﺮﺿﻰ اﻟﺴﻜﺮيﻷ ةرﻮهﻲ ﻋﻮاﻣﻞ اﻟﺨﻄض اﻟﺸﺮﻳﺎن اﻟﺘﺎﺟﻲ اﻣﺮأ وﻓﻲ اﻟﺪم 
  
ﺟﺮاء  ﺑﺎﺛﻠﺜﻲ اﻷﻃﺒﺎء ﻗﺎﻟﻮا أﻧﻬﻢ ﻳﻮﺻﻮا ﻣﺮﺿﺎهﻢ، أآﺜﺮ ﻣﻦ اﻷﻃﺒﺎءﺑﺎﻟﻤﻌﻠﻮﻣﺎت اﻟﺘﻲ أدﻟﻰ ﺑﻬﺎ ﻤﺮﺿﻰ اﻟ ﻣﻠﻔﺎت  ﺑﻴﺎﻧﺎثﺑﻤﻘﺎرﻧﺔ
 ٪ ﻣﻦ ﻣﻘﺪﻣﻲ68أآﺜﺮ ﻣﻦ . ﻠﻤﺮﺿﻰ أآﺪت هﺬﻩ اﻟﺘﻮﺻﻴﺔ ﻟﻣﻦ اﻟﻤﻠﻔﺎت اﻟﻄﺒﻴﺔ(  ٪6.71)، وﻟﻜﻦ ﻓﻘﻂ اﻟﺘﺮاآﻤﻲﻓﺤﺺ اﻟﺴﻜﺮ 
 اﻟﻤﺮﺿﻰ أﻇﻬﺮت  ﻣﻠﻔﺎت ٪ ﻣﻦ6.54 ﻓﻘﻂ  و ﻟﻜﻦﻤﺮﺿﻰ ﺑﻔﺤﺺ ﻋﻴﻮﻧﻬﻢ ﻋﻨﺪ أﺧﺼﺎﺋﻲ اﻟﻌﻴﻮن اﻟﻮاﻮﺻﻳ ﻢأﻧﻬاﻟﺨﺪﻣﺔ ذآﺮوا 
 . نﻮ أي وﻗﺖ ﻣﻀﻰ ﻻﺟﺮاء ﻓﺤﻮص اﻟﻌﻴﻓﻲ  ﻗﺎﻣﻮا ﺑﺘﺤﻮﻳﻠﻬﻢأن أﻃﺒﺎﺋﻬﻢ
  
  ٪3.72  ﻧﺴﺒﺔ ، وﻜﺎن ﻋﻤﻠﻬﻢﺻﻤﺎء ﻓﻲ ﻣ ﻏﺪد أﺧﺼﺎﺋﻲ  ﻋﻦ وﺟﻮد أﺧﺒﺮوا ٪ ﻣﻦ ﻣﺠﻤﻮع اﻷﻃﺒﺎء6.3، ﻓﻘﻂ ﺔﺪراﺳاﻟ  هﺬﻩﻓﻲ
 .ﺗﻐﺬﻳﺔﻳﻮﺟﺪ ﺑﻬﺎ أﺧﺼﺎﺋﻲ  ٪ ﻣﻦ هﺬﻩ اﻟﻌﻴﺎدات 5.43، ﻓﻲ أﻣﺎآﻦ ﻋﻤﻠﻬﻢ ﻃﺒﻴﺐ ﻋﻴﻮن ﻣﻦ اﻷﻃﺒﺎء ﻗﺎﻟﻮا اﻧﻬﻢ ﻳﻤﻠﻜﻮن
  
  ﻣﻀﺎﻋﻔﺎت ﺑﻴﻨﺖ اﻟﻌﻮاﻣﻞ اﻟﻤﺆﺛﺮة ﻓﻲ ادارة ﻓﻲ ﻓﻠﺴﻄﻴﻦ واﻟﺘﻲ ﻮﻋﻬﺎأﻧﻬﺎ اﻷوﻟﻰ ﻣﻦ ﻧ ﻣﻦ أهﻢ ﻣﻴﺰات هﺬﻩ اﻟﺪراﺳﺔ :اﻻﺳﺘﻨﺘﺎج
 اﻟﺘﺰام،  ﻣﻦ ﻗﺒﻞ اﻟﻤﺮﻳﺾﺸﺨﺼﻴﺔاﻟﻤﺘﺎﺑﻌﺔ اﻟ, ﻠﻤﺮﺿﻰ ﻟاﻟﻤﺴﺘﻮى اﻟﺘﻌﻠﻴﻤﻲ , اﻟﺠﻨﺲ, اﻟﻌﻤﺮ . اﻟﺜﺎﻧﻲﻣﺮض اﻟﺴﻜﺮي ﻣﻦ اﻟﻨﻮع 
 ﻣﻀﺎﻋﻔﺎت ﻓﻲ ادارةﺆﺛﺮ  ﻧﻈﺎم اﻟﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ ، هﻲ اﻟﻌﻮاﻣﻞ اﻟﺮﺋﻴﺴﻴﺔ اﻟﺘﻲ ﺗ ﺗﺮآﻴﺒﺔإدارة ﻣﺮض اﻟﺴﻜﺮي وﺑﺪﻟﻴﻞ ﻷﻃﺒﺎء ا
 ﻧﻈﺎم ﺗﻌﺪﻳﻞ.  ﺑﻜﻴﻔﻴﺔ ادارة ﻣﺮض اﻟﺴﻜﺮي ﺑﻀﺮورة وﺿﻊ ﺑﺮﻧﺎﻣﺞ ﻟﻠﺘﻮﻋﻴﺔﻲﻮﺻﻧهﺬا و. اﻟﺜﺎﻧﻲﻣﺮض اﻟﺴﻜﺮي ﻣﻦ اﻟﻨﻮع 
 .ﺿﻊ ﻗﺎﻧﻮن ﻟﺤﻤﺎﻳﺔ اﻟﺪﻟﻴﻞ اﻟﻮﻃﻨﻲ ﻻدارة ﻣﺮض اﻟﺴﻜﺮيﻮﻟ  هﻨﺎك ﺣﺎﺟﺔ ﻣﻠﺤﺔ.اﻟﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ  وﻓﻘﺎ ﻻﺣﺘﻴﺎﺟﺎت اﻟﻤﺮﺿﻰ
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Chapter One.   Background and Significance 
1.1 Background: 
 
In 1999, WHO defined diabetes mellitus as “a metabolic disorder of multiple 
etiology, characterized by chronic hyperglycemia with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action, or both. The effects of diabetes mellitus include long-
term damage, dysfunction and failure of various organs” (WHO, 1999). Thus, 
the metabolic abnormalities of diabetes result from inadequate insulin action on 
target tissues, due to deficient insulin secretion or insensitivity to insulin action, 
or a combination of both (International Diabetes Federation, 2003; WHO, 
1999). 
 
The classification of diabetes mellitus has evolved considerably over time, taking into account 
recent advances in the diabetes field. The classification is now primarily based on the etiology 
(causes) of the disease, rather than its treatment. The revised classification encompasses both 
clinical stages and etiological types of hyperglycemia and results from improved 
understanding of the causes of diabetes mellitus (WHO, 1999). 
 
There are two main types of diabetes: type 1 (requiring insulin for survival) and type 2 (may 
or may not require insulin for metabolic control).  Type 2 is the most common form of 
diabetes and is characterized by disorders of insulin action and insulin secretion, either of 
which may be the predominant feature. Both are usually present at the time that this form of 
diabetes is clinically manifest. The specific reasons for the development of these abnormalities 
are not yet known (Diabetes Care, 2005). 
 
Diabetes type 2 can be prevented but if occurred physician should work with their patients to 
have a good management whether to prevent the occurrence of any complications, if 
complications started, to stop its dramatic effect which might lead to death. Research studies 
like DCCT and EDIC are reported that control of blood glucose, blood pressure and blood 
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lipid levels help prevent complications in people with type 2 diabetes. (DCCT, 1993; EDIC, 
2005), AHRQ-funded research has shown that glycemic control can be achieved and 
complications of diabetes postponed. (Miller et al., 2000) 
1.2  Problem statement 
 
Over the past three decades, key social and economic changes have occurred in the majority of 
the Eastern Mediterranean nations. These include progressive urbanization, decreasing infant 
mortality and increased life expectancy. Increasingly sedentary lifestyles, the obesity 
pandemic and the higher life expectancy have led to a dramatic rise in type 2 diabetes in many 
countries of the Region (WHO, 2006) 
 
Diabetes complications are multi-factorial. Several of these risk factors can be modified so to 
improve the health condition of the patient and at the same prevent the occurrence of other 
complications.  The major factors that were shown by literature to have a major role are, 
patients socio-demographic characteristics, follow up at the personal level, compliance of 
physicians with the diabetes management guidelines and the services provided to these 
patients (Task force on community preventive services, 2002; Lobo CM et al., 2003). There  is  
now  clear  evidence  that  an  effective control  of  blood  glucose  and  blood  pressure  
significantly  decreases  the  risk  of complications  in both  type 1 and  type 2 diabetes  
(Khunti K et al.,  2001). 
 
The burden of diabetes is due to its complications, so the most important target for diabetes 
management to reduce these complications or postpone them. Several factors are playing role 
in diabetes complications management like, health care system, background of physicians and 
patients themselves and their follow at personal level.  
 
Quality of care of diabetic patients can be influenced by health care system, practice 
organization and by patients themselves (Lobo CM et al., 2003; Khunti et al., 1999). Health 
care system has its impact on how care for patients is organized, funded, how the medicines 
are reimbursed, how the educational materials are prepared and distributed etc. Practice 
organization  requires  adequate  practice  management,  for  example,  by  adequate 
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organization of medical practice by systematic delegation of health promotion activities to  the  
ancillary  staff. Written  diabetes  protocols  and  the  degree  to which  the  general 
practitioners  and  ancillary  staff  work  as  a  team  are  also  important,  as  these  foster 
teamwork and provide a sense of direction (Lobo CM et al., 2003). Waiting time, list size, 
practice type and location, record-keeping are just a few of the practice organization factors 
important in quality of care. Background characteristics of general practitioners (GPs) and 
practices associated with diabetes guideline adherence may contribute substantially  to 
variations in  healthcare  delivery  and  are  associated  with  adherence  to  preventive  
guidelines. 
 
In Palestine, in particularly the West Bank, the reported new cases of diabetes in the 
governmental primary health care clinics (PHC) diabetic clinics was 2,214 cases in 2007, in 
Jenin and Tubas districts, in particular, was 306 cases. Nephropathy, retinopathy and 
neuropathy are the most important complications of diabetes. The distribution of the reported 
visits to government PHC diabetic clinic fro year 2007, by complications was: 5,277 visits 
with nephropathy, 14,248 with retinopathy and 21,816 visits with neuropathy. (MOH, 2007). 
However, there have been few studies that estimated the determinants of type 2 diabetes 
complications. Abdul Rahim et al., investigated the prevalence of diabetes and associated 
factors in a cross-sectional survey of an urban Palestinian population of 492 men and women 
aged 30-65 years. Diabetes was found in 12.0% of the survey population (including 9.4% 
previously diagnosed), and impaired glucose tolerance in 5.9%. Logistic regression analysis 
controlling for age and sex revealed body mass index, waist-to-hip ratio and family history of 
diabetes to be significantly independently associated with diabetes (Abdul Rahim et al., 2001). 
Ali Shaar in his study conducted in 1996, revealed that, clinical services offered to diabetic 
patients have no or minimal effect in determining the health status of population. Low quality 
of educational services was due to lack of trained human resources (Shaar, 1996). Ziad Al-
Khdoor in his study revealed the prevalence of diabetic complications among type 1 diabetics 
as follows: retinopathy 36.4%, neuropathy 26.2 and nephropathy 7.5%. He found a significant 
association between retinopathy and neuropathy with HbA1c, disease duration and sex (P< 
0.05) (Al-Khdoor, 2007) 
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This study is planned to be the first baseline study in two districts; i.e. Jenin and Tubas 
districts that investigated the role of the health care services, as one of the factors affecting the 
diabetes complications. 
 
The result of this study will help the policymakers to evaluate the effectiveness of health 
service institutions, which allows better planning to decrease or postpone the complications of 
diabetes. 
 
1.3  Study justification 
 
As mentioned earlier in this chapter, diabetes mellitus is a prevalent disease in Palestine. 
According to the Palestinian Ministry of Health, DM is considered the 9th leading cause of 
death with a proportion of 4.1% of the total (heart disease 2nd, renal failure 5th).  The 
prevalence rate of diabetes mellitus, by a study conducted in 2000 in cooperation with Al 
Quds University, was about 9%.  
 
The Palestinian health care system is a mixture of governmental, non-governmental, United 
Nation Relief and Work Agency (UNRWA) and private (profit and non-profit) services 
delivery. These health providers are over lapping in services, and none of these sector can 
provide comprehensive health services.  
In  Palestine,  the  system  of  public  health  care  is  responsible  for  diabetes  care,  with 
primary health care bearing main responsibility. The care of people with type 2 diabetes 
requires natural and flexible opportunities for consultations both within  the health care centre  
in  question  and  within  the  specialized  system  of  medical  care.  In  principle, prevention 
of type 2 diabetes is also the responsibility of the primary health care system. However, since  
the primary health care system  is vested with overall responsibility for population  in  each  
region,  the other  forms of basic  care  (e.g.  for  infections)  for these diabetic groups are 
generally provided  in health care centers.  In development of care, the  principal  rule  is  to  
improve  co-operation  between  primary  health  care  and specialized medical care, an 
appropriate division of  labour  (“shared care model"), and straightforward consultation 
opportunities in both directions (DEHKO, 2001-2010). In Palestine, the care of diabetic 
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patients has been shifted to the primary health care system, but when specialized care is 
needed the system has flexibility to refer patients to secondary health care institutions.   
General Practitioner is an old specialty in Palestine. Care provided by GPs is comprehensive, 
not limited by gender, age or diagnostic category. GPs are providing health care for diabetes 
patients in all health care institutions (MOH, NGOs, UNRWA and private sector). In general 
they provide care without undergo any specific training in diabetes management. 
 In Jenin and Tubas districts, most  patients with  type  2  diabetes  in receive care from GPs. 
The diabetes nurse and endocrinologist are not  available at  the hospitals. The specialized 
health care is provided by internists. 
Clinical practice guidelines (CPG) are systematically developed statements to assist the 
decisions of the practitioner and patient about appropriate healthcare for specific clinical 
circumstances (Field MJ et al., 1990).   It is expected that clinical practice guidelines improve 
healthcare quality, reduce inappropriate variations between providers and predispose 
dissemination of the evidence-based medicine concept in daily practice. Policymakers and 
payers see guidelines as a tool for making healthcare more consistent and efficient. 
The WHO has developed guidelines for the prevention, management and care of diabetes 
mellitus.  Before 2008, there was no protocol or guidelines for management of diabetes in the 
Palestinian ministry of health. In 2008, in cooperation with World Health Organization 
(WHO) and Austrian Development Cooperation, Ministry of Health adopted a “quick 
reference guide for the management and care of Diabetes Mellitus”, which totally builds on 
WHO guidelines (Quick Guide, MOH, 2008). 
 
To improve  the quality of  the care of diabetic patients,  Ministry of Health and UNRWA  
have developed a guideline for management of  type 2 diabetes. The MOH guide, i.e. the 
“quick reference guide for the management and care of diabetes mellitus”, (MOH; 2008) and 
the UNRWA “technical instructions and management protocols on prevention and control of 
Noncommunicable diseases” (UNRWA; 2004). Both protocols are, in somehow, are built on 
the WHO guidelines for year 2006, with some differences between them and some times 
between them and WHO guidelines. Both protocols of MOH and UNRWA adopted the WHO 
 6
recommendations about patient educations and advice on diet and the types of oral antidiabetic 
agent and combined therapy with insulin. 
To have an overview of the management of diabetes type 2 in Jenin district, we carried out 
several interviews with key persons at the diabetes department in the central governmental 
primary health care center in Jenin. From these interviews we found that the Ministry of 
Health is the main health provider for patients with type 2 diabetes, as they have 5224 files for 
those with type 2 diabetes and who was born after 1970. (diabetes clinic report; 2008). They 
used for the management of diabetes WHO guidelines in general and some times guidelines 
from American Diabetes Association, and this depends on the interest of GPs them selves to 
read and enlarge their knowledge (personal communication, Abdel Hafez, 2009).  
The second health care provider at Jenin district is the united nation for relief work agency 
(UNRWA).  There are 1600 patients with type 2 diabetes who are registered at the UNRWA 
primary health care clinics. According to an interview with Doctor Jamal (personal 
communication, Jamal Sa’di, 2009) The UNRWA has developed their own guidelines and 
protocols for the management of diabetic patients.  These guidelines was published under the 
name “technical instructions and management protocols on prevention and control of 
Noncommunicable diseases” (UNRWA; 2004), which is not specifically for diabetes alone. 
Also, we had some interviews with physicians working at the private sector. No unified 
protocol was used for dealing with the diabetic patients.  Each physician is using his own 
protocol according to his own belief is the best to be used.  
It is not yet known if diabetes care guidelines are incorporated into the daily practice of 
primary care. In Palestine, information about general practitioners' attitudes towards  
guidelines, about their ability to adopt and interpret guidelines as well as about the need for 
additional support to implement guidelines into everyday general practice is very scanty. 
There is an increasing interest and belief, both nationally and internationally, that working out 
clinical practice guidelines has a major impact on quality of care. The patient-,practices and 
practice management-based barriers may prevent implementation of evidence based practices 
(Larme AC et al., 2001; Zgibor JC et al., 2001). It has been found that attitudes, rather than 
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knowledge, may impede primary care provider adherence to standards of care (Kirkman MS et 
al., 2002). 
Therefore as researchers, we suspect that the mismanagement, various health systems for 
follow up and lack of adherence to the international guidelines  of diabetes is leading to 
serious complications which could be lethal in many cases. So, we planned to perform this 
baseline study to identify the determinants of diabetes complications management in Jenin and 
Tubas districts  
1.3 Study Aim and objectives 
 
To examine the determinants of management of diabetes mellitus type 2 complications at 
Jenin and Tubas districts. 
 
General objectives 
 
1- To determine the factors affecting diabetes management at the health care system and 
its association with diabetes’ complications 
2- To determine the factors affecting diabetes management at the personal level and its 
association with diabetes’ complications. 
 
Specific Objectives: 
 
1- To examine the association between the physicians compliance to diabetes guidelines 
and diabetes’ complications 
 
2- To evaluate the health care systems arrangements for diabetes management and its 
association with diabetes’ complications 
 
3- To examine the association between diabetic patients personal follow up and his 
diabetes’ complications 
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4- To examine the association between the personal characteristics and health status and 
the diabetes’ complications 
 
1.4 Study limitations 
 
Some physicians could not be reached for the following reasons: 
 
1- Traveling out of country for continuing study 
2- Traveling out of district for working in another city 
3- Physicians managers, who are not involved in diabetes treatment 
4- We could not take permission from ministry of health to do personal interview with 
diabetes patients during the working hours. 
5- In the medical files we could not found the date of diagnosis for each complication. 
6- Absence of filling system at the private sector and private clinics 
 
1.5 Thesis chapters’ description 
 
The thesis will consist of 6 chapters. In chapter one, we will discuss the aim, problem 
statement and study justification, and the objectives.  Also, it includes study hypothesis and its 
limitations. Chapter two presents the literature review of previous studies that are related to 
research topic. While in chapter three, the theoretical and conceptual frame work for the study 
will be discussed. In chapter four study methodology, and data collection methods, sample 
size, piloting and statistical analysis of data are presented.  While in chapter five, study results 
will be presented and demonstrated in form of tables and figures. While in chapter six, the 
study results and its findings will be discussed and recommendations will be presented. 
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Chapter two.    Literature Review 
2.1 Introduction: 
 
The literature review in this chapter will focus on dependent and independent variables that 
are related to the study and this will include the impact of intensive therapy, self management, 
adherence to diabetes guidelines, health care system impacts on diabetes complication and the 
impact of socio-demographic characteristics on development of diabetes complications. 
 
2.2 Previous studies 
 
The previous studies that are related to our study will be divided into: 
2.2.1 The impact of intensive therapy on achieving glycemic control and good                      
management 
 
2.2.2 The impact of Self Management on diabetes complications 
  
2.2.3 The impact of Level of adherence to diabetes guidelines on diabetes complications 
 
2.2.4 The impact of health care system on diabetes complications 
 
2.2.5 The impact of socio demographic characteristics on diabetes complications 
 
Worldwide, the prevalence of Type 2 diabetes is 150 million cases worldwide 2002 (WHO 
Meeting, 2002). The incidence of Type 2 diabetes, i.e. new cases diagnosed per year is 
798,000. (CDC, 2004) 
 
It is predicted that between 2000 and 2025, the size of the world’s adult population will 
increase from less than 4 billion to 5.5 billion, mainly on account of a 60% increase in 
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developing countries. The number of adults with diabetes in the world is predicted to increase 
from 150 million in 2000 to 300 million in 2025 (IDF, 2003). In industrialized countries, the 
number of diabetics will increase by about one third between 2000 and 2025, while in 
developing countries that number will more than double (IDF, 2003) 
The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 
and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 
million in 2000 to 366 million in 2030. The prevalence of diabetes is higher in men than 
women, but there are more women with diabetes than men. The urban population in 
developing countries is projected to double between 2000 and 2030. The most important 
demographic change to diabetes prevalence across the world appears to be the increase in the 
proportion of people >65 years of age.  
These findings indicate that the "diabetes epidemic" will continue even if levels of obesity 
remain constant. Given the increasing prevalence of obesity, it is likely that these figures 
provide an underestimate of future diabetes prevalence (Sarah et al., 2004). 
The International Diabetes Federation (IDF) published new data in 2006 indicating the 
enormity of the diabetes epidemic. The Federation’s Diabetes Atlas show that the disease now 
affects 246 million people worldwide, with 46% of all those affected in the 40-59 age group. 
Previous figures underestimated the scope of the problem, while even the most pessimistic 
predictions fell short of the current figure. The new data predict that the total number of 
people living with diabetes will rise to 380 million within twenty years if nothing is done 
(IDF, 2003).  
 
2.2.1 The impact of intensive therapy on achieving glycemic control and good                      
management 
Substantial evidence points to the admission of glucose level as an independent predictor of 
early and late mortality after MI in patients with and without diabetes (Capes et al., 2000). The 
DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) study 
suggests that strict glycemic control for 3 months can significantly improve survival at 1 and 3 
years after myocardial infarction (MI) (Nesto et al., 1998; Malmberg et al., 1999).  
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For patients with newly recognized diabetes, this provides an opportunity for prompt referral 
to a diabetes management team, in addition to a program of cardiac rehabilitation. 
The Diabetes Control and Complications Trial (DCCT) was a major clinical study conducted 
from 1983 to 1993 and funded by the National Institute of Diabetes and Digestive and Kidney 
Diseases. The study showed that keeping blood glucose levels as close to normal as possible 
slows the onset and progression of the eye, kidney, and nerve damage caused by diabetes. In 
fact, it demonstrated that any sustained lowering of blood glucose, helps, even if the person 
has a history of poor control. 
The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical 
centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 
year but no longer than 15 years. They also were required to have no, or only early signs of, 
diabetic eye disease. 
The study compared the effects of standard control of blood glucose versus intensive control 
on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as 
close as possible to the normal value of 6 percent or less. The A1C blood test reflects a 
person’s average blood glucose over the last 2 to 3 months. Volunteers were randomly 
assigned to each treatment group. 
When the DCCT ended in 1993, researchers continued to study more than 90 percent of 
participants. The follow-up study, called Epidemiology of Diabetes Interventions and 
Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease 
events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications 
related to the eye, kidney, and nerves. The EDIC study is also examining the impact of 
intensive control versus standard control on quality of life. Another objective is to look at the 
cost-effectiveness of intensive control. 
DCCT Study finds that, intensive blood glucose control reduces risk of: 
• eye disease  by 76% reduced risk  
• kidney disease by 50% reduced risk  
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• nerve disease by 60% reduced risk  
EDIC Study finds that, intensive blood glucose control reduces risk of: 
• any cardiovascular disease event by 42%  reduced risk.  
• nonfatal heart attack, stroke, or death from cardiovascular causes by 57% reduced risk.  
The goal of treatment of diabetes mellitus is to control blood glucose and ultimately prevent 
long-term complications, as shown by major diabetes studies like the United Kingdom 
Prospective Diabetes Study group and Diabetes Control and Complications  
Trial (UKPDS 38, 1998; UKPDS 33, 1998; DCCT , 1993). Insulin therapy is necessary to 
control hyperglycemia in type 1 diabetes mellitus. 
 
Provided hyperglycemia is mild in type 2 diabetes, patients may be given at least a one month 
trial of diet, exercise and weight management in order to control hyperglycemia. If this 
regimen does not lead to adequate blood glucose control, the physician will need to prescribe 
oral anti-hyperglycemic agents and/or insulin(DCCT, 1993) . 
Results of the DCCT and EDIC studies have important implications for preventing diabetes 
complications in people with type 2 diabetes because the microvascular disease development 
process is likely to be similar for both type 1 and type 2 diabetes. One study of people with 
type 2 diabetes, the United Kingdom Prospective Diabetes Study, demonstrated that 
controlling blood glucose levels reduced the risk of diabetic eye disease and kidney disease. 
Research studies have shown that, the most important factors in preventing diabetes 
complications are the control of blood glucose, blood pressure, and blood lipid levels which, 
helps prevent complications in people with type 1 or type 2 diabetes. (DCCT, 1993; EDIC, 
2005) 
The Atlanta researchers reviewed several earlier studies that focused mostly on patients in 
primary care settings and found that significant percentages of patients had HbA1c levels 
above 8 percent (Martin et al 1995; wealtherspoon et al., 1994). When comparing their own 
study to one of these earlier studies (Harris et al., 1999), the AHRQ-funded Atlanta team 
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found that patients in their study were more likely than those in the earlier study to be using 
oral hypoglycemic medications plus insulin (31 percent vs. 3 percent). Also, the Atlanta 
patients taking insulin were more likely to be injecting three or more times per day (42 percent 
vs. 4 percent).  
The Atlanta researchers stated that "the discrepancies between our data and those of primary 
care studies (showing less success in achieving glycemic control) may be because of factors 
other than the type of treating physician (Miller et al., 2000)."  
The following factors were mentioned by the researchers:  
• The earlier primary care studies date from the early 1990s and may not reflect current 
practices.  
• Patient motivation may have differed.  
• A broader array of medications was available at the time of the Atlanta study.  
• The ability to do rapid on-site HbA1c measurements was available for the Atlanta 
physicians. 
Conclusion 
AHRQ-funded research shows that patients can achieve good diabetic control if providers 
recommend intensive therapies, use a team approach, furnish appropriate preventive care, and 
put into practice proven strategies that help patients better manage their care. Few patients 
have type 2 diabetes without other diagnoses (Glasgow et al., 1999), and others have multiple 
chronic disease, for both the physician should try to achieve blood glucose control. 
2.2.2     The impact of Self Management on diabetes complications 
 
Diabetes is a major growing health care problem. At the present rate of increase in type 2 
diabetes, it will be one of the world's commonest diseases and among the most serious 
problems of public health within a few decades. (Diamond J, 2003). The most  important  
challenge  in  the  care  of  diabetic  patients  is  to  avoid  or  postpone several  complications  
of  the  disease.  There  is  now  clear  evidence  that  an  effective control  of  blood  glucose  
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and  blood  pressure  significantly  decreases  the  risk  of complications  in both  type 1 and  
type 2 diabetes .( Khunti et al.,2001) 
 
According to Collaborative management of chronic illness, Self-management is defined as: (1) 
engaging in activities that protect and promote health; (2) monitoring and managing symptoms 
and signs of illness; (3) managing the impacts of illness on function, emotions, and 
interpersonal relationships; and (4) adhering to treatment regimens ( Von Korff et al., 1997 ). 
patients are more likely to comply with a practitioner's instructions to take medicines as 
instructed when the patients can observe the impact of their behaviors(Gardiner et al.,2006; 
DeWalt et al.,2006). 
 
By CDC 2003, Diabetes self-management education (DSME) is also referred to as diabetes 
self-management training (DSMT). DSME is the process of teaching individuals with diabetes 
to manage their disease and is an integral component of the treatment plan (CDC, 2003). In 
order to maintain optimal control of this condition, individuals or caregivers  of individuals 
with diabetes must be directly involved in the day-to-day management of the disease. As such, 
diabetes is considered a self-managed disease. The national standards for DSME state that 
DSME is an interactive, collaborative, ongoing process that involves the person with diabetes 
and the educator (Mensing, 2007). The standards note that the individual with diabetes needs 
the knowledge and skills to make informed choices, to facilitate self-directed behavior 
changes and, ultimately, to reduce the risk of complications. Mensing, 2007 conclude the main 
components of the process of DSME:   
•  Assessment of the individual’s specific education needs  
•  Identification of the individual’s specific diabetes self-management goals   
•  Education and behavioral intervention directed toward helping the individual achieve 
identified self-management goals  
•  Evaluation of the individual’s attainment of identified self-management goals (Mensing, 
2007)  
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The American Association of Diabetes Education (AADE) talked about the characteristics of 
diabetes health educator, who should be a skilled and experienced healthcare professional with 
recent education in diabetes, educational principles and behavior change strategies (AADE, 
1999). The scope of practice for diabetes educators and standards of practice for diabetes 
educators notes that a diabetes educator is “defined as a healthcare professional who has 
mastered the core of knowledge and skills in the biological and social sciences, 
communication, counseling, and education and who has experience in the care of people with 
diabetes. 
 
The American Diabetes Association recommends: People with diabetes “should receive 
diabetes self-management education/training according to the National Standards for Diabetes 
Self-Management Education when their diabetes is diagnosed and as needed thereafter” and 
DSMT “should be provided by health care providers who are qualified to provide DSME 
based on their professional training and continuing education. (ADA, 1999). DSMT should 
also be considered for people at risk for developing diabetes. (DSMT,  2003). DSME is 
considered “the cornerstone of treatment for all people with diabetes” by the Task Force to 
Revise the National Standards for Diabetes Self-Management Education Programs,(ADA, 
1995) a group representing national public health and diabetes-related organizations.  
 
Several studies have been done with purpose to ascertain the effectiveness of self-management 
programs on achieving glycemic control. Norris et al. (2001) conducted a systematic review 
for 72 studies in 84 articles were identified. The studies were heterogeneous with respect to 
patient population, educational intervention, outcomes assessed, study quality, and 
generalizability. Studies with short-term (i.e., less than six months) follow-up demonstrated 
positive effects of self-management training on knowledge, frequency and accuracy of self-
monitoring of blood glucose, self-reported dietary habits, and glycemic control. With longer 
follow-up, interventions that used regular reinforcement throughout follow-up were sometimes 
effective in improving glycemic control. Educational interventions that involved patient 
collaboration may be more effective than didactic interventions. The authors concluded that 
evidence supports the effectiveness of self-management training in type 2 diabetes, 
particularly in the short-term (Norris et al.,2001).    
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In 2002 Norris et al. (2002) performed a meta-analysis to ascertain the efficacy of DSME in 
adults with type 2 diabetes, to provide summary measures of its effect on glycemic control, 
and to identify predictors of effect. A total of 31 studies were included in the review. It was 
noted that, on average, the intervention decreased the glycated hemoglobulin (GHb) by 0.76% 
more than the control group at immediate follow-up; by 0.26% at one to three months’ follow-
up; and by 0.26% at greater than four months’ follow-up. The authors concluded that the 
meta-analysis provides evidence of the efficacy of DSME for individuals with type 2 diabetes 
for glycemic control. It was noted that GHb improves with DSME, with an average change of 
0.76%, when measured at immediate follow-up. The authors concluded that self-management 
education improves GHb at immediate follow-up, and increased contact time increased the 
effect. In addition, they noted that the benefit declines one to three months after the 
intervention ceases, which suggests that learned behavior changes over time. The authors note 
that further research is needed to develop interventions effective in maintaining long-term 
glycemic control(Norris et al.,2002).     
 
Ellis et al. (2004) conducted a meta-analysis of randomized, controlled trials of diabetes 
patient education published between 1990 and December 2000 to assess and characterize the 
effect of patient education on GHb. The study included 21 articles, with twenty-eight 
educational interventions (n=2439). It was noted that the net glycemic change was 0.320% 
lower in the intervention group than in the control group. Further analysis indicated that 
interventions which included face-to-face delivery, cognitive reframing teaching method, and 
exercise content were more likely to improve glycemic control. The authors concluded that 
current patient education interventions modestly improve glycemic control in adults with 
diabetes(Ellis et al.,2004).   
   
Deakin et al. (2005) conducted a Cochrane systematic review to assess the effects of group-
based, patient-centered training on clinical, lifestyle and psychosocial outcomes in people with 
type 2 diabetes. The selection criteria included randomized controlled and controlled clinical 
trials which evaluated group-based education programs for adults with type 2 diabetes 
compared with routine treatment, waiting list control or no intervention.  
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The review included only studies that assessed outcome measures six months or more from 
baseline. Fourteen publications that described 11 studies were included, involving 1532 
participants. The results of this meta-analyses that favored group-based diabetes education 
programs included: reduced GHb at four to six months, 12–14 months and two years; reduced 
fasting blood glucose levels at 12 months; reduced body weight at 12–14 months; improved 
diabetes knowledge at 12–14 months; and reduced systolic blood pressure at four to six 
months. The authors noted that it was not possible to carry out a meta-analysis for several of 
the main outcome measures (e.g., self-management skills, empowerment/self-efficacy and 
quality of life) due to significant heterogeneity between studies. It was also noted that 
educational interventions are complex interventions, and it is difficult to identify the active 
“ingredient(s)” with any precision. The review also indicated that, although group-based 
diabetes education programs result in clinical and statistically significant health outcomes, the 
exact mechanism of action can be discussed but not identified. The authors concluded that 
group-based training for self-management strategies in people with type 2 diabetes positively 
impacts health outcomes by improving fasting blood glucose levels, glycated hemoglobulin 
and diabetes knowledge and reducing systolic blood pressure levels, body weight and the 
requirement for diabetes medication(Deakin et al.,2005).  
 
Wattana et al. (2007) conducted a randomized, controlled study to determine the effects of a 
diabetes self-management program on glycemic control, coronary heart disease (CHD) risk, 
and quality of life. The study involved 147 patients with type 2 diabetes. The patients will 
randomized into two groups for a period of six months. The experimental group received the 
diabetes self-management program and the control group received the usual nursing care. 
Using pretest and age as covariates, the results indicated that the experimental group had 
statistically significant lower GHb than the control group at 24 weeks (P<0.05). The number 
of patients in the experimental group who reached the GHb level recommended by ADA 
(GHb<7%) was greater than that in the control group (12% compared to 1.39%, respectively). 
The experimental group was noted to have a decrease in the CHD risk factors, including total 
cholesterol, triglycerides, low-density lipoprotein cholesterol, diastolic blood pressure and 
body mass index (BMI) and a greater increase in HDL cholesterol levels as compared to the 
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control group. The results indicated that the experimental group demonstrated a significant 
decrease in the GHb level and CHD risk, with an increase in quality of life as compared to the 
control group. The authors concluded that the diabetes self-management program was 
effective for improving metabolic control and quality of life for individuals with diabetes and 
that further studies should be replicated using larger groups over a longer time frame(Wattana 
et al.,2007).   
 
Diabetes Control and Complications Trial (DCCT,1993) and the Kumamoto study, (Ohkubo et 
al., 1995; Wake et al., 2000) which demonstrated that tight glycemic control improves 
microvascular outcomes in type 1 and type 2 diabetes, respectively. Reductions of caloric and 
fat intake are associated with weight control and improved glycemic control,(Reaven et al., 
1985; Wing et al., 1987; Watts et al., 1990; ADA, 2001) and physical activity is associated 
with improved glycemic control(ADA,2001). Aspirin use, which offers the same 
cardiovascular protection for people with and without diabetes, ( ADA,2001) is recommended 
for all people with diabetes aged>30 years in the absence of contraindications (ADA, 
2001).Smoking increases morbidity and mortality from microvascular and macrovascular 
complications of diabetes.( ADA,2001) 
 
the importance of promoting exercise as a vital component of the prevention as well as 
management of type 2 diabetes must be viewed as a high priority. It must also be recognized 
that the benefit of exercise in improving the metabolic abnormalities of type 2 diabetes is 
probably greatest when it is used early in its progression from insulin resistance to impaired 
glucose tolerance to overt hyperglycemia requiring treatment with oral glucose-lowering 
agents and finally to insulin.(ADA,2002) 
 
Results of the lunch study for a type 2 diabetic subject indicate that the recovery time of the 
post-prandial blood glucose level can be adjusted to 4 hours, which is comparable to the 
typical time interval for non-diabetics: 3 to 4 hours. A moderate lifestyle adjustment of light 
supper coupled with morning swimming of 20 laps in a 25 m pool for 40 minutes enabled the 
subject to reduce his A1c level from 6.7 to 6.0 in six months and to maintain this level for the 
subsequent six months (Hsin-i WuA, 2005). 
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In a small survey in Michigan in 2005, 67% of patients with diabetes reported receiving two 
HBA1c tests, 68% one dilated eye exam, and 67% one foot exam, during a one year period. 
These three exams are standard care, but only 34% reported receiving all three services. The 
good news is that patients who received DSMT were 2.1 times more likely to report receiving 
all three preventive care services as compared to adults with diabetes who had never received 
DSMT, even after adjusting for the effects of age, sex, race, and education, marital and 
smoking status (Michigan et al., 2005).  
 
Self-management is significantly less costly to medical care insurance providers (Fitzmaurice 
et al.,2005). Scientific evidence shows that DSMT, because it correlates with a decrease in 
HbA1C levels, is also associated with reductions in health care costs.   A study published in 
The Journal of the American Medical Association indicated that a sustained reduction in A1c 
among adults with diabetes was associated with a cost reduction of $685 to $950 less per 
person per year within one to two years of improved glycemic control. (Wagner et al. 2001). 
Managed care patients with type 2 diabetes, who improved or achieved glycemic control, 
saved $369 per patient per year in total diabetes related costs as compared to those with higher 
A1c levels. (Shetty, S. 2005)  
 
2.2.3    The impact of Level of adherence to diabetes guidelines on diabetes complications 
Disease management programs help health care organizations address many of the issues 
patients and physicians face when dealing with a chronic disease like diabetes.( National 
Pharmaceutical Council , 2004) Those health care organizations that use disease management 
programs appear to have lower medical costs over the long term while improving results (A1c 
testing, A1c levels, eye exams, LDL levels, nephropathy screening, and hypertension) ( 
Snyder et al., 2003; Lynne et al.,2004). Patients with diabetes in disease management 
programs also appear to have lower hospitalization rates, make fewer emergency room visits, 
and comply more often with recommended office visits.(Lynne et al., 2004; Villagra et al., 
2004). Adherence to guidelines was associated with significantly reduced rates of 
hospitalization. (Frank A, et al., 2004) 
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For vision-related complications to be treated promptly, the American Diabetes Association 
recommends that, physician should advise diabetic patients to have comprehensive periodic 
dilated eye and vision examinations by an ophthalmologist or optometrist (ADA, 2001). 
Nearly all of the benefits would come from the early detection and prompt treatment of 
macular edema in patients whose type 2 diabetes began before age 45. 
The level of compliance with diabetes management guidelines is vary among physicians in 
different countries: 
Patrick et al reported in his study conducted in United states that, screening of diabetes based 
on family or personal history was reported for 83% of the patients and on cardiovascular risk 
factors for 69%. Counseling for dietary changes was reported for 91% of diabetic patients and 
for 79% for physical activity, but only for 66% 
and respectively 60% of pre-diabetic patients. Among diabetic patients, regular HbA1c control 
was reported for 65%, yearly fundoscopy for 62%, yearly feet examination for 65%, yearly 
microalbuminuria control for 49%, regular blood pressure control for 96%, and yearly lipid 
profile for 89%. Regular screening of microangiopathic complications was reported for only 
33% of diabetic patients. (Patrick et al.,2007) 
 
Carolyn Rutledge revealed in his study in 2002 that, overall 54.5% of patients received care 
according to the ADA guidelines. During the year of the study, 93.5% had a cardiovascular 
exam, 87.0% were tested for creatinin clearance, 76.6% had foot exam, 71.4% had home 
glucose monitoring, 67.5% of patients were tested for (HbA1c) level, 62.3% had dilated eye 
exam and 50.6% had lipid profile.( Carolyn Rutledge ,et al.,2002) 
Most Medicare beneficiaries diagnosed with type 2 diabetes had at least one physician visit 
per year, but rates of screening (eye examinations and HbA1c, lipid, Microalbumin and urine 
tests) fell far short of recommendations. Correlations among use rates for various types of 
screening were positive but far less than one, suggesting that failure to screen reflects a 
complex set of underlying factors. Increased rates of adherence were observed for HbA1c and 
lipid testing over the observation period. Higher use was associated with lower rates of 
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hospitalization for complications of diabetes (vascular (p=0.007), renal ((p=0.002), and other 
complication (p=0.005)). 
 
In Jordan, the compliance of physicians with diabetic protocol in year 2004 was as follows:  
Medical history     35%   
Clinical examination    0%   
Counseling     35%   
Laboratory tests    0%   
Referral     35%  
Average    26%  
 
Source: Quality Assurance in the Jordan Primary Health Care System - BEST PRACTICES, 
February 2004 
 
Adherence to ECG and foot assessment parameters was poor among SOC cases, while poor 
adherence to weight and foot assessment parameters was seen in the polyclinics. There was 
poorer adherence to blood pressure and ECG parameters in the SOCs, but better adherence 
was seen for weight assessment. Among the SOC cases, Cluster A fared better than Cluster B 
in ECG monitoring. In the polyclinics, better adherence was seen in Cluster A for urinary 
protein, serum creatinin, lipids, ECG, retinal and foot assessment parameters.( Keng Boon, 
2006) 
 
Overall 52% of the doctors' consultations were not optimal. Some important aspects for a 
positive consultation environment were fulfilled in only about half of the doctors' 
consultations: ensuring privacy of consultation (49%), eye contact (49%), good attention 
(52%), encouraging asking questions (47%), and emphasizing on the patients' understanding 
of the provided information (52%). The doctors enquired about adverse effects of anti-diabetes 
drugs in less than 10% of consultations. The quality of the nurses' consultations was sub-
optimal in about 75% of 85 consultations regarding aspects of consultation environment, care 
and information.( Nadia Abdulhadi,et al., 2006) 
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AHRQ-funded study suggests strategies oriented toward assisting the provider can help 
patients receive needed care. An AHRQ-funded study showed that one way in which providers 
increased their ability to follow protocols was through completing questionnaires that served 
as a self-survey about the appropriateness of glycemic goals and whether their patients were 
well controlled (El-Kebbi et al., 1999). Both physicians and nurses were asked to fill out one-
page multiple-choice questionnaires after each office visit over a 3-month period. In this 
study, conducted at a diabetes clinic treating African-American patients, adherence to 
protocols calling for intensification of therapy when indicated (e.g., putting patients previously 
treated by diet alone on medication or adding sulfonylurea medication to insulin) increased 
from 55 percent to 63 percent when providers completed a questionnaire after every patient 
visit. 
2.2.4.    The impact of health care system on diabetes complications: 
The development of diabetes complications has a huge impact on the health service provider 
and the individual's quality of life. Investment in clinical systems to improve diabetes care 
may benefit both providers and patients. Intensive education in diabetes self-management, use 
of intensive insulin regimens, and adoption of the empowerment approach to diabetes 
management have been cited as preventative solutions to the development of complications. 
(WHO and ADA, 2004). Because of the chronic nature of diabetes, the severity of its 
complications, and the methods required to control them, diabetes is a disease with substantial 
human costs for the affected individual and his or her family; these costs affect people 
everywhere. Intangible costs of diabetes and secondary complications such as pain, anxiety 
and inconvenience have an impact which is large but also difficult to quantify (Wilson and 
Cleary, 1995; Jacobson et al, 1994). 
Improved blood glucose control to prevent diabetes complications has been highlighted since 
the release of results from the Diabetes Control and Complications Trial (DCCT, 1993). These 
results represented the largest randomized longitudinal study of the effects of glycemic control 
ever conducted. Two groups of participants were involved in the study, with one group using 
'conventional' methods (one or two insulin injections per day and one or two blood glucose 
tests) and the other using 'intensive' methods (frequent blood glucose monitoring and daily 
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adjustment of food and insulin to regulate blood glucose to as near normal as possible). Nearly 
half the intensively treated group used continuous subcutaneous insulin infusion (insulin pump 
therapy) to achieve levels of control that are optimum. 
The DCCT Research Group (1993) clearly demonstrated that those individuals achieving 
improved blood glucose control (a 2% lower HbA1c value on average) had a tremendous 
decrease in their risk of long-term complications of diabetes, and an increased quality and 
length of life. Risk of diabetic eye disease decreased by 76%, with reductions to the risk of 
kidney and nerve damage being 60% and 56% respectively. These results were so significant 
that the DCCT Research Group was compelled to end the study I year early. This gave the 
conventionally treated patients the opportunity to have the benefits of intensive diabetes 
management. 
With the evidence that high blood glucose levels increase the risk of developing complications 
of diabetes, tight blood glucose control has become the benchmark for successful diabetes 
management (Diabetes UK, 2000; DCCT, 1993). 
Research has highlighted that more intensive diabetes care and thorough patient education can 
result in improved glycemic control, leading to fewer microvascular complications in people 
with type 1 and type 2 diabetes (Dose Adjustment For Normal Eating (DAFNE) Study Group, 
2001; Gray et al, 2000; Gilmer et al, 1997). If the health care system invests in the diabetes 
control and this investment may include intensive therapies, closer monitoring and increased 
patient education; however, they are outweighed by reduced incidence of complications and 
an improved quality of life for the individual (Skyler, 2000; Jacobson et al, 1994). Other 
studies have also indicated that the health care system investments in diabetes care can 
improve glycemic control (Skyler, 2000; O'Connor et al, 1996; Eckman et al, 1995). 
For most countries, the largest single factor in diabetes expenditure is hospital admission for 
the treatment of long-term complications such as heart disease and stroke, kidney failure and 
foot problems (WHO, 2002; O'Connor et al, 1996; Eckman et al, 1997). Many of these are 
potentially preventable if the health system provide a comprehensive care, given effective 
patient and professional education and comprehensive long-term care (Diabetes UK, 2000). 
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World health organization (WHO) recommend referral of diabetes patients to different kinds 
of specialists for follow up, WHO emphasize on multi disciplinary team for care about 
diabetics. Health care system should include, diabetes educator, to evaluate patient’s ability to 
perform self-monitoring of blood glucose and his/her ability to interpret the data, dietician, 
foot-care specialist, ophthalmologist for annual retinal screening, or more often as indicated, 
nephrologists, neurologist, and cardiologist, if needed. The use of multidisciplinary mini 
clinics for diabetes care has the potential to improve clinical outcome. These provide team 
care by a physician, nurse, dietician, chiropodist and health educator that will improve 
treatment and help establish a referral system for diabetic complications. (WHO, 2006) 
 
Combination of intensive therapy and team approach promotes good outcomes. Even though 
the treatment of diabetes is complex and major barriers to achieving good outcomes exist, 
Agency for Health Care Research and Quality (AHRQ-funded research), has shown that 
glycemic control can be achieved and complications of diabetes postponed through a 
combination of intensive drug therapy and a team approach. 
A retrospective study, academic endocrinologists in Atlanta examined the clinical records of 
151 diabetes patients (121 with type 2 diabetes and 30 with type 1) in their own practice 
(Miller et al., 2000). Most of these patients had complications as a result of their diabetes, 
including peripheral neuropathy (78 percent), retinopathy (22 percent), hypertension (80 
percent), hyperlipidemia (64 percent), coronary heart disease (27 percent), and peripheral 
vascular disease (14 percent)—not unusual for patients who had had diabetes, on average, for 
12 years.  
Investigators found that half the patients made at least four visits during the study year. 
Patients alternated between visits that included both a physician and a nurse practitioner and 
visits with a nurse practitioner alone. Nurse practitioners, who were also directly available at 
other times for phone contact, were able to facilitate more frequent adjustment of therapy 
when necessary. The average HbA1c of patients with type 2 diabetes was 6.9 percent; 87 
percent achieved good control of blood sugar (8 percent or less HbA1c) by the use of complex 
treatment regimens, 78 percent were managed with more than diet alone or a single oral agent, 
and many patients received either two oral hypoglycemic or one oral hypoglycemic plus 
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insulin injections. The average HbA1c of patients with type 1 diabetes was 7.1 percent; 80 
percent achieved good control of blood sugar with an average of 3.4 injections of insulin per 
day . In addition, screenings were performed at recommended intervals for major 
complications, including eye and foot problems, high lipid levels, and hypertension. 
 
Miller et al., recommend team approach for diabetes care: 
• 4 or more visits per year for many patients.  
• Visits with both physicians and nurse practitioners alternating with visits with a nurse 
practitioner.  
• Direct telephone availability of nurse practitioners.  
• Dietitian visits with patients.  
• Screening for complications.  
• Self-monitoring. 
” The AADE (1997) notes that “Multidisciplinary instructional staff who are collectively 
qualified to teach the required content areas shall include as least: 1) a registered dietician and 
2) either a registered nurse or other health professional who is a certified diabetes educator 
(CDE).”   
 
In Australia, a one-time, advanced diabetes education program teaching intensive insulin self-
management with an empowerment style can lead to sustained improvement inpatient 
outcomes and reduce use of hospital services for people with Type 2 diabetes on insulin 
(Lowe et al., 2009). In United states, only by teamwork between primary care physician and 
ophthalmologist can blindness from diabetic retinopathy be reduced (Sinclair et al., 2004). A 
multifaceted approach to improving diabetes management has led to improved performance in 
clinical measures related to diabetes care that have been shown to reduce the risk of patients 
with diabetes developing diabetes- related complications. 
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Diabetes self-management education (DSME), the process of teaching people to manage their 
diabetes,(ADA,1995). has been considered an important part of management of diabetes since 
the1930s and the work of Joslin.( Bartlett et al.,1986). The American Diabetes Association 
(ADA) recommends assessing self-management skills and knowledge of diabetes at least 
annually and providing or encouraging continuing education (ADA,2001). 
The researchers emphasized that "good glycemic outcomes are attributable to a commitment 
to achieving normal metabolic status that is reinforced through multiple contacts, including 
not only physician appointments but also nurse practitioner visits, dietitian visits, and 
telephone calls. (Miller et al., 2000)  
Diabetes management strongly recommended. Disease management of diabetes- as prescribed 
in Task Force on Community Preventive Services (2002) - in the clinical setting is an 
organized, proactive, multicomponent approach to healthcare delivery for all members of a 
population with diabetes or for a subpopulation with specific health risk factors. It embraces 
all aspects of the delivery system. Care is focused on, and integrated across, the entire 
spectrum of the disease and its complications as well as the prevention of co morbid 
conditions. The goal is to improve short- and long-term health or economic outcomes, or both, 
in the entire population with diabetes. The essential components of disease management are 
(1) identification of individuals or populations with diabetes (or a subset with certain risk 
factors); (2) use of guidelines or performance standards to manage those identified; (3) 
information systems to track and monitor interventions and patient-,practice-, or population-
based outcomes; and (4) measurement and management of patient and population outcomes. 
Other interventions may be incorporated into disease management interventions, and these 
interventions can be focused on (1) the healthcare system (e.g., practice redesign, electronic 
information systems, changes in models of care), (2) the provider (e.g., reminders, education, 
feedback, decision support), or (3) the patient or population (e.g., patient-centered care 
strategies, DSME, reminders, feedback, telephone call outreach). 
 
Disease management is strongly recommended by the Task Force based on strong evidence of 
its effectiveness in improving glycemic control, provider monitoring of glycated hemoglobin 
(GHb), and screening for diabetic retinopathy. Sufficient evidence is also available of its 
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effectiveness in improving provider screening of the lower extremities for neuropathy and 
vascular changes, urine screening for protein, and monitoring of lipid concentrations. This 
recommendation is applicable to adults with diabetes in the settings of managed care 
organizations and community clinics in the United States and Europe. Although a number of 
other important health outcomes were examined, including blood pressure and lipid 
concentrations, data were insufficient to make recommendations based on these outcomes. 
 
Forum three, conducted in USA in 1996, which discussed the Changes in the U.S. Health Care 
System That Would Facilitate Improved Care for Non-Insulin-dependent Diabetes Mellitus, 
emphasized on several recommendations to improve the health care delivery for diabetic 
patients that will help in preventing the complications. 
 
The forum recommended that the U.S. health care delivery system be amended so that the 
important secondary preventive care that diabetic patients need through most of their illness be 
available to them regardless of employment status, insurance coverage, and other factors that, 
if not addressed, would result in the uneven availability of preventive services. The concepts 
of secondary and tertiary prevention in diabetes, however, are supported by existing data from 
several previous studies, the most recent and impressive of which is the Diabetes Control and 
Complications Trial (DCCT) 
 
Forum members recognized that 90% to 95% of diabetes care in the United States is directed 
by the primary care physician, with the remaining fraction directed by physicians with special 
interest and training in diabetes and other metabolic disorders. With the current emphasis on 
primary care in the U.S. health care delivery system, it is unlikely that this ratio will change in 
the foreseeable future. However, most patients with diabetes would be well served during their 
illness if they had access to specialists as complications develop. In addition to specialty care 
for complications, a system of "shared care" between primary care physicians and diabetes 
specialists has been proposed (Fisher et al.,1994). The specialist and specialty team would 
review the overall status of the progress of diabetes care at periodic intervals, reset goals and 
directions as appropriate, and make recommendations to the primary care physician on how to 
carry out this plan. Making decisions about starting insulin therapy, identifying and 
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recommending strategies for managing cardiovascular disease risk factors, and periodically 
screening for diabetes complications (for example, detection of microalbuminuria) are 
examples of how diabetes specialists could interact with primary care physicians and share 
responsibility for patients' management. A common data system for everyone offering care to 
a given patient would integrate this care into a seamless system and would also enhance 
reporting procedures and facilitate clinical research. 
The forum also recommended that the continuing education modalities serving primary care 
physicians assume the responsibility for updating this large physician population on intensive 
management for NIDDM. These modalities include the medical literature, review articles in 
the medical literature, local and national continuing medical education programs, hospital-
based medical staff continuing education activities (grand rounds, clinical conferences, and so 
forth), and protocol development within managed care systems.  
The U.K. Prospective Diabetes Study (UKPDS) documented that optimal glycemic control can 
also benefit most individuals with type 2 diabetes. To achieve optimal glucose control, the 
person with diabetes must be able to access health care providers who have expertise in the 
field of diabetes. Treatment plans must include self-management training, regular and timely 
laboratory evaluations, medical nutrition therapy, appropriately prescribed medication(s), and 
regular self-monitoring of blood glucose (SMBG) levels. The American Diabetes Association 
position statement "Standards of Medical Care for Patients with Diabetes Mellitus" outlines 
appropriate medical care for people with diabetes (ADA, 2001). 
To  achieve  higher  quality  in  taking  care  of  patients  with  chronic  diseases,  clinical  
practice  guidelines  (CPG)  are  often  developed  and  used  as  guidance. CPGs integrate 
generic recommendations for specific medical circumstances. They have been defined as 
systematically developed statements to assist practitioner and patient decisions about 
appropriate health care for specific medical circumstances.  They  are  designed  to compile  
the  best medical  knowledge  in  order  to  provide  physicians with  a  practical decisional 
aid. Clinical practice guidelines aim to eliminate clinician errors and promote best medical 
practice. (Ivika Oja; 2005)  
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Canadian Diabetes Association Clinical Practice Guidelines suggest that care of the person 
with Diabetes be organized using a team approach and the Guidelines give us a structured care 
approach to prevention and treatment. It has been repeatedly demonstrated that a structured 
care approach improves outcomes. The conclusion is that structured care saves lives and 
reduces morbidity. (CDA, 2003) 
 
 
2.2.5  Socio demographic characteristics and diabetes complications: 
 
Several socio demographic factors can effect development of diabetes microvascular 
complications. Several studies have shown age as a risk factor for having retinopathy among 
diabetic patients.  In Oman was higher in age groups 50-59 and 60-69 (R. Khandekar et al., 
2003). In Iran the prevalence of retinopathy was higher 37% (Ali Javadi et al., 2009). The 
strong positive association with duration is frequently reported  (Goldberg, 1972; H.A. Kahn, 
1975), prevalence of retinopathy rose with age (Draper, 1968). 
Education is also a powerful and unique predictor of health outcomes.  Lower levels of 
education are associated with poor health, and higher levels of education are associated with 
better health (Al-khdoor, 2007). In China, no significant association between retinopathy and 
educational level was seen (Chen MS et al., 1992). In the UnitedStates of America, 
retinopathy was weakly associated with lower education level (Moniques, 2000). In Sweden, a 
study showed that the group in poor metabolic control was characterized by a lower education 
level (Dick larsson, 1999). 
 
In Egypt multivariate logistic regression analysis revealed that diabetic patients over 49 years 
of age, were more likely to develop chronic diabetic complications (M.El-Shazly et al., 2009). 
Poor glycemic control, hypertriglyceridemia, and longer duration of diabetes were 
independently associated with prevalent microalbuminuria and macroalbuminuria 
(BessieA.Young et al., 2005). Male gender has been associated with the development of 
nephropathy in diabetes in many studies. Gall et al., in a prospective observational study 
involving 176 patients with type-2 diabetes, found that males had a 2.6 times greater risk of 
developing incipient or overt nephropathy. In Mexico, female gender associated significantly 
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with reduced nephropathy (Dante Amato, 2005). Male sex (OR 2.6 (95% CI 1.2-5.4); P<0.02) 
(Mari-Anne gall, 1997). In Canada, female sex appears to be protective (Amrit et al., 2007). 
 
In UK, a cross-sectional multicentre study was performed to establish the prevalence of 
peripheral neuropathy in Type 2 (non-insulin-dependent) diabetic patients it was 32.1 % . It 
increases with both age and duration of diabetes, until it is present in more than 50% of Type 2 
diabetic patients aged over 60 years. (Young et al., 1992) 
The prevalence of diabetic neuropathy across Europe was 28 %.Significant correlations were 
observed between the presence of diabetic peripheral neuropathy with age (p < 0.05), duration 
of diabetes (P< 0.001). (Tesfaye et al., 1996). Age significantly 
independent predictors for first foot ulceration (P 0.01). (Caroline et al., 1998) 
In Iran statistically significant relationships were found between neuropathy and age, gender, 
quality of diabetes control and duration of disease (P values in the order: 0.04, 0.04, < 0.001 
and 0.005). More attention must be paid to elderly male diabetic patients with poor diabetes 
control (Fargol Booya  et al., 2005). The presence of clinical neuropathy correlated with 
greater age, longer duration of IDDM, and male gender. The somatic and autonomic test 
results confirm the relationship between age, diabetes duration, and male gender and diabetic 
neuropathy. These results support an effect of age and gender on the development of diabetic 
complications (DCCT, 1988). In New York this study demonstrates that the males in the study 
population developed neuropathy earlier than did the females (Aaberg, 2008). 
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2.3 Summary: 
 
A critical point of care is patients' adherence to it. Adherence to glucose monitoring and 
medication regime varies between 60-80% in different studies. (WHO, 2003) Adherence to 
diet varies more, between 30-70%. Quality of care of diabetic patients can be influenced by 
health care system, practice organization and by patients themselves .( Lobo et al., 2003; 
Khunti , 1999) Health care system has its impact on how care for patients is organized, 
funded, how the medicines are reimbursed, how the educational materials are prepared and 
distributed etc. Practice organization  requires  adequate  practice  management,  for  example,  
by  adequate organization of medical practice by systematic delegation of health promotion 
activities to  the  ancillary  staff. Written  diabetes  protocols  and  the  degree  to which  the  
general practitioners  and  ancillary  staff  work  as  a  team  are  also  important,  as  these  
foster teamwork and provide a sense of direction. ( Lobo et al., 2003) Waiting time, list size, 
practice type and location, record-keeping are just a few of the practice organization factors 
important in quality of care. Background characteristics of general practitioners (GPs) and 
practices associated with diabetes guideline adherence may contribute substantially  to 
variations in  healthcare  delivery  and  are  associated  with  adherence  to  preventive  
guidelines. Quality improvement initiatives will be more efficient when we know which GPs 
or practices are most, or least, likely to comply with clinical prevention. ( Lobo et al., 2003) 
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Chapter three:   Theoretical and conceptual framework 
3.1 Introduction 
 
In this chapter we will discuss issues related to diabetes mellitus management definition. In 
addition, an overview of the study conceptual model used will also be presented.  
 
3.2 Diabetes mellitus complications  
 
According to WHO, the diabetes complications divided into tow groups; Acute and Chronic 
complications. 
 
1- Acute complications of diabetes Mellitus: 
 
a. Hypoglycemia 
 
Hypoglycemia in patients with diabetes mellitus is an abnormally low concentration of 
glucose in the blood caused by insufficient food intake, excessive exercise, or over dosage 
with oral hypoglycemic agents or insulin (WHO, 2006) 
 
b. Hyperglycemic crisis 
 
It is rare for people with type 2 diabetes mellitus to develop ketoacidosis. It is much more 
known for them to develop the hyperglycemic hyperosmolar state in the face of severe 
infection or other major undercurrent illness. They usually present with dehydration, 
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circulatory compromise and a change in mental state. Acidosis is uncommon, except when 
related to lactic acidosis due to hypo perfusion (WHO, 2006). 
 
c. Infections 
 
People with poorly controlled diabetes are more prone to develop bacterial (in particular 
anaerobic), mycobacterium and fungal infections. Diabetics are more prone to urinary tract 
infections after bladder instrumentation than non-diabetic individuals. Urinary tract infections 
may also result from obstruction or neutrogena bladder. Pyelitis and pyelonephritis aggravate 
diabetic nephropathy. Chronic painless infection may destroy a neuropathic and/or ischemic 
foot (WHO, 2006). 
 
2- Chronic complications of diabetes 
 
a. Atherosclerosis 
 
Atherosclerosis is the most common macro vascular complication of diabetes mellitus (WHO, 
2001; Ramachandran et al., 1999). It accounts for 75% of diabetes-related deaths, a figure two 
to three times higher than that in people without diabetes. In the Eastern Mediterranean 
Region, some studies have indicated that the occurrence of clinical events related to coronary 
artery disease is four times higher in patients with diabetes (Shera et al., 1995; Haider et al., 
1981). Coronary and cerebrovascular diseases are also two to three times more known and 
post-infarction mortality higher (WHO; 2006). 
 
These increase in atherosclerosis in diabetic individuals are seen in all populations, whether 
the general incidence of atherosclerosis is high or low. In developing and rural societies, 
changes in lifestyle to a pattern similar to that of more industrialized and urban societies are 
often associated with a general increase in atherosclerosis. Although the largest numbers of 
diabetic ischemic events occur in people with type 2 diabetes mellitus, the risk of 
atherosclerosis is also high in type 1 and may be manifested at a young age. One feature 
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unique to women with diabetes is the loss of protection from atherosclerosis prior to 
menopause. (WHO; 2006) 
Patients with diabetes have an approximately threefold risk for all cardiovascular diseases 
(Garcia et al., 1974; Stamler et al., 1993), and their relative risk of death from all causes is 
increased by 75% (Panzram, 1987; Walter et al. 1994). 
The morbidity and mortality associated with macro vascular events far outweigh the risks of 
micro vascular complications in older people with diabetes. In the United Kingdom 
Prospective Diabetes Study (UKPDS), 9% of type 2 diabetic patients developed micro 
vascular disease after 9 years of follow-up, compared to rates of 20% for macro vascular 
complications (Turner et al., 1996). In the United States, where diabetes is the fourth most 
common cause of death, atherosclerotic macro vascular disease accounts for as much as 75% 
of all mortality in type 2 diabetes (Geiss et al., 1995). 
A recent prospective study indicated that patients with type 2 diabetes without a history of 
prior heart attack have equal, if not greater, risks of myocardial infarction (MI) compared to 
those without diabetes who have had prior heart attacks (20.2% vs. 18.8% incidence of MI, 
respectively, over 7 years) (Haffner et al, 1998), These data suggest that older diabetic patients 
should be treated as aggressively for diabetes and cardiovascular risk factors as the secondary 
prevention efforts currently aimed at people with known cardiovascular disease. 
Recently, a published UKPDS data showed no negative effects of intensive therapy with 
sulfonylurea or insulin on macro vascular events (UKPDS 33, 1998). To the contrary, MI rates 
were lower with improved glycemic control (HbA1c 7.9% vs. 7.0%).The Diabetes Control and 
Complications Trial (DCCT) in type 1 diabetic patients also found lower macro vascular 
complications with improved glycemic control (HbA1c 9.0% vs. 7.0%) (DCCT, 1993). These 
trials clearly show a lack of adverse effects and suggest a benefit of improved glycemic 
control with sulfonylurea or insulin on macro vascular outcomes. 
Of note, metformin, an agent related to  less weight gain and fewer hypoglycemic attacks, did 
demonstrate statistically significant reductions in MI rates with improved glycemic control 
(HbA1c 8.0% vs. 7.4%) among overweight diabetic patients after 10 years of treatment (RR 
 35
0.61, 95% CI 0.41–0.89, P = 0.01) (UKPDS 34, 1998). It is possible that macrovascular 
benefits of improved glycemic control with sulfonylurea or insulin are partially offset by 
adverse effects of weight gain on lipids and blood pressure, 
Spread of hypertension in type 2 diabetic patients rises from 40% at age 45 to 60% by age 75, 
a factor that contributes significantly to both macro- and micro vascular disease complications 
(Vijan et al.; UKPDS 38, 1998). Therefore, screening for and aggressive treatment of 
hypertension are critical components of diabetes care. In most cases, therapy should be 
instituted if blood pressure (BP) exceeds 140/90 mmHg, and expert opinion suggests a 
treatment goal of BP <130/85 for patients with type 2 diabetes (JNCDETHBP, fifth Report, 
1993). 
Despite the association between hyperlipidemia and cardiovascular events declines with age, a 
significant association has been shown to continue into the eighth decade of life (Corti et al., 
1997). Further, primary prevention trials with older adults up to age 73 years and secondary 
prevention trials involving adults up to age 75 years clearly manifested that lowering 
cholesterol levels can significantly reduce cardiovascular event rates in older adults with and 
without diabetes (Downs et al., 1998; Sacks et al., 1996; Pyorala et al., 1997). 
Significantly elevated blood glucose following a meal is a very common problem in people 
with diabetes. A recent study showed that over 84% of people with type 2 diabetes experience 
significantly elevated post-meal blood glucose (Bonora et al., 2001). This is a major concern 
because of the link between elevated post-meal glucose and diabetes complications, 
particularly cardiovascular disease (Ceriello et al., 2005) – the leading cause of death in people 
with diabetes (Niskanen et al., 1998). 
Many studies have demonstrated that lowering HbA1c levels reduces the development or 
progression of diabetes complications (DCCT, 1995; UKPDS 33, 1998). However, studies 
have also shown that elevated post-meal glucose is an independent risk factor for 
cardiovascular disease even when HbA1c is within the normal, non-diabetes range (Ceriello et 
al., 2005). 
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Among 14 multicenter heart failure treatment trials or data registries that indicated diabetes as 
a co morbidity of the study population, diabetes was present in 7974 of 32 649 patients, 
representing an overall spread of 24%. The spread of diabetes ranged from 14% to 28% in 
these studies. It is worth mentioning that many of the heart failure multicenter trials published 
in the last 5 years did not indicate the spread of diabetes. 
Only a few trials have indicated the outcome of patients with diabetes relative to the non 
diabetic population (Shindler et al., 1996; Gustafsson et al., 1999; MERIT-HF Study Group, 
1999; Jimenez-Navarro et al., 1999). Even fewer report the results of the medical intervention 
separately in the patients with diabetes. The available data do uniformly demonstrate that 
persons with diabetes and heart failure represent a very-high-risk group with a substantially 
worse prognosis than those without diabetes. Data from the Survival and Ventricular 
Enlargement trial (Jimenez-Navarro et al., 1999) also demonstrate a significant increase in 
mortality in insulin-dependent patients compared with non–insulin-dependent patients (41% 
versus 26%, P<0.001).  
In summary, diabetes is a main risk factor for the development of heart failure, both systolic 
and diastolic. Moreover, for patients with heart failure, diabetes represents a major risk factor 
for cardiac complications and death. Intensive management of diabetes to reach a glycemic 
control (HbA1c within normal range) is very important to prevent or postpone diabetes cardiac 
complications. 
        b. Acute Myocardial Infarction  
In-hospital and long-term mortality rates after acute myocardial infarction (AMI) are twice as 
high among individuals with diabetes as among those without diabetes (Jacoby et al., 1992; 
Arnoson et al., 1997). Approximately 30% of hospitalized patients with AMI will have 
diabetes, compared with a diabetes prevalence of 6% to 8% in the general population. Diabetes 
is also a major risk factor for adverse outcomes in patients with unstable angina.  
Persons with diabetes, particularly in the setting of autonomic neuropathy, have impaired 
angina recognition and may not consider shortness of breath, nausea, vomiting, unexplained 
fatigue or diaphoresis, or disturbances of glycemic control as symptoms of cardiac ischemia 
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(Nesto et al., 1988). Atypical symptoms could also prevent recognition of AMI by caregivers 
and be a cause of treatment delay. Too often, AMI is the first clinical expression of cardiac 
heart disease (CHD) in the patient with diabetes, who may have experienced prior, unheeded 
symptoms of cardiac ischemia. Furthermore, one should not assume that the absence of angina 
in the post–myocardial infarction (MI) patient is a reliable index of CHD stability. Surveillance 
with noninvasive testing may be of benefit in some persons with diabetes (Nesto et al., 1999). 
Factors specific to diabetes may not only increase the risk of MI (Silva et al., 1998) but also 
adversely affect its outcome. Autonomic nervous system (ANS) dysfunction results in 
sympatho-vagal imbalance and may lower the threshold for life-threatening arrhythmia and 
increase the risk of hemodynamic instability. Up to 50% of individuals with type 2 diabetes 
(with disease duration >10 years) have ANS dysfunction manifested as impaired heart rate 
variability. Fibrinogen levels may be elevated in patients with diabetes, particularly in the 
setting of proteinuria or poor glycemic control. Elevated levels of plasminogen activator 
inhibitor-1 indicate impaired fibrinolysis, and diabetic platelets are more agreeable than no 
diabetic platelets. Such diabetes-related alterations may increase the risk of thrombosis at the 
site of plaque disruption and possibly increase the risk of reinfarction after thrombolytic 
therapy. The diabetic ventricle is more prone to maladaptive remodeling, which increases the 
risk of heart failure and cardiogenic shock. The status of the noninfarct zone, an important 
determinant of the remodeling process, may be affected by silent infarction, ANS-related 
diastolic or systolic dysfunction, diabetic or hypertensive cardiomyopathy, impaired micro 
vascular perfusion, and more extensive epicedial CHD (Nesto et al., 2001). 
c. Retinopathy 
 
Diabetic retinopathy is the leading cause of blindness and visual impairment in adults in many 
societies. Almost, everyone with younger-onset type 1 diabetes will develop diabetic 
retinopathy after 20 years of the disease. At some time, during their lives, 75% will develop 
the most severe stage, proliferate diabetic retinopathy. In older-onset type 2 diabetes mellitus, 
almost 60% will develop diabetic retinopathy and at some time during their lives about 10% 
will develop proliferate retinopathy and about 2% become blind. (WHO; 2006) 
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The increase of diabetic retinopathy and nephropathy mainly occurs when the fasting glucose 
is 7.8 mmol/L or greater (Jarret , Keen, 1976; CDAEC, 1997). However, fasting glucose levels 
of greater than 6.0 mmol/ L are related to  a higher incidence of cardiovascular disease (Jarret , 
Keen, 1976; Pettitt et al., 1980). This information led the Canadian and American Diabetes 
Associations to develop new, lower criteria for the diagnosis of diabetes (CDAEC, 1997; 
ECDCDM, 1997).  
 
 
It is concluded based on studies that diabetes is the most frequent cause of blindness and renal 
failure in the United States, and the micro vascular complications of diabetes rise with 
increasing duration of disease and worsening glycemic control (Klein et al., 1996; Vijan et al., 
1997). Although improving glycemic control clearly reduces micro vascular complications, it 
is important to recognize that the incidence of severe or end-stage micro vascular 
complications is much lower for type 2 diabetic patients than for type 1 patients, presumably 
because of their older age of onset and increased competing risks for death (Vijan et al., 1997). 
As previously outlined, the absolute benefits of developed glycemic control on micro vascular 
complications appear to be greatest when moving from poor control (HbA1c >11%) to 
moderate-to-good glycemic control (HbA1c 8–9%) (Vijan et al., 1997).So, as demonstrated in 
the UKPDS trials, further reductions in HbA1c below 8% clearly further reduce micro vascular 
complications, but because of the lower overall complication rates at these levels of HbA1c, 
the marginal number of events prevented is smaller (UKPDS 33, 1998; UKPDS 34, 1998). 
Thus, although the UKPDS trial achieved a 25% risk reduction in aggregate micro vascular 
endpoints (much of which was due to a reduction in the need for retinal photocoagulation) in 
association with glycemic control of HbA1c of 7.9 versus 7.0%, the absolute risk reduction was 
2.8 events per 1,000 patient-years (number needed to treat = 35 patients for 10 years to prevent 
one micro vascular event) (UKPDS 33, 1998). 
d. Diabetic nephropathy 
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Diabetic nephropathy (kidney disease) is the most common reason  of renal failure in many 
Eastern Mediterranean Region countries (Al-Khader, 2001; Al-Zaid et al., 1994) and a major 
reason of premature death in diabetic patients. Diabetic patients are 17 times as prone to 
kidney disease as non-diabetic people. It is a multistage condition that requires several years to 
become clinically overt. (WHO; 2006)  
 
While the cumulative risk of diabetic nephropathy in type 1 diabetes mellitus is about 30%–
40% after 25–30 years, it varies considerably in type 2 diabetes mellitus depending on ethnic 
origin, and can be as low as 15% in some groups of European origin after 25 years of disease. 
(WHO; 2006) 
In the United States, diabetes is the leading reason of end-stage renal disease (ESRD), which 
includes the need for kidney dialysis or transplantation. Unfortunately, the 5-year survival rate 
of ESRD patients with diabetes is only 20%, largely because of a very high incidence of 
cardiovascular disease (CVD) (Patsan et al., 1998; Levey et al., 1998). The causes for this 
excess CVD are inadequately explored, but hypertension, dyslipidemia, and anemia probably 
play important roles. A major goal, therefore, should be early recognition of kidney damage so 
that measures can be undertaken to prevent progressive loss of renal function. 
The clinical course of nephropathy in both type 1 and type 2 diabetes is similar, consisting of 
an initial period of supranormal glomerular filtration rate lasting 10 or more years followed by 
5 years with microalbuminuriaand then macroalbuminuria and loss of glomerular filtration rate 
(Parving et al., 2000; Nelson et al., 1996; Myers et al., 1991). Microalbuminuria is found in 
both types of diabetes and identifies the patients destined to develop progressive kidney 
damage. For screening, yearly testing for albuminuria is required (at the onset of type 2 
diabetes and after 7 years of type 1 diabetes). Regular evaluations of glucose control and 
monitoring of the rate of loss of renal function are indicated for each patient (ADA, 1992). For 
the older patient with type 2 diabetes, the possibility of coexisting kidney diseases should be 
evaluated. Numerous reports emphasize the prominent position microalbuminuria holds as an 
identifier of incipient renal insufficiency. It also predicts CVD. To reach the largest number of 
persons with diabetes (especially in the setting of primary care), the simple spot, early-
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morning-urine sample for determining the microalbumin-to-creatinine ratio should be 
encouraged as the first-line test.  
In addition to serving as an identifying marker for the presence of kidney disease, it is possible 
that proteinuria plays a role in the pathogenesis of kidney damage. This is controversial, 
because the degree of proteinuria may simply reflect the severity of kidney damage. 
Regardless, successful treatment of hypertension reduces the degree of proteinuria and 
generally results in reduced kidney damage (Ruggennti et al., 1998; Lewis et al., 1993).  
It is common that hypertension is known in patients with diabetic nephropathy. Angiotensin-
converting enzyme inhibitors (ACEIs) are widely recommended for controlling blood pressure 
in any hypertensive patient with kidney disease because proteinuria responds well to ACEIs 
even though blood pressure is not always controlled (Bakris et al., 2000; Lewis et al., 1993). In 
the Heart Outcomes Prevention Evaluation study, ACEIs also was found to have significant 
beneficial effects on CVD and the progression of kidney damage in patients with diabetes 
despite producing only a modest decrease in blood pressure (HOPE study and MICRO-HOPE 
sub study, 2000; Yusuf et al., 2000). The therapeutic goal should be to achieve a blood 
pressure <130/85 mm Hg and to reduce proteinuria by restricting dietary salt and adding 
ACEIs or other blood-pressure lowering drugs (Bakri et al., 2000).  
These considerations lead to guidelines for the therapy of patients with diabetic nephropathy. 
First, treatment should include strict control of blood glucose to HbA1c <7.0%, as 
recommended after successful trials in controlling the progression of nephropathy in patients 
with both types of diabetes (ADA, 1999).Patients who have progressive renal insufficiency 
despite these measures or who develop increasing macroalbuminuria should be referred to a 
nephrologist. Blood pressure should be strictly controlled (Bakris et al., 2000). In addition to 
dietary salt restriction, initial therapy should include an ACEI (whether differences in the 
efficacy of ACEIs on tissue angiotensin converting enzyme are critical is unsettled).  Dietary 
protein should be limited in patients who have progressive renal insufficiency to reduce the 
accumulation of nitrogen-containing waste products and to take advantage of the 
antiproteinuric effects of dietary protein restriction and its beneficial influence on progression 
of renal insufficiency. 
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e. Diabetic neuropathy 
 
Diabetic neuropathy can be defined as a nerve disorder that may be clinically evident or sub-
clinical, and which occurs in diabetes mellitus in the absence of other evident etiology. 
Manifestations may occur in both the peripheral and the autonomic nervous systems (Morgan 
et al., 2000). 
Diabetic neuropathy affects over 50% of patients who have had type 2 diabetes for more than 
15 years, and, as with other microvascular complications, improved glycemic control appears 
to reduce the incidence of neuropathy (Klein et al., 1996; UKPDS 33, 1998; Vijan et al., 
1997). Similar risk reductions in micro vascular risks were observed with intensive glycemic 
control efforts (HbA1c 8.0 vs. 7.4% ) (UKPDS 34, 1998). 
f. Neuropathic foot 
 
It has become familiar that more and more hospital beds are occupied by diabetic patients with 
foot problems than by those with all other consequences of diabetes. The problem of limb 
amputation in people with diabetes is of such a serious and global nature that a special section 
giving guidelines for prevention was felt to be warranted in this publication (WHO, 1994; 
Chobanian et al., 2003) 
 
Diabetes is associated with increased frequency of lower-limb amputations, many of which are 
potentially preventable. Epidemiological data suggest that >50% of the 120000 non-traumatic 
lower-limb amputations in the United States of America are associated with diabetes and that 
the overall risk of amputation in people with diabetes is 15 times that in people without 
diabetes (WHO, 2006). 
 
Evidence based on analytical studies confirmed that improved glucose control delays the onset 
of complications in type 2 diabetes. In a cohort study of 114 patients followed for 5 years, the 
incidence of progression of retinopathy increased linearly as a function of the HbA1C level: 
2% in those with HbA1C less than 0.070 and 62% in those with HbA1C greater than 0.090 
(Morisaki et al.,1994). In a randomized secondary prevention intervention trial of diabetic 
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patients (majority type 2 diabetes) who had suffered an myocardial infarction (MI), those who 
had intensive insulin treatment had an absolute reduction of mortality of 11% (44% vs 33%) 
compared to the regular therapy group after 3.4 years of follow-up (Malmberg et al., 1997). In 
a randomized trial of 110 patients with type 2 diabetes, those who received multiple insulin 
injections had an absolute reduction in the progression of retinopathy of 24%, and of 
nephropathy of 20%, after 6 years of follow-up, when compared with a conventional therapy 
group (Okhubo et al., 1995). Preliminary results of a large prospective randomized trial, that is 
examining the relationship of glucose control to complications of diabetes in type 2 diabetics, 
show an improvement in HbA1C levels in patients who received treatment, whether with 
sulfonylurea, metformin or insulin (UKPDS, 1998).  
Recent findings from the UKPDS trials have demonstrated the effectiveness of tight glucose 
control on slowing the progression of microvascular and macrovascular complications in 
newly diagnosed type 2 diabetic patients (UKPDS 33, 1998). 
In Palestine, in the West Bank, the reported new cases in the governmental primary health 
care clinics (PHC) diabetic clinics in the West Bank was  2,214 cases in 2007, in Jenin district, 
in particular, was 306 cases.  The same report showed the following distribution of the 
reported visits to government PHC diabetic clinic, by complications:   
 
Table 3.1: Distribution of reported visits of diabetes patients to government PHC centers 
 
Nephropathy- 5,277 
Retinopathy- 14,248 
Neuropathy- 21,816 
Cerebro-vascular diseases-  2,817 
Cardio-vascular disease-  17,910 
Diabetic foot- 4,655 
Other-  8,898 
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Number of visits of type 2 diabetic patients to diabetes clinic in Jenin district for the year 2008 
as the following, by type of management: (Jenin, 2008) 
 
Table 3.2: Distribution of diabetes patients by management regime. 
 
Diet only 171 
Tablets 17573 
Combined therapy 562 
Insulin only 3814 
 
3.2 Management of diabetes mellitus definition 
 
Based on  literature, “Disease Management” according to diabetes in the guide for case 
managers was "a strategy that is usually used by managed care organization or integrated 
delivered systems to address chronic illness such as diabetes mellitus, heart failure, asthma, 
and many others" (Diane L. Huber; 2005).  Accordingly, disease management programs were 
shown to have various forms with certain core components that are invariably present in any 
of these programs.   These components start with a mechanism to identify people with the 
disease in question from a database of the health care system. After identifying the patients, 
clinical care guidelines were specified to deal with those patients. The professionals and 
patients agree on the intervention methodology and those patients are monitored to have 
certain expected outcomes as result of such program. (Diane L. Huber; 2005) 
 
Diabetes management was also defined by Couch (Couch, 1998).  He observed that it is 
“Knowledge-based process intended to improve continuously the value of health care delivery 
from the perspectives of those who receive, purchase, provide, supply and evaluate it (Couch, 
1998). Couch (1998) outlined the following seven components of a model of Disease 
management: 
1- knowledge-base creation (medical and stakeholder requirements) 
2- Goal setting / Disease management team development 
3- Risk stratification and intervention planning (design and development) 
4- Communication of intervention 
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5- Behavior modification  
6- Clinical process / environment redesign 
7- Outcomes measurement and management 
 
The Disease Management Association of America (DMAA) has defined Diabetes 
Management, as follows: “A System of coordinated health Care interventions and 
communications for populations with conditions in which patient self-care efforts are 
significant. (DMAA, 2004) 
…. “Supports the physician or practitioner / patient relationship and plan of care, confirms 
prevention of exacerbation and complications utilizing evidence-based practice guidelines and 
patient empowerment strategies, and evaluates clinical, humanistic and economic outcomes on 
an ongoing basis with the goal of improving overall health” (DMAA, 2004) 
 
The Team methodology in managing diabetes is a crucial aspect. The disease should be 
managed by the patient, the physician, the nurse, the health care system and the socio-cultural 
environment as a whole. Defects in any of these components would lead to less than optimal 
results in the fight against diabetes. (Diane L. Huber; 2005) 
 
Diabetes mellitus should not be managed based on symptoms alone. Glycemic goals are based 
on evidence of what glucose levels constitute a risk for developing complications. It is, 
however, inappropriate to aggressively approach target glucose levels when it may adversely 
affect the patient. Treatment goals must, therefore, be individualized. (WHO; 2006) 
 
Disease management of diabetes- as prescribed in Task Force on Community Preventive 
Services (2002) - in the clinical setting is an organized, proactive, multi-component approach 
to healthcare delivery for all members of a population with diabetes or for a subpopulation 
with specific health risk factors. It embraces all aspects of the delivery system. Care is focused 
on, and integrated across, the entire spectrum of the disease and its complications as well as 
the prevention of co morbid conditions. The goal is to improve short- and long-term health or 
economic outcomes, or both, in the entire population with diabetes. The essential components 
of disease management are (1) identification of individuals or populations with diabetes (or a 
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subset with certain risk factors); (2) use of guidelines or performance standards to manage 
those identified; (3) information systems to track and monitor interventions and patient-, 
practice-, or population-based outcomes; and (4) measurement and management of patient and 
population outcomes. Other interventions may be incorporated into disease management 
interventions, and these interventions can be focused on (1) the healthcare system (e.g., 
practice redesign, electronic information systems, changes in models of care), (2) the provider 
(e.g., reminders, education, feedback, decision support), or (3) the patient or population (e.g., 
patient-centered care strategies, DSME, reminders, feedback, telephone call outreach). (Task 
Force on Community Preventive Services, 2002)  
 
Disease management is strongly recommended by the Task Force based on strong evidence of 
its effectiveness in improving glycemic control, provider monitoring of glycated hemoglobin 
(GHb), and screening for diabetic retinopathy. Sufficient evidence is also available of its 
effectiveness in improving provider screening of the lower extremities for neuropathy and 
vascular changes, urine screening for protein, and monitoring of lipid concentrations. This 
recommendation is applicable to adults with diabetes in the settings of managed care 
organizations and community clinics in the United States and Europe. Although a number of 
other important health outcomes were examined, including blood pressure and lipid 
concentrations, data were in-sufficient to make recommendations based on these outcomes. 
(Task Force on Community Preventive Services, 2002) 
 
After this revision of literature about the definition of Diabetes Management, we can conclude 
our understanding to that term as, the good management of diabetes will lead to glycemic 
control to avoid or delay the complications of diabetes. We can achieve a good management 
by integration of several factors: good self management, physicians’ compliance with diabetes 
guideline, personal characteristics, patient compliance with the management plan and good 
health care system for diabetes.  
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3.4 Guidelines for diabetes management used in Palestine 
 
The protocols description and difference between the MOH and UNRWA used 
protocols: 
 
The MOH guide, i.e. the “quick guide for the management and care of diabetes mellitus”, 
(MOH; 2008) and the UNRWA “technical instructions and management protocols on 
prevention and control of Noncommunicable diseases” (UNRWA; 2004).  The following 
issues are summarized. Both protocols are, in somehow, are built on the WHO guidelines for 
year 2006, with some differences between them and some times between them and WHO 
guidelines. Both protocols of MOH and UNRWA adopted the WHO recommendations about 
patient educations and advice on diet and the types of oral antidiabetic agent and combined 
therapy with insulin. 
The WHO adopted the following diagnostic values for diabetes mellitus: 
 
Diabetes mellitus: fasting ≥126 mg/dl; 2-hour post-75 g  ≥200 
 
IGT (Impaired Glucose Tolerance): Fasting (if measured) and <126; 2-hour post-75 g 
glucose load  ≥140 and <200 
 
IFG (Impaired Fasting Glucose): fasting and (if measured)  ≥100 and <126; 2-hour post-75 
g glucose load <140 
 
Both protocols, the MOH and the UNRWA use the WHO definitions and classifications for 
diabetes and diabetes types. UNRWA and MOH agree with these values, except IFG, 
UNRWA considered it between 110 and 126 mg/dl. 
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A- The screening program 
 
Screening of asymptomatic adults for type 2 diabetes mellitus by WHO should be done on the 
following groups: 
• individuals aged ≥35 years; 
• overweight (body mass index ≥  25 kg/m2); 
• first-degree relative with type 2 diabetes; 
• women with previous history of gestational diabetes mellitus or who delivered a 
      baby weighing > 4 kg; 
• individuals diagnosed previously with IFG or IGT; 
• hypertensive individuals with blood pressure >140/90 mmHg; 
• HDL cholesterol level  ≤0.9 mmol/L (35 mg/dL) and/or triglyceride level >2.82 
      mmol/L (250 mg/dL); 
• other medical conditions associated with insulin resistance like polycystic ovarian 
      syndrome or acanthosis nigricans; 
• History of vascular disease. 
 
MOH adopted all these risk groups but regarding the individual age, they consider it over 40 
years old. However, the UNRWA does not consider the age as an important factor, so they did 
not mention it, they emphasize on smoking and sedentary life style in addition to the weight, 
family history and other vascular diseases. 
 
B- Therapy 
Both MOH and UNRWA adopted the WHO objectives of therapy: 
• To eliminate symptoms of hyperglycemia. 
• To achieve optimum control. 
• To reduce or eliminate microvascular and macrovascular complications of diabetes 
mellitus. 
• To treat associated disorders. 
• To allow the patient to achieve as normal a lifestyle as possible. 
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MOH quick guide adopted the WHO marker for diabetes mellitus control are blood glucose 
and HbA1c, by WHO, the patient must repeat it quarterly but by quick guide every sex 
months.  However, the UNRWA adopted just blood glucose as a marker for diabetes control. 
 
C) Components of the clinic visit  
 
World health organization (WHO), recommend for diabetes health care providers a lot of 
services which the patient should receive when attending diabetes clinic. Physicians should 
ask diabetes patients about their medical history (symptoms, home blood glucose 
monitoring,… etc), visit must include a patients’ physical examination ( weight, BP, 
fundoscopy, … etc), and follow up diagnostic studies should be performed (FBA, RBS, 
HbA1c,….etc) (see annex 6). 
 
Quick guide of MOH just mention the medical history and full physical examination without 
details, but according to the laboratory test it provides us with which test should the patient 
perform in diabetic clinic: 
 
• Fasting plasma glucose. 
• HbA1c Q 3-6 months. 
• Fasting lipid profile (14 hours). 
• Ophthalmologic examination. 
• Serum Creatinin in adults; and in children if proteinuria is present. 
• Urinalysis: glucose, ketones, protein, sediment. 
• Test for microalbuminuria (quantitative). 
• Urine culture if sediment is abnormal or symptoms are present. 
• Thyroid-stimulating hormone (TSH) in all diabetes type 1 patients. 
• Electrocardiogram (ECG) in adults. 
 
Technical instructions of UNRWA adopted the questions which the physician should ask the 
patient and adopted all elements of physical examination and added for them, the sexual 
maturity staging, thyroid palpation, hand/nail appearance and skin examination. 
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MOH protocol adopted the recommendation of WHO regarding repeat all lab tests in each 
visit, but UNRWA in this issue has own system. 
 
In initial assessment, the patients do the following lab tests: FBG and after 2 hours blood 
glucose, total cholesterol, HDL, LDL, Triglyceride and Creatinin. 
 
In annual assessment the patients repeat, Creatinin, total cholesterol, FBG. The routine follow-
up visit (quarterly) include, blood sugar after 2 hours of eating, body mass index, blood 
pressure measurement, foot examination, and fundus examination. 
 
Follow up criteria at the MOH at the UNRWA, and the private sector: 
 
According to interviews with key persons at the MOH, there are certain procedures that are 
applied at the MOH-PHC for diabetic patients. There is no screening program for insured 
patients to check for their blood sugar.  Most newly discovered cases happened accidentally, 
or when the patient starts complaining about symptoms related to diabetes.  Each newly 
discovered case is referred to the central governmental clinic.  At this clinic, the GP takes the 
full medical history of the patient, and carried out a full physical examination.  Each patient 
has to perform certain tests to establish the diagnosis, determine the degree of glycemic 
control and define associated complications and risk factors.  After the completion of this 
stage, patients are referred to a nutritionist to have a consultation for their diet.    For follow 
up, according to the MOH policy, patients should come after 6 months for reassessment of 
their diabetic conditions, unless any sign of diabetes complications appear. Therefore, patients 
visit the PHC monthly only to get their regular medications and can see their GP (personal 
interview, 2009), (Abdel Hafez, 2009). 
 
At the UNRWA, according to personal interviews with general practitioners and reviewing the 
technical instruction, the follow up system includes a screening program for risk group clients. 
The new discovered cases in and out UNRWA clinics undergo the lab tests which include 
FBS, kidney function and lipid profile to establish the diagnosis and to determine other 
disorders. Based on the lab results the GP determine the treatment plan for the patient. After 
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one month the patient attend the clinic for RBS, if RBS over 180 mg/dl (uncontrolled), the 
doctor correct the treatment and require from him to return back to clinic after one month for 
another RBS. If RBS below 180 mg/dl, the GP should give the patient medications enough for 
three months.  
 
Follow up for the diabetic patients in private sector is performing without systems and 
regulations, from the interviews conducted with some internist specialists and GPs working in 
own private clinics  and working in private hospitals and private medical centers, we found 
that, each physician exams the diabetic patients who visit his clinic and order for them 
laboratory analysis based on his own knowledge which he get from various resources, from 
university, reading new article or from workshop, but not based on any protocol or guidelines. 
Patients attend private clinics just when they get sick tired from diabetes symptoms or 
complications. Almost of these diabetic patients who attend private clinics at the same time 
they attend the governmental clinics and/or UNRWA clinics for medications and for free lab 
tests. Private physicians do not have in their clinics files for their patients, but they give the 
patients visit card, where the write the diagnosis and results of lab tests.  The patients do not 
visit the private clinics for follow, because they must to pay for this service. The specialist in 
the private sector can change the medication regime for the patients and refer him from tablet 
to insulin therapy, by writing these changes in prescription sheet, and the patient go with this 
sheet to MOH or UNRWA clinics and they adopt this sheet and add it to his file and start to 
give the patients medicines according the specialist prescription. 
 
The following table, table 3.3, summarizes the similarities and differences between the used 
guidelines.  
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Table 3.3: similarities and differences in the used protocols 
 
WHO MOH 
Quick Guide 
UNRWA 
Technical instructions 
Medical history 
-Symptoms of hyperglycemia or hypoglycemia 
-Results of prior HbA1c and -home blood glucose records 
-Meal patterns including frequency and content, and any change in 
weight 
-Lifestyle and psychosocial elements  
-Any acute complications such as infection, hypoglycemia or 
ketoacidosis 
-Any chronic complications related to vision, kidney, nerve, or the 
cardiovascular system 
-Any associated cardiovascular risk factors such as a positive 
family history, hypertension, dyslipidaemia 
-Review of all medications; ask if the patient is taking aspirin 
Take a medical history (without 
details) 
Frequency, causes and severity of 
hypoglycemia or hyperglycemia 
Problems in compliance with 
treatment regimens 
Life style changes 
Symptoms suggesting development 
of complications of diabetes 
Other medical illnesses 
Current medications 
Physical examinations 
-Height and weight 
-Vital signs, including blood pressure supine and sitting 
-Fundoscopic examination, looking for any signs of retinopathy 
-Oral examination, including gums 
-Cardiovascular including evaluation for pulses and bruits 
-Abdominal exam, assess liver size 
-Foot examination, for deformities  
-Neurological examination: light, touch, vibration sense, reflexes, 
motor strength. 
Full physical examination WHO and the sexual maturity 
staging, thyroid palpation, hand/nail 
appearance and skin examination. 
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Table 3 continues 
WHO MOH 
Quick Guide 
UNRWA 
Technical instructions 
Diagnostic Criteria 
Diabetes mellitus 
 fasting ≥126 
 2-hour post-75 g  ≥200 
IGT (Impaired Glucose Tolerance) 
 Fasting (if measured) and <126 
 2-hour post-75 g glucose load  ≥140 and <200 
IFG (Impaired Fasting Glucose) 
fasting and (if measured) 
  ≥100 and <126  
 2-hour post-75 g glucose load <140 
 
WHO 
 
WHO, except IFG, considered it between 
110 and 126 
Repeating laboratory testing each visit 
-Fasting and 2-hour postprandial glucose, if feasible 
-Quarterly HbA1c  
-Yearly chemistry panel, fasting lipid profile, urine 
analysis (including microscopy and urine 
Microalbumin screening) 
-Thyroid stimulating hormone for type 1 and for type 
2, as indicated 
-ECG in adults at baseline, and then as clinically 
indicated 
 
provide us with tests, which should be 
done in initial visit: 
-Fasting plasma glucose.  
-HbA1c Q 3-6 months. 
-Fasting lipid profile (14 hours). 
-Ophthalmologic examination. 
-Serum Creatinin in adults; and in 
children if proteinuria is present. 
-Urinalysis: glucose, ketones, protein, 
sediment.  
-Test for microalbuminuria (quantitative).  
-Urine culture if sediment is abnormal or 
symptoms are present. 
-Thyroid-stimulating hormone (TSH) in 
all type 1 patients. 
-Electrocardiogram (ECG) in adults. 
 
in initial assessment: 
FPG and after 2 hours blood glucose, total 
cholesterol, HDL, LDL, Triglyceride and 
Creatinin 
In annual assessment the patients repeat, 
Creatinin, total cholesterol, FBG. 
The routine follow-up visit (quarterly) 
include, blood sugar after 2 hours of 
eating, body mass index, blood pressure 
measurement, foot examination, and 
fundus examination. 
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Table 3 continues 
WHO MOH 
Quick Guide 
UNRWA 
Technical instructions 
Marker for diabetes mellitus control 
Blood Glucose 
HbA1c Quarterly 
 
Blood Glucose 
HbA1c every six months 
 
Blood Glucose level 
Objective of therapy 
-to eliminate symptoms of hyperglycemia; 
-to achieve optimum control; 
-to reduce or eliminate microvascular and 
macrovascular complications of diabetes 
mellitus; 
-to treat associated disorders; 
-to allow the patient to achieve as normal a 
lifestyle as possible. 
WHO WHO 
Referral to specialists 
-diabetes educator, to evaluate patient’s ability 
to perform self-monitoring of  
blood glucose and his/her ability to interpret 
the data 
− dietician 
− foot-care specialist 
−ophthalmologist for annual retinal screening, 
or more often as indicated 
−nephrologists, neurologist, and cardiologist, if 
needed. 
 
Referral criteria of patients with diabetes to central 
diabetic clinic 
-Uncertain classification of diabetes e.g. diabetes 
associated with endocrinopathy such as acromegaly, 
Cushing’s syndrome or genetic defect of beta-cell 
function. 
- Type 1 diabetes patients.  
-Patients with frequent hypoglycemia, 
hyperglycemia or HbA1c greater than glycemic  
control after  
a good trial of control according to the guidelines..  
- Plan of pregnancy (diabetic women) and 
gestational diabetes. 
-Multiple severe complication of diabetes. 
-Patients incompliance. 
- Frequent emergency room or hospital admissions. 
- Family problems or psychiatric problems 
interfering with treatment 
In specific situation: 
-Diabetic women planning to have a 
child 
-Diabetic mothers during pregnancy 
for obstetric advice 
-Early ocular, cardiovascular or renal 
complications 
-Recurrent episodes of hyper-or 
hypoglycemia 
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Table 3 continues 
 
WHO MOH 
Quick Guide 
UNRWA 
Technical instructions 
Multidisciplinary team: 
- physician  
- Nurse 
- Dietician 
- Chiropodist 
- Health educator 
WHO, except Chiropodist GP and nurse 
Control criteria: 
Plasma values: 
 
Pre-meal glucose, mg/dL 90–130       
Bedtime glucose,mg/dL110–150   
 
HbA1c   <7.0 
WHO plus: 
Post-prandial plasma glucose      140-180 mg/dl 
Lipids≥ 40 mg/dl  ( Men ) 
 
 HD≥50 mg/ dl ( women ) 
LDL < 100 mg/dl 
Triglycerides < 150 mg/dl 
Blood pressure<130/80  mmHg 
Post-prandial plasma glucose ≤180 
Fasting plasma glucose ≤126 
Total serum cholesterol < 250 
Blood pressure < 140/90 
Pharmacological therapy: 
Oral hypoglycemic agents groups: 
-Insulin secretagogues  
Sulfonylurea 
-Insulin sensitizers 
-Alpha-Glycosidase 
Inhibitors 
 
WHO WHO, except Alpha-Glucosidase 
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3.5 Study conceptual framework 
 
According to the literature review and study objectives, we developed this study 
conceptual framework.  The above definitions, review for guidelines, factors affecting 
diabetes complications at the personal and system level has been discussed.   Each group 
will be discussed later on whom it will of great importance in managing and controlling 
diabetes complication initiation and progress.  
 
 
 
Figure 3.1: Study conceptual Frame Work 
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3.6 Summary: 
 
Disease Management is a strategy that is usually used by management care organization or 
integrated delivered systems to address chronic illness such as diabetes mellitus. 
Accordingly, disease management programs were shown to have various forms with 
certain core components that are invariably present in any of these programs.   
 
So, disease management is strongly recommended by several health care associations 
based on strong evidence of its effectiveness in improving glycemic control, provider 
monitoring of glycated hemoglobin (GHb), and screening for diabetic retinopathy. 
Sufficient evidence is also available of its effectiveness in improving provider screening of 
the lower extremities for neuropathy and vascular changes, urine screening for protein, and 
monitoring of lipid concentrations. 
 
In Palestine, to improve  the quality of  the care of diabetic patients,  Ministry of Health 
and UNRWA  has developed a guideline for management of  type 2 diabetes. The MOH 
guide, i.e. the “quick guide for the management and care of diabetes mellitus”, (MOH; 
2008) and the UNRWA “technical instructions and management protocols on prevention 
and control of Noncommunicable diseases” (UNRWA; 2004). Both protocols are, in 
somehow, are built on the WHO guidelines for year 2006, with some differences between 
them and some times between them and WHO guidelines. So, our conceptual framework 
includes socio demographic characteristics, follow up at the patients’ personal level, health 
care system follow up and physicians compliance with guidelines, which effect the 
diabetes' complications. 
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Chapter four:  Study methodology 
4.1 Introduction 
 
This study focuses on management of type 2 diabetic patients in Jenin and Toubas districts.  
In this chapter the research methodology will be presented.  The study area, study 
population, study design, study tools, and the sampling method are described.  
 
4.2 Socio-demographic and geographic area description 
 
Jenin governorate lies in the northern part of the West Bank, in the central part of Palestine 
(Jenin map, see annex (7)). It is a regional center due to its proximity to the Israeli, 
Jordanian, Lebanese and Syrian borders. It is also a well-known stop-over for pilgrims to 
Nazareth and Jerusalem. The area of the Jenin governorate measures 1,059,752 dunums, 13 
municipalities, 68 local councils and 3 project committees.(Ministry of Interior, 2008) 
 
Demographic trends in Jenin district, as is the case of other districts in the west bank, have 
been closely related to the political situation. According to the population statistics 
estimated by the Palestinian Center Bureau of Statistics (PCBS), the end total population of 
2007 was around 256,619 individuals, which includes one refugee camp population. 
Approximately 4% (10176) lives in Jenin camp. Sex ratio (male per 100 female) was 
103.2. Jenin district has a very young population with 40.0% of the population id (100,701) 
under 14 years of age. (PCBS, 2007). The Jenin governorate is an agricultural area with 
over 580,000 dunums of fertile, high quality soil that produce considerable harvests. The 
agricultural sector of the Jenin Governorate contributes 30% of the Palestinian National 
Income, and supplies work for 25% of the Palestinian population as farmers. ( Ministry of 
Interior, 2008).   
 
Toubas governorate is a small Palestinian city in the northeastern West Bank, located 
21 kilometers northeast of Nablus, a few kilometers west of the Jordan River (Tubas map, 
see annex (8)). Its urban area consists of 2,271 dunums. As of 2005, its total land area 
consists of 295,123 dunams , of which 2,271 is classified as built-up, roughly 150,000 used 
for agricultural purposes and about 180,000 confiscated by Israel for military bases and 
buffer zone. (Wikipedia, 2009). Demographic trends in Tubas district, as is the case of 
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other districts in the west bank, have been closely related to the political situation. 
According to the population statistics estimated by the Palestinian Center Bureau of 
Statistics (PCBS), the end total population of 2007 was around 50,261 individuals. Sex 
ratio (male per 100 female) was 103.3. Tubas district has a very young population with 
40.5% (19,505) under 14 years. (PCBS, 2007)  
 
4.3 Health services in Jenin and Tubas districts 
 
The Palestinian health care system is a mixture of governmental, non-governmental, 
United Nation Relief and Work Agency (UNRWA) and private (profit and non-profit) 
services delivery. These health providers are over lapping in services, and none of these 
sector can provide comprehensive health services. 
 
a- Primary Health Care Services  
 
The main health care providers for diabetic patient in Jenin district are: Jenin Health 
Department at Ministry of Health, UNRWA, NGOs and the primary health care clinics at 
private sector. Jenin Health Department is considered the major provider of primary health 
care services as it operates 43 PHC facilities out of 76 representing 63.4% of total PHC 
facilities, where as local NGO’s operates 28.4%, followed by UNRWA that operates 4 
clinics (Jenin, 2008).   
 
43
29
4
MOHNGOsUNRWA
 
Figure 4.1: distribution of primary health care provider in Jenin district. 
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There are approximately 10 primary health care clinics (PHC) in Tubas district, 7 are 
sponsored by the ministry of health (MOH), one PHC clinic is operating by UNRWA, and 
non-governmental organizations runs 2 PHC centers and mobile clinic which provide 
health care services for 10 remote areas. (Personal communications, Bani Odeh, 2009) 
 
MOH
70%
UNRWA
10%
NGOs
20%
 
Figure 4.2: distribution of primary health care provider in Tubas district. 
 
Primary health care cervices in both districts, provide various kinds of health services, 
medicines, heath education and lab tests, for details see annex 1. 
 
b-Secondary health care services 
 
Four hospitals provide the secondary health care services to the residents of Jenin district. 
The main hospital is the governmental Jenin hospital, which is always crowded and 
patients must wait several weeks for appointment.  Another three hospitals are operated by 
NGOs and private sector. 
 
In Tubas district there is no hospitals. People who needed hospital care get it either in Jenin 
or Nablus districts. 
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c- Health services for diabetics 
 
Three main health care providers provide health care for diabetes type 2 patients; MOH, 
UNRWA and PMRS primary health care centers in Jenin district and Tubas districts. 
 
The governmental health sector is providing special health services to diabetes patients 
through clinics present in seven locations in Jenin district and two PHC centers in Tubas, 
UNRWA is operating four clinics in Jenin district, while PMRS provide health services 
through three primary health care centers.  
 
MOH developed special diabetes clinics for diabetic patients where the diabetic patients 
get their consultation by the GPs.  At the UNRWA and PMRS the same GP provide health 
services for all clients with various health problems. Laboratory diagnostic tests at MOH 
include CBC (in four centers), FBS, RBS, HbA1c (some times and not in all centers), KFT, 
liver function tests, lipid profile, and urine analysis for free. PMRS offers the same lab 
tests, but not for free. UNRWA adopted the same MOH package except HBA1c, and also 
here patients do not pay for these services. Urine for microalbumin test is not available in 
all health providers. Nutritionist is available at the MOH central clinic. This service is not 
available at UNRWA and PMRS. Health educator specialist is not available at PMRS 
primary health care centers, MOH has one in central clinic and UNRWA provides this 
service in one center. Chronic diseases program at MOH is operating by internist, 
UNRWA and PMRS operate this service by GP. MOH has no ophthalmologist, but they 
refer diabetics for follow up to private sector with special form by which patient can get 
some exemption. In UNRWA also this service is not available, but UNRWA buy this 
service from Sant John hospital in Toulkarem and Jerusalem. PMRS refer to private sector. 
Nephrologist is not available in all health providers, mainly GP who manage kidney 
diseases. In Jenin and Tubas districts endocrinologist not available. For more details about 
diabetes services (see annex 5).    
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4.4 Study population  
 
a. Medical files  
 
To achieve the objectives of our study we have two study samples. The first one is medical 
files for type two diabetes patients in PHC centers which are operating by various 
providers such as MOH, UNRWA and PMRS, we select those providers because only 
these providers in Jenin and Tubas have filling system for diabetics. 
The original sample consists of all files of type two diabetes patients of both males and 
females in the different age groups. The total number of files in 16 PHC centers is 7361 
files. We choose 50 files randomly from each PHC center. Information about these patients 
was extracted from these files. 
 
 MOH UNRWA PMRS 
 No. of 
centers 
No. of 
Patients 
No. of 
centers 
No. of 
Patients 
No. of 
centers 
No. of 
Patients 
Jenin 7 350 4 200 3 150 
Tubas 2 100 0 0 0 0 
Total  
 
9 450 4 200 3 150 
 
Our sample extracted from 800 medical files distributed by 16 PHC centers. 
 
56.3
25
18.7
MOHUNRWAPMRS
 
Figure 4.3: Distribution of patients’ medical files by health provider. 
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b- Physicians 
 
The second targeted population was physicians working in the study centers.  The original 
sample consists of all physicians who deal with type two diabetes patients. We get a list of 
all physicians in Jenin and Tubas districts who registered in the medical association, and 
then we chose those physicians just who deal with diabetes patients(GPs, internists, 
endocrinologists, diabeticians, gynecologists, nephrologists, neurologists). 
 
The total number of physicians in both districts who are registered in the medical 
association is 230 physicians with different kinds of specialties. From those 230 physicians 
just 156 physicians are GPs, internists, Endocrinologists, diabeticians, gynecologists, 
nephrologists and neurologists. Four physicians from 156 are not working as physicians 
(managers, teacher assistants), two physicians have no patients in their clinics, and eight 
physicians were out of country at the time of research.  
 
Total No. of 
registered 
physicians 
Candidates 
physicians 
Not candidates 
physicians 
Respondents 
physicians 
Not 
respondents 
physicians 
230 142 14 139 (97,8%) 3 (2,2 %) 
 
 
4.5 Study design 
 
The study design was a cross-sectional. This design was chosen to meet the objective of 
the study, namely to identify the determinants of type 2 diabetes complications 
management in Jenin and Tubas districts. The information on diabetes complications 
management was collected from diabetic patients’ medical files, and by interviewing all 
physicians dealing with type 2 diabetes in both districts. 
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4.6 Study tools and equipments 
 
4.6.1 The interview questionnaire 
 
A pre-designed questionnaire was used by the researcher. Previously validated study 
questionnaires were used by the researcher as references for developing the study 
questionnaire. The questionnaires was selected from different previous studies such as “the 
Patient and physician perspectives regarding treatment of diabetes: compliance with 
practice guidelines” (Frank H. Lawler; 1997) and “Guidelines for type 2 diabetes: 
knowledge, attitudes and self-reported behavior among general practitioners” (Ivika Oja, 
2005). Questionnaire was developed for the study with the aim to cover the most important 
areas of interest regarding the physicians' compliance with diabetes management 
guidelines and health care system structure for diabetes care. 
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4.6.2 Diabetes patients’ medical files 
Data about the patients regarding demographic information, complications, and follow up 
criteria for the past year will be extracted from their medical files at health care provider 
institution.  
4.6.3 Validation and Piloting the study tool 
After developing the questionnaire, the questionnaire was sent to 3 experts of the field of 
diabetes and diabetes local guidelines in Al-Quds university, Al-Makased and Al-Muttala’ 
hospitals for validation. The questionnaire was piloted before using in the field.  Ten 
doctors from Jenin and tubas districts were asked to fill in the questionnaire to examine the 
clarity and suitability of the study questionnaire. Physicians were selected from MOH, 
UNRWA, PMRS and private sector. Interviews were held at their work places after the 
physician was explained about the aim of the study.  
 
For piloting the patients’ questionnaire, 10 medical files were selected randomly from each 
health provider organization to insure the suitability of the information recoded in these 
files. . 
 
The physicians questionnaires: 
The questionnaire had a cover letter that explains the study purpose and the objective.  
It included the following parts: 
Part 1:  questions that covers the demographic characteristics of the respondents  
Part 2: questions related to the various aspects of health care system for the management of 
diabetes. 
Part 3: questions that covers physician’s compliance with diabetes guidelines 
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4.7 Data collection 
 
Patients' file data: 
The researcher randomly chose 50 files for type 2 diabetes patients from each PHC center. 
Data about patients’ demographic characteristics, complications, follow up at patients’ 
level and history of diabetes and previous chronic diseases have been extracted. 
Physicians filled the questionnaires themselves.  
 
4.8 Ethical considerations 
 
Before beginning the study letters were sent from Al-Quds University to MOH, UNRWA 
and PMRS headquarters, in which the study was explained and an official permission has 
been asked for the researcher to visit the clinics and to work on type 2 diabetes patients’ 
medical files. The clinics were visited before beginning of the study in order to get to know 
the place, to introduce the researcher, and to explain the staff about the research and to ask 
them about the working hours. 
 
Before giving questionnaire to the physician, a briefly explanation about the purpose of the 
study and what the results will be used for were provided. An informed consent was given 
to each physician to sign before filling in the questionnaire (see annex 4).    
 
4.9 Data analysis 
The collected data was entered and analyzed by using the statistical package for the social 
science (SPSS version 15.0). The analysis process divided into different stages.  
Frequencies and p values (p < 0.05 was used to describe the study variables. A  univariate 
analysis was done to study the associations between the various diabetes microvascular 
complications (neuropathy, retinopathy and nephropathy) with all other variables 
(demographic, previous history of other diseases and follow up tests) using person chi-
square test of significance at 5% significance level. For physicians we compare self 
reported familiarity with diabetes management guidelines and all other variables 
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(demographic, patients’ follow up, work place characteristics, clinical exam and adherence 
to the guidelines), using person chi-square test of significance at 5% significance level. 
In the multivariate analysis, three logistic regression models for the various major 
complication; i.e. retinopathy, neuropathy and nephropathy were developed.   for 
microvascular diabetes complications (neuropathy, retinopathy and nephropathy).  
Variables that showed a significant difference with each complication were included at 
each model.   
4.10   Operational definition of variables 
Age: The age of patient (in completed years at the time of registration at health provider)  
Age category: composed of four categories 
A- 20 – 39 years 
B- 40 – 59 years 
C- 60 – 79 years 
D- 80 – 99 years 
Gender: Male or female of the participant 
Marital status: In the term of legal status at the time of registration at health provider, 
divided into four scales single, married, widow and divorced. 
Place of residence: Place in which participant live (City, Village and Camp). 
Educational level: finished stage of education, divided into six categories (Alliterative, 
Elementary, Secondary, high school, Diploma and University). 
Occupation: composed of two categories (worker and not worker) 
Type 2 diabetes: Non insulin dependant diabetes mellitus diagnosed usually in old age 
people. 
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Type 2 diabetes reported complications: 
A- Retinopathy: Diabetes affect patients’ eye, extracted from patients’ medical file.  
B- Nephropathy: Diabetes affect patients’ kidney, extracted from patients’ medical file.  
C- Neuropathy: Diabetes affect patients’ nerves, extracted from patients’ medical file. 
4.11 Summary 
This study is a cross-sectional study of determinants of type 2 diabetes complications 
management in Jenin and Tubas districts, it is comprised of two samples (type 2 diabetes 
patients’ medical files at MOH, UNRWA and PMRS and physicians who manage type 2 
diabetes). All diabetes microvascular complications were extracted from medical files.  
The survey instrument consisted of 46-items to assess physicians' background 
characteristics and to assess the compliance of physicians with guidelines and health care 
system arrangements for diabetic patients.  
 
Patients’ data regarding demographic information, complications and follow up criteria 
with past year were extracted from their medical files.  However, physicians had a self-
administered questionnaire.  
Univariate analysis for diabetes microvascular complications (neuropathy, retinopathy and 
nephropathy) with all other variables (demographic, previous history of other diseases and 
follow up tests) using person chi-square test of significance at 5% significance level were 
done.  Also, multivariate analysis for microvascular diabetes complications (neuropathy, 
retinopathy and nephropathy) with those variables which significantly associated with the 
complication, using logistic regression. 
The above analysis will be discussed on chapter 6.  Study conclusion and 
recommendations will also be presented. 
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Chapter Five. The Results 
5.1 Introduction 
 The study aim was to examine the determinants of management of diabetes mellitus type 2 
complications at Jenin and Toubas districts. 
The data analysis will be done in two parts: part 1 analysis for patients determinants for 
their complications for data which was extracted from their personal file, and part 2 for 
data collected at the interviews with physicians.  In part 1 the analysis will be presented in 
two sections.  Section 1 presents the descriptive data for the patients’ files; section 2 
presents univariate analysis for patients’ files 
5.2     Part 1 results:  Patients' file records data 
5.2.1  Descriptive analysis 
5.2.1.1: Study population Socio-demographic characteristics 
The number of type 2 diabetes patients medical files was 800 files, i.e. 50 files from each # 
centers. In the study, more than half of diabetic patients were found to be registered at the 
MOH clinics (see Figure 5.1).  
56.3
25
18.7
MOHUNRWAPMRS
 
          Figure 5.1: Distribution of study population by health provider 
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The mean age of the group was 58,8 ± 11,4 (mean ± S.D) (see figure 5.2), the mean 
duration of disease was 10.46 ± 7.43. Of the study population, 81.9% were married (see 
figure 5.3).  A 64% of diabetic patients in this study were males (see figure 5.4). A 93,8 % 
of patients live in villages (see figure 5.5). Half of the patients (48,5%) were not workers 
(see figure 5.6). More than third of study population are illiterate (see figure 5.7). 
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Figure 5.3: Distribution of study population by 
marital status 
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 Figure 5.4: Distribution of study  
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5.2.1.2  Study population health condition   
Interestingly, 65.5% of the study population showed positive family history of diabetes 
(see figure 5.8) 
negative
family history
26.9%
positive
family history
65.5%
 
      Figure 5.8: Distribution of study population by family history 
In the study, 43,1% of the study population had hypertension, 39,3% were obese, 28,1% 
were suffering from dislepedimia and 11,3%  had coronary artery diseases (see figure 5.9) 
43.1
39.3
28.1
11.3
HypertensionObesityDyslipidemiaCAD
 
     Figure 5.9: Distribution of study population by presence of diabetes risk factors 
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5.2.1.3   Follow up at personal level 
The data extracted from patients medical files showed that 33,1% of study population had 
their fasting blood sugar test once in the last month, 17,6% did HbA1c test before three 
months, 81,6% of study population tested their lipid profile (cholesterol and triglyceride) 
once in the last year, kidney function test was done for 70,5% of study population, urine 
for Microalbumin was repeated for just 15,6% for the last year of study population, 
ophthalmologist’s report was found in the 45,6% of files of study population for the last 
year and electrocardiogram (ECG) was done for 43,6% of study population at least once as 
base line (see figure 5.10) 
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       Figure 5.10: Distribution of study population by follow up criteria   
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5.2.1.4   Home monitoring 
Of the study population, 38,8% have their own glucometer for follow up their blood sugar 
at home conditions (see figure 5.11) 
have 
glucometer
12.6%
no glucometer
38.8%
 
       Figure 5.11: Distribution of study population by glucometer ownership 
5.2.1.5    Medical regime 
Two third of study population ( 61,4%) were treated by tablet, and just 3,3% by diet only 
(see figure 5.12) 
33.3
31.5
61.4
tablet plus
insulin
diet onlyinsulintablet
 
       Figure 5.12: Distribution of study population by medical regime type 
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5.2.1.6    Presence of diabetes complications among study population 
Of our study, more than the third of study population (38,4%) suffering from Neuropathy, 
retinopathy came in the second place with 26,8% of study population, erectile dysfunction 
was recorded for 0.1% only (see figure 5.13)   
In our study we selected three complications (neuropathy, retinopathy and nephropathy) as 
indicators because of their high prevalence among study population.  
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Figure 5.13: Distribution of study population by presence of complications 
Of our study population 5.8% was registered in the medical center because of another 
chronic disease and during follow up of that disease the patient developed diabetes. 
; 
absent; 33.6%
presence; 5.8%
 
    Figure 5.14: Distribution of study population by presence of previous chronic diseases  
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Section two: 
 
5.2.2   Univariate analysis for patients' file data:  Complications determinants 
Of our study, more than the third of study population (38,4%) suffering from Neuropathy, 
retinopathy came in the second place with 26,8% of study population, erectile dysfunction 
was recorded for 0.1% only (see figure 5.13)   
In our study we selected three complications (neuropathy (38.4%, retinopathy (26.8%) and 
nephropathy (20.5%)) as indicators because of their high prevalence among study 
population. The other complications like erectile dysfunction (0.01%), diabetic foot 
(12.5%), hypoglycemia (2.4%), heart attack (9.5%) and organ amputation with 1.1% 
prevalence.  
5.2.2.1    Retinopathy as recorded in patients' file 
 
A- Retinopathy and demographic factors 
 
A significant difference was found between the frequency of retinopathy with the health 
provider institution, age category and educational level (P <0.05, see table 5.1). No 
association was found between the presence of retinopathy with the job category (worker 
or not worker), gender, marital status and place of residency (P >0.05, see table 5.1). 
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Table 5.1: The distribution of reported retinopathy with various demographic 
variables for 800 medical files in Jenin and Tubas district 
 
 
 
 
 
 
 
 
Variable Retinopathy 
No: 214 
(26.8%) 
No-
retinopathy 
No:586 (73.3) 
Total 
No: 800 (100%) 
P value 
 
 
Health provider 
MOH 
UNRWA 
PMRS 
 
168 (78.5%) 
29 (13.6%) 
17 (7.9%) 
 
 
282 (48.1%) 
171 (29.2%) 
133 (22.7%) 
 
 
450 (56.3%) 
200 (25.0%) 
150 (16.7%) 
 
 
 
0.000 
Age 
20-39 years 
40-59 years 
60-79 years 
80-99 years 
 
4 (1.9%) 
70 (32.7%) 
130 (60.7%) 
10 (4.7%) 
 
26 (4.5%) 
320 (54.8%) 
224 (38.4%) 
14 (2.4%) 
 
30 (3.8%) 
390 (48.9%) 
354 (44.4%) 
24 (3.0%) 
 
 
0.000 
Job 
Worker 
Not worker 
 
66 (34.9%) 
123 (65.1%) 
 
152 (36.5%) 
265 (63.5%) 
 
218 (36.0%) 
388 (64.0%) 
 
0.7 
Gender 
Male  
Female 
 
88 (41.1%) 
126 (58.9%) 
 
202 (34.5%) 
384 (65.5%) 
 
290 (36.3%) 
510 (63.8%) 
 
0.083 
Marital status 
Single 
Married 
Widow 
Divorced 
 
5 (2.4%) 
173 (82.0%) 
32 (15.5%) 
1 (0.5%) 
 
21 (3.7%) 
482 (85.5%) 
59 (10.5%) 
2 (0.4%) 
 
26 (3.4%) 
655 (84.5%) 
91 (11.7%) 
3 (0.4%) 
 
 
0.26 
Educational level 
Alliterative 
Elementary 
Secondary 
High School 
Diploma 
University 
 
90 (42.7%) 
69 (32.7%) 
31 (14.7%) 
12 (5.7%) 
7 (3.3%) 
2 (0.9%) 
 
185 (33.2%) 
165 (29.6%) 
103 (18.5%) 
55 (9.9%) 
26 (4.7%) 
24 (4.3%) 
 
275 (35.8%) 
234 (30.4%) 
134 (17.4) 
67 (8.7%) 
33 (4.3%) 
26 (3.4%) 
 
 
 
0.013 
Residency 
Village 
City 
Camp 
 
201 (93.9%) 
8 (3.7%) 
5 (2.3%) 
 
549 (94.5%) 
21 (3.6%) 
11 (1.9%) 
 
750 (94.3%) 
29 (3.6%) 
16 (2.0%) 
 
 
 0.921 
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B-   Retinopathy and various follow up criteria 
A significant difference was found between the frequency of retinopathy with lipid profile 
test (P <0.05, see table 5.2). No association was found between the presence of retinopathy 
with FBS, HbA1c, and ophthalmologist visit  (P >0.05, see table 5.2) 
 
Table 5.2: The distribution of reported retinopathy with various follow up criteria for 
800 medical files in Tubas and Jenin districts 
 
 
 
C-  Retinopathy and diabetes family history and history of previous chronic 
diseases 
 
Retinopathy was significantly associated with diabetes family history and previous 
coronary artery disease (P <0.05, see table 5.3). No significant association was found 
between retinopathy and previous dislepedimia, hypertension and obesity (P >0.05, see 
table 5.3) 
 
 
 
 
 
Variable Retinopathy 
No: 214 (26.8%)
No-
retinopathy 
No:586 (73.3) 
Total 
No: 800 
(100%) 
P value 
 
 
FBS 
Yes 
No 
 
65 (31.6%) 
141 (68.4%) 
 
200 (34.7%) 
377 (65.3%) 
 
265 (33.8%) 
518 (66.2%) 
 
0.418 
HbA1c 
Yes 
No 
37 (17.5%) 
174 (82.5%) 
104 (17.8%) 
479 (82.2%) 
141 (17.8%) 
653 (82.2%) 
 
0.921 
Lipid profile 
Yes 
No 
164 (77.4%) 
48 (22.6%) 
489 (83.4%) 
97 (16.6%) 
653 (81.8%) 
145 (18.2%) 
 
0.049 
Ophthalmologist 
Yes 
No 
109 (51.4%) 
103 (48.6%) 
256 (43.9%) 
327 (56.1%) 
 
365 (45.9%) 
430 (54.1%) 
 
0.06 
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Table 5.3: The distribution of reported retinopathy with diabetes family history and 
other diabetes risk factors for 800 medical files in Jenin and Tubas districts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Retinopathy 
No: 214 (26.8%) 
No-retinopathy
No:586 (73.3) 
Total 
No: 800 (100%) 
P value 
 
 
Family history 
Positive 
Negative 
157 (78.5%) 
43 (21.5%) 
367 (68.1%) 
172 (31.9%) 
524 (70.9%) 
215 (29.1%) 
 
0.006 
Hypertension 
Yes 
No 
86 (40.2%) 
128 (59.8%) 
259 (44.2%) 
327 (55.8%) 
345 (43.1%) 
455 (56.9%) 
 
0.311 
Dislepedimia 
Yes 
No 
54 (25.2%) 
160 (74.8%) 
171 (29.2%) 
415 (70.8%) 
225 (28.1%) 
575 (71.9%) 
 
0.272 
CAD 
Yes 
No 
38 (17.8%) 
176 (82.2%) 
52 (8.9%) 
534 (91.1%) 
90 (11.3%) 
710 (88.8%) 
 
0.000 
Obesity 
Yes 
No 
75 (35.0%) 
139 (65.0%) 
239 (40.8%) 
347 (59.2%) 
314 (39.3%) 
486 (60.8%) 
 
0.141 
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5.2.2.2.  Nephropathy as recorded in patients' file 
 
A- Nephropathy and demographic factors 
 
A significant difference was found between nephropathy with the health provider 
institution, age category and gender (P <0.05, see table 5.4), but no association was found 
between the presence of nephropathy with the job category (worker or not worker), 
educational level, marital status and place of residency (P >0.05, see table 5.4). 
Table 5.4: The distribution of reported nephropathy with various demographic 
factors 
Variable Nephropathy 
No: 164 
(20.5%) 
No-
Nephropathy 
No:636 (79.5%) 
Total 
No: 800 (100%) 
P value
 
 
Health provider 
MOH 
UNRWA 
PMRS 
 
 
147 (89.6%) 
16 (9.8%) 
1 (0.6%) 
 
303 (47.6%) 
184 (28.9%) 
149 (23.4%) 
 
450 (56.3%) 
200 (25.0%) 
150 (16.7%) 
 
 
 
0.000 
Age 
20-39 years 
40-59 years 
60-79 years 
80-99 years 
 
1 (0.6%) 
63 (38.4%) 
97 (59.1%) 
3 (1.8%) 
 
29 (4.6%) 
327 (51.6%) 
257 (40.5%) 
21 (3.3%) 
 
30 (3.8%) 
390 (48.9%) 
354 (44.4%) 
24 (3.0%) 
 
 
0.000 
Job 
Worker 
Not worker 
 
58 (39.7%) 
88 (60.3%) 
 
160 (34.8%) 
300 (65.2%) 
 
218 (36.0%) 
388 (64.0%0 
 
0.278 
Gender 
Male  
Female 
 
77 (47.0%) 
87 (53.0%) 
 
213 (33.5%) 
423 (66.5%) 
 
290 (36.3%) 
510 (63.8%) 
 
0.001 
Marital status 
Single 
Married 
Widow 
Divorced 
 
5 (3.1%) 
136 (83.4%) 
21 (12.9%0 
1 (0.6%) 
 
21 (3.4%) 
519 (84.8%) 
70 (11.4%) 
2 (0.3%) 
 
26 (3.4%) 
655 (84.5%) 
91 (11.7%) 
3 (0.4%) 
 
 
0.901 
Educational level 
Alliterative 
Elementary 
Secondary 
High School 
Diploma 
University 
 
54 (33.3%) 
63 (38.9%)  
26 (16.0%) 
11 (6.8%) 
7 (4.3%) 
1 (0.6%) 
 
221 (36.4%0 
171 (28.2%) 
108 (17.8%) 
56  (9.2%) 
26 (4.3%) 
25 (4.1%) 
 
275 (35.8%) 
234 (30.4%) 
134 (17.4%) 
67 (8.7%) 
33 (4.3%) 
26 (3.4%) 
 
 
 
0.053 
 
Residency 
Village 
City 
Camp 
 
159 (97.5%) 
2 (1.2%) 
2 (1.2%) 
 
591 (93.5%) 
27 (4.3%) 
14 (2.2%) 
 
750 (94.3%) 
29 (3.6%) 
16 (2.0%) 
 
 
0.126 
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B-  Nephropathy and various follow up criteria 
 
Table 5.5 present the association between nephropathy with various follow up criteria, a 
significant association was found with kidney function tests and urine for microalbumin 
test (P <0.05).  
 
Table 5.5: The distribution of reported nephropathy with various follow up criteria 
for 800 medical files in Jenin and Tubas district 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Nephropathy 
No: 164 (20.5%) 
No-Nephropathy 
No:636 (79.5%) 
Total 
No: 800 
(100%) 
P value 
 
 
FBS 
Yes 
No 
49 (31.0%) 
109 (69.0%) 
216 (34.6%) 
409 (65.4%) 
265 (33.8%) 
518 (66.2%) 
 
0.400 
HbA1c 
Yes 
No 
32 (19.9%) 
129 (80.1%) 
109 (17.2%) 
524 (82.8%) 
141 (17.8%) 
653 (82.2%) 
 
0.431 
Lipid profile 
Yes 
No 
133 (81.6%) 
30 (18.4%) 
520 (81.9%) 
115 (18.1%) 
653 (81.8%) 
145 (18.2%) 
 
0.931 
Kidney function 
Yes 
No 
136 (83.4%) 
27 (16.6%) 
428 (67.4%) 
207 (32.6%) 
564 (70.7%) 
234 (29.3%) 
 
0.000 
 Microalbumin 
Yes 
No 
42 (26.1%) 
119 (73.9%) 
83 (13.2%) 
548 (86.8%) 
125 (15.8%) 
667 (84.2%) 
 
0.000 
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C-  Nephropathy and diabetes family history and history of previous chronic diseases 
 
Table 5.6 provide us with significant association between nephropathy and family history 
of diabetes and previous hypertension (P <0.05) 
 
Table 5.6: The distribution of reported nephropathy with diabetes family history and 
other diabetes risk factors for 800 medical files in Jenin and Tubas districts 
 
 
 
 
5.2.2.3      Neuropathy as recorded in patients' file 
 
A-Neuropathy and demographic factors 
 
Table 5.7 presents the association between neuropathy with various demographic variables, 
however, a significant association was found with health provider institution, age category 
and gender (P <0.05). 
 
 
Variable Nephropathy 
No: 164 (20.5%) 
No-
Nephropathy 
No:636 (79.5%) 
Total 
No: 800 (100%) 
P value 
 
 
Family 
history 
Positive 
Negative 
224 (75.4%) 
73 (24.6%) 
300 (67.9%) 
142 (32.1%) 
524 (70.9%) 
215 (29.1%) 
 
0.124 
Hypertension 
Yes 
No 
110 (35.8%) 
197 (64.2%) 
235 (47.7%) 
258 (52.3%) 
345 (43.1%) 
455 (56.9%) 
 
0.123 
Dislepedimia 
Yes 
No 
77 (25.1%) 
230 (74.9%) 
148 (30.0%) 
345 (70.0%) 
225 (28.1%) 
575 (71.9%) 
 
0.049 
CAD 
Yes 
No 
42 (13.7%) 
265 (86.3%) 
48 (9.7%) 
445 (90.3%) 
90 (11.3%) 
710 (88.8%) 
 
0.008 
 
Obesity 
Yes 
No 
98 (31.9%) 
209 (68.1%) 
216 (43.8%) 
277 (56.2%) 
314 (39.3%) 
486 (60.8%) 
 
 0.133 
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Table 5.7: The distribution of reported neuropathy with various demographic 
variables or 800 medical files in Jenin and Tubas districts 
 
 
 
 
 
 
 
Variable Neuropathy 
No: 307 (38.4%) 
No-Neuropathy 
No:493 (61.6%) 
Total 
No: 800 (100%) 
P value
 
 
Health 
provider 
MOH 
UNRWA 
PMRS 
 
269 (87.6%) 
30 (9.8%) 
8 (2.6%) 
 
 
181 (36.7%) 
170 (34.5%) 
142 (28.8%) 
 
 
450 (56.3%) 
200 (25.0%) 
150 (18.7%) 
 
 
 
0.000 
Age 
20-39 years 
40-59 years 
60-79 years 
80-99 years 
5 (1.6%) 
129 (42.0%) 
167 (54.4%) 
6 (2.0%) 
5 (1.6%) 
129 (42.0%) 
167 (54.4%) 
6 (2.0%) 
30 (3.8%) 
390 (48.9%) 
354 (44.4%) 
24 (3.0%) 
 
 
0.000 
Job 
Worker 
Not worker 
108 (38.7%) 
171 (61.3%) 
110 (33.6%) 
217 (66.4%) 
218 (36.0%) 
388 (64.0%) 
 
0.195 
Gender 
Male  
Female 
126 (41.0%) 
181 (59.0%) 
126 (41.0%) 
181 (59.0%) 
290 (36.3%) 
510 (63.8%) 
 
0.026 
Marital status 
Single 
Married 
Widow 
Divorced 
11 (3.6%) 
254 (83.3%) 
39 (12.8%) 
1 (0.3%) 
15 (3.2%) 
401 (85.3%) 
52 (11.1%) 
2 (0.4%) 
26 (3.4%) 
655 (84.5%) 
91 (11.7%) 
3 (0.4%) 
 
 
0.873 
Educational 
level 
Alliterative 
Elementary 
Secondary 
High School 
Diploma 
University 
108 (35.9%) 
103 (34.2%) 
47 (15.6%) 
24 (8.0%) 
14 (4.7%) 
5 (1.7%) 
167 (35.7%) 
131 (28.0%) 
87 (18.6%) 
43 (9.2%) 
19 (4.1%) 
21 (4.5%) 
275 (35.8%) 
234 (30.4%) 
134 (17.4%) 
67 (8.7%) 
33 (4.3%) 
26 (3.4%) 
 
 
 
0.153 
Residency 
Village 
City 
Camp 
291 (95.1%) 
9 (2.9%) 
6 (2.0%) 
459 (93.9%) 
20 (4.1%) 
10 (2.0%) 
750 (94.3%) 
29 (3.6%) 
16 (2.0%) 
 
0.698 
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B-Neuropathy and various follow up criteria 
Neuropathy was significantly associated with FBS, HbA1c and ECG, while, no significant 
association only with lipid profile testing (P >0.05, see table 5.8). 
 
Table 5.8: The distribution of reported neuropathy with various follow up criteria for 
800 medical files in Jenin and Tubas district 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Neuropathy 
No: 307 (38.4%)
No-Neuropathy 
No:493 (61.6%) 
Total 
No: 800 (100%) 
P value
 
 
FBS 
Yes 
No 
 
85 (28.6%) 
212 (71.4%) 
180 (37.0%) 
306 (63.0%) 
265 (33.8%) 
518 (66.2%) 
 
0.016 
HbA1c 
Yes 
No 
 
67 (22.1%) 
236 (77.9%) 
74 (15.1%) 
417 (84.9%) 
141 (17.8%) 
653 (82.2%) 
 
0.012 
Lipid profile 
Yes 
No 
 
244 (80.0%) 
61 (20.0%) 
409 (83.0%) 
84 (17.0%) 
653 (81.8%) 
145 (18.2%) 
 
0.292 
ECG 
Yes 
No 
 
218 (72.7%) 
82 (27.3%) 
131 (26.7%) 
359 (73.3%) 
349 (44.2%) 
441 (55.8%) 
 
0.000 
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C-Neuropathy and diabetes family history and history of previous chronic diseases 
 
A significant difference was found between the frequency of neuropathy and family history 
of diabetes, hypertension and obesity (P <0.05. No significant association was found with 
dislepedimia and previous coronary artery disease (P >0.05 see table 5.9) 
 
Table 5.9: The distribution of reported neuropathy with diabetes family history and 
other diabetes risk factors for 800 medical files in Jenin and Tubas districts 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Neuropathy 
No: 307 (38.4%) 
No-Neuropathy 
No:493 (61.6%) 
Total 
No: 800 (100%) 
P value 
 
 
Family 
history 
Positive 
Negative 
224 (75.4%) 
73 (24.6%) 
300 (67.9%) 
142 (32.1%) 
524 (70.9% 
215 (29.1%) 
 
0.027 
Hypertension 
Yes 
No 
110 (35.8%) 
197 (64.2%) 
235 (47.7%) 
258 (52.3%) 
345 (43.1%) 
455 (56.9%) 
 
0.001 
Dislepedimia 
Yes 
No 
77 (25.1%) 
230 (74.9%) 
148 (30.0%) 
345 (70.0%) 
225 (28.1%) 
575 (71.9%) 
 
0.131 
CAD 
Yes 
No 
42 (13.7%) 
265 (86.3%) 
48 (9.7%) 
445 (90.3%) 
90 (11.3%) 
710 (88.8%) 
 
0.086 
 
Obesity 
Yes 
No 
98 (31.9%) 
209 (68.1%) 
216 (43.8%) 
277 (56.2%) 
314 (39.3%) 
486 (60.8%) 
 
0.001 
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5.2.3  Section three: Patients' file: Multivariate analysis:  
 
5.2.3.1.  Retinopathy 
 
From the regression analysis, we can see that there is an increased estimated risk to 
develop retinopathy among patients attending the MOH(5 folds) compared to those 
attending the PMRS clinics.  The risk to develop retinopathy also increased by the age (3.5 
folds) within those patients between 80-99 years compared to those between 20-39. Those 
patients who have a previous history of coronary artery disease, have a double risk to 
develop retinopathy. For those patients that did not check their lipid profile yearly, they 
also have an increase estimated risk (1.7 folds) compared to those who regularly check 
their serum lipids. Higher educational level is a preventive factor for retinopathy. 
Table 5.10: Logistic regression analysis for retinopathy. 
Variable Retinopathy- 
yes 
AOR CI P value 
Health provider 
MOH 
UNRWA 
PMRS 
 
168 (78.5%) 
29 (13.6%) 
17 (7.9%) 
 
1.00 
0.284 
0.196 
 
1.00 
0.174 - 0.463 
0.106 - 0.362 
 
0.000 
Age 
20-39 
40-59 
60-79 
80-99 
 
4 (1.9%) 
70 (32.7%) 
130 (60.7%) 
10 (4.7%) 
 
1.00 
0.987 
2.263 
3.556 
 
1.00 
0.308 - 3.157 
0.692 - 7.397 
0.826 - 15.310 
 
0.000 
 
Educational 
level 
Alliterative 
Elementary 
Secondary 
High School 
Diploma 
University 
 
0 (42.7%) 
69 (32.7%) 
31 (14.7%) 
12 (5.7%) 
7 (3.3%) 
2 (0.9%) 
 
1.00 
1.019 
0.864 
0.653 
0.874 
0.231 
 
1.00 
0.653 - 1.590 
0.491 - 1.518 
0.304 - 1.402 
0.334 - 2.290 
0.051 - 1.049 
0.013 
Lipid profile 
Yes 
No 
 
164 (77.4%) 
48 (22.6%) 
 
1.00 
1.759 
 
1.00 
1.106 - 2.797 
 
 
0.049 
CAD 
Yes 
No 
 
38 (17.8%) 
176 (82.2%) 
 
2.152 
1.00 
 
1.252 - 3.700 
1.00 
 
0.000 
Ophthalmologist 
visit 
Yes 
No 
 
 
109 (51.4%) 
103 (48.6%) 
 
 
1.00 
0.641 
 
 
1.00 
0.431 - 0.954 
 
 
 
0.06 
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5.2.3.2. Nephropathy 
 
 From the regression analysis, we can see that there is an increased estimated risk to 
develop nephropathy among patients attending the MOH(61 folds) compared to those 
attending the PMRS clinics.  The risk to develop nephropathy also increased by the age (15 
folds) within those patients between 60-79 years compared to those between 20-39.  Males 
have an a higher risk than females to develop nephropathy (1.6 folds).Those patients who 
have a previous history of coronary artery disease, have a double risk to develop 
nephropathy. Patients who regularly perform serum creatinin and urine for microalbumin 
have a greater chance to be early diagnosed with nephropathy. 
 
Table 5.11: Logistic regression analysis for nephropathy. 
 
 
 
Variable Nephropathy- 
yes 
AOR CI P value 
 
 
Health provider 
MOH 
UNRWA 
PMRS 
 
147 (89.6%) 
16 (9.8%) 
1 (0.6%) 
 
1.00 
0.201 
0.016 
 
1.00 
0.113 - 0.358 
0.002 - 0.122 
 
0.000 
 
Age 
20-39 
40-59 
60-79 
80-99 
 
1 (0.6%) 
63 (38.4%) 
97 (59.1%) 
3 (1.8%) 
 
1.00 
7.535 
15.356 
7.757 
 
1.00 
0.972 - 58.428 
1.971 - 119.656 
0.694 - 86.733 
 
0.000 
 
Gender 
Male 
Female 
 
77 (47.0%) 
87 (53.0%) 
 
1.629 
1.00 
 
1.101 – 2.412 
1.00 
 
0.001 
KFT 
Yes 
No 
 
136 (83.4%) 
27 (16.6%) 
 
1.00 
0.771 
 
1.00 
0.452 - 1.314 
 
0.000 
Microalbumin 
Yes 
No 
 
42 (26.1%) 
119 (73.9%) 
 
1.00 
0.636 
 
1.00 
0.393 - 1.031 
 
0.000 
Dislepedimia 
Yes 
No 
 
36 (22.0%) 
128 (78.0%) 
 
0.872 
1.00 
 
0.541 - 1.404 
1.00 
 
0.049 
CAD 
Yes 
No 
28 (17.1%) 
136 (82.9%) 
 
1.953 
1.00 
 
1.057 - 3.611 
1.00 
 
0.008 
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5.2.3.3. Neuropathy 
 
From the regression analysis, we can see that there is an increased estimated risk to 
develop neuropathy among patients attending the MOH(17 folds) compared to those 
attending the PMRS clinics.  The risk to develop neuropathy also increased by the age (5 
folds) within those patients between 60-79 years compared to those between 20-39. Males 
are at higher risk to develop neuropathy. Checking hemoglobin A1c regularly each three 
months has no effect in developing retinopathy. The risk to develop retinopathy was 
slightly affected by previous history of hypertension. Regular FBS and HbA1c testing help 
in early diagnosis of neuropathy. 
Table 5.12: Logistic regression analysis for neuropathy. 
Variable Neuropathy- yes AOR CI P value 
 
 
Health provider 
MOH 
UNRWA 
PMRS 
 
269 (87.6%) 
30 (9.8%) 
8 (2.6%) 
 
1.00 
0.218 
0.058 
 
1.00 
0.121 - 0.394 
0.026 - 0.126 
0.000 
Age 
20-39 
40-59 
60-79 
80-99 
 
5 (1.6%) 
129 (42.0%) 
167 (54.4%) 
6 (2.0%) 
 
1.00 
3.065 
5.889 
2.254 
 
1.00 
1.016 - 9.250 
1.924 - 18.026 
0.468 - 10.861 
0.000 
Gender 
Male 
Female 
 
126 (41.0%) 
181 (59.0%) 
 
1.178 
1.00 
 
0.807 - 1.720 
1.00 
 
0.026 
FBS 
Yes 
No 
 
85 (28.6%) 
212 (71.4%) 
 
1.00 
0.766 
 
1.00 
0.491 - 1.195 
 
 
0.016 
HbA1c 
Yes 
No 
 
67 (22.1%) 
236 (77.9%) 
 
1.00 
0.976 
 
1.00 
0.602 - 1.584 
 
0.012 
ECG 
Yes 
No 
 
218 (72.7%) 
82 (27.3%) 
 
1.00 
0.312 
 
1.00 
0.209 - 0.465 
 
0.000 
HTN 
Yes 
No 
 
110 (35.8%) 
197 (64.2%) 
 
1.090 
1.00 
 
0.734 - 1.619 
1.00 
 
0.001 
Obesity 
Yes 
No 
 
98 (31.9%) 
209 (68.1%) 
 
0.607 
1.00 
 
0.408 - 0.903 
1.00 
 
0.001 
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5.3  Part 2 results: Physicians data 
The first part of physicians’ results presents the physicians’ demographic characteristics, as 
reported by physicians themselves in the self administered questionnaire. The second part 
shows various aspects of health care system for the management of diabetes. The third part 
presents physicians compliance with diabetes guidelines. 
 
5.3.1  Physicians’ Demographic characteristics 
 
The response rate of physicians was 97,8% (n=13). The total number of physicians in both 
districts who were registered at the medical association was 230 physicians with various 
types of specialties. From those 230 physicians, just 156 physicians were included in our 
study, i.e. general practitioners, internists, Endocrinologists, diabeticians, gynecologists, 
Nephrologists and Neurologists. Four physicians from 156 were not working as physicians 
(managers, teacher assistants), two physicians had no diabetic patients in their clinics, and 
eight physicians were out of country at the time of research.  
 
Total No. of 
registered 
physicians 
eligible 
physicians 
Not eligible 
physicians 
Respondents 
physicians 
Not 
respondents 
physicians 
230 142 14 139 (97,8%) 3 (2,2 %) 
 
 
In the study, 82.7% of physicians were males (see figure 5.15). The mean age of the 
physicians was 42.8± 10.6  years(mean± S.D) (see figure 5.16). Of the study population, 
40.2% graduated from Soviet Union Republics, followed by the universities presented in 
the various Arab countries (see figure 5.17). Two third of physicians in our study were 
general practitioners (GPs) (see figure 5.18). Of the study physicians 36.7% were working 
at the Primary Health Care Departments of the Ministry of Health (MOH) (see figure 
5.19). Also, 46.7% had secondary job at private clinics, but 35.3% have no secondary job 
(see figure 5.20). 
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Figure 5.15 Distribution of physicians by  
gender    
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Figure 5.19: Distribution of physicians by their 
essential job 
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5.3.2 Compliance of physicians with type 2 diabetes guidelines 
 
1- Home monitoring and HbA1c testing 
 
Of study population 82% of physicians recommend  their patients for glucose home 
monitoring (see figure 5.21). 
no
18%
yes
82%
 
        Figure 5.21: Recommend type 2 diabetics for glucose home monitoring 
 
 Of the physicians, 28.8%  recommend patients to check it  once weekly (see figure 5.22).   
 
0.7
4.3
8.6
10.8
12.9
18
28.8
no needday after daymonthlynot
determined
twice dailyonce dailyweekly
 
     Figure 5.22: How often physicians recommend patients to check their blood sugar  at 
home 
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From our study population 94.2%  were familiar with a test called a glycosylated 
hemoglobin or a hemoglobin A1C (see figure 5.23).  
94.2
5.8
yesno
 
       Figure 5.23: Familiar physicians with a test called hemoglobin A1C 
 
61.2% of our study population routinely use HbA1c test to help them manage their 
diabetics (see figure 5.24).  
61.2
94.2
Use HbA1c test in managementfamiliar with HbA1c
 
     Figure 5.24: Use HbA1c test for managing type 2 diabetes patients 
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A 35.3% of physicians recommend their patient to repeat HbA1c quarterly (see figure 
5.25).  
0.71.4
7.9
32.4
35.3
yearlyno needmonthlyevery 6 monthsevery 3 months
 
     Figure 5.25: How often physicians recommend their diabetics to repeat HbA1c test 
  
10.8% of physicians are not use HbA1c test due to the high cost of the test and 10.2% 
found it unnecessary for type 2 diabetes patients management (see figure 5.26). 
2.9
5
10.1
10.8
I don't know what is
HbA1c
not availablenot necessaryhigh cost
 
      Figure 5.26: causes of not using HbA1c test for patients management 
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2-Ophthalmologist visit 
 
In the study, 86.3% of study population recommended routine ophthalmologic examination 
for their diabetic patients (see figure 5.27). 
86.3
12.9
YesNo
 
      Figure 5.27: Physicians recommend routine ophthalmologic examination for diabetic 
patients 
 
 49.6% of physicians recommend routine ophthalmologic examination every six months    
(see figure 5.28).  
49.6
30.2
4.32.9
every 6 monthsyearlyevery 3 monthsas the patient can
 
      Figure 5.28: how often physicians recommend ophthalmologic examination for their 
diabetic patients 
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A 77% from those physicians receive a report from an ophthalmologist. 25.9% have 
phondoscope at their work place, and more than two third of physicians believe that they 
need training in using phondoscope (see figure 5.29 
86.3
25.9
69.1
77
refer to
ophthalmologist 
phondoscope
available
training needreceiving report 
 
    Figure 5.29: Availability of phondoscope in the work place and physician’s training 
need 
 
3- Diabetes patients follow up 
 
Of the study population 45.3% repeat fasting blood sugar (FBS) once monthly. Of 
physicians 23.7% perform electrocardiography in yearly basis (see figure 5.30) 
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 Figure 5.31: How often physicians repeat diagnostic studies for healthy type 2 diabetics 
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4-Endocinologist’s consult 
 
In our study 44.6% of study population refer their type 2 diabetes patients to be seen by 
endocrinologist (see figure 5.32).  
no
55,4% yes
44.6%
 
    Figure 5.32: percentage of physicians who refer patients to endocrinologist 
 
21.6% of physicians said that the endocrinologist consult is not needed (see figure 5.33).  
33.8
21.6
no endocrinologistno need
 
       Figure 5.33: Why physicians do not refer patients to endocrinologist 
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Of the study population 84.9% said that the endocrinologist is available in another district 
(see figure 5.34). 
2.2
12.9
84.9
in the same buildingin the same cityin another city
 
    Figure 5.34: The distance between physicians and endocrinologist 
 40.3% of physicians in our study can use phone consultation with an endocrinologist (see 
figure 5.35)  
 
40.3
59.7
yesno
 
       Figure 5.35: Physicians ability to use phone consultation with an endocrinologist 
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5-Availability of various specialists in the work place 
3.6% of physicians have endocrinologist in their work place, 34.5% of study population 
have nutritionist in their work place (see figure 5.36).  
 
 
 
 
 
 
 
 
         Figure 5.36: Availability of specialists in the work place 
 
Of our study population 74.1% have brushers and posters about diabetes in their work 
place, 30.9% of physicians conducted group health education for diabetic patients in their 
work place (see figure 5.37). 
74.1
66.2
30.9
brochures and posters individual health education  group health education
 
          Figure 5.37: Availability of health Education tools in the work place 
                                                                              
 
 
 
 
 
 
 
3.6
10.1
27.328.1
34.5
en
do
cri
no
log
ist
 
po
dia
tris
t 
op
hth
alm
olo
gis
t 
ne
ph
rol
og
ist
 
nu
trit
ion
ist
 
 98
6-Appointment system 
 
Of our study population 18% believe that an otherwise healthy diabetic should be seen for 
his/her diabetes by his/her physician once per month (see figure 5.38). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.38: How often an otherwise healthy diabetic should be seen for his/her diabetes 
by his/her physician 
 
83.5% of physicians said that their diabetic patients can call them for counseling in any 
time (see figure 5.39). 
 
They can
83.5%
They can not
16.5%
 
    Figure 5.39: patients can call physicians for counseling in any time  
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7- Physical exam during diabetes clinic visit  
 
Of our study population, 71.9% required results of blood glucose at home, 18% perform 
phundus exam (see figure 5.40) 
 
71.970.567.666.2
48.9
18
blood sugarfeet examblood pressuremouth examneurological
exam
phundus exam
 
         Figure 5.40: Physical exam during clinic visit 
 
8- Physical exam in gynecological clinic 
 
Of 23 gynecologists, 16.5% required results of blood glucose at home and 1.4% perform 
phundus exam (see figure 5.41)  
16.5
12.912.9
10.1
7.2
1.4
 weight blood
pressure
feet exammouth examneurological
exam
phundus exam
 
       Figure 5.41: Patients physical exam in gynecological clinic 
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Of 23 gynecologists, 21 (91.3%)  refer their diabetic patients to diabetician before giving 
any medication (see figure 5.42) 
I don’t refer
8.7%
I refer
91.3%
 
            Figure 5.42: Referring patients before giving any medication by Gynecologists 
 
9- Familiarity with guidelines 
 
Of the study population 40.3% of physicians are familiar with a guidelines for management 
of type 2 diabetic patients, 20.9% of physicians have a copy of the guidelines in the work 
place and 25.2% of physicians said undergo special training to use the guidelines (see 
figure 5.43).  
40.3
25.2
20.9
familiarity with guidelinestraining on guidelinesCopy of guidelines
 
       Figure 5.43: Familiarity of physicians about diabetes management guidelines 
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In the study 24.5% of physicians were never adhere these guidelines in diabetes 
management (see figure 5.44). 
 
24.5
20.9
14.4
10.1
nevermostlyrarealways
 
          Figure 5.44: Adherence of physicians for diabetes management guidelines 
 
7.9% of physicians assessed the guidelines as widely applicable in the work place (see 
figure 5.45).  
7.9
36
12.2
w idely applicablepartially applicablenot applicable at all
 
        Figure 5.45: The applicability of guidelines in the work place 
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21.6% of physicians are familiar with the diabetes management guidelines of MOH, 
followed by WHO (13.7%) (see figure 5.46) 
 
0.71.4
2.93.6
13.7
21.6
medical
literature
ADAPMRSUNRWAWHOMOH
 
          Figure 5.46: Who developed guidelines 
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10- Obstacles for adherence diabetes management guidelines 
 
46.8% of study population considered that the most problematic factor was unavailability 
of guidelines followed by the absence of supervisors support (37.4%) (see figure 5.47) 
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 Figure 5.3.26: Problematic factors in adherence to the guidelines 
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5.3.3  Physicians data univariate analysis 
 
5.3.3.1  Self reported familiarity with diabetes management guidelines and 
demographic characteristics of physicians 
 
A statistically significant difference was observed between the self reported familiarity 
with the diabetes management guidelines and type of specialty, gender and place of 
essential job for physicians. No association was found between self reported familiarity 
with the guidelines and age category and country of graduation (P > 0.05, see table 5.13). 
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Table 5.13: Association between self reported familiarity with guidelines and 
physicians demographic characteristics 
 
Variable Familiar with 
guidelines 
No: 56 
(40.3%) 
Not familiar 
with guidelines 
No: 83 (59.7%) 
Total 
No: 139 
(100%) 
P value
 
 
Specialty 
Endocrinologist 
Diabetician 
Internist 
Ophthalmologist 
Nephrologist 
Gynecologist 
Neurologist 
GP 
 
1   (1.8%) 
2   (3.6%) 
7   (12.5%) 
0   (.0%) 
0   (.0%) 
4   (7.1%) 
0   (.0%) 
42 (75.0%) 
 
0   (.0%) 
1   (1.2%) 
7   (8.4%) 
5   (6.0%) 
3   (3.6%) 
19 (22.9%) 
2   (2.4%) 
46 (55.4%) 
 
1    (.7%) 
3    (2.2%) 
14  (10.1%) 
5     (3.6%)  
3     (2.2%) 
23   (16.5%) 
2    (1.4%) 
88  (63.3%) 
 
 
 
 
0.02 
Gender 
Male 
female 
51 (91.1%) 
5 (8.9%) 
64 (77.1%) 
19 (22.9%) 
115 (82.7%) 
24 (17.3%) 
 
0.033 
Age category 
25-40 years 
41-55 years 
56-70 years 
27 (48.2%) 
23 (41.1%) 
6 (10.7%) 
45 (54.2%) 
25 (30.1%) 
13 (15.7%) 
72 (51.8%) 
48 (34.5%) 
19 (13.7%) 
 
0.369 
Country of 
graduation 
West Europe 
East Europe 
Soviatian Union 
Arab country 
China  
 
4 (7.1%) 
17 (30.4%) 
17 (30.4%) 
17 (30.4%) 
1 (1.8%) 
2 (2.4%) 
18 (21.7%) 
39 (47.0%) 
24 (28.9%) 
0 (.0%) 
6 (4.3%) 
35 (25.2%) 
56 (40.3%) 
41 (29.5%0 
1 (0.7%) 
 
 
 
0.163 
Essential Job 
Health department 
UNRWA 
CBO 
Private sector 
Private clinic 
Governmental 
hospital 
Medical force service 
PMRS 
26 (46.4%) 
6 (10.7%) 
4 (7.1%) 
4 (7.1%) 
7 (12.5%) 
4 (7.1%) 
0 (.0%) 
5 (8.9%) 
25 (30.1%) 
0 (.0%) 
3 (3.6%) 
13 (15.7%) 
16 (19.3%) 
20 (24.1%) 
3 (3.6%) 
3 (3.6%) 
 
51 (36.7%) 
6 (4.3%) 
7 (5.0%) 
17 (12.2%) 
23 (16.5%) 
24 (17.3%) 
3 (2.2%) 
8 (5.8%) 
 
 
 
 
 
0.001 
Number of years in 
the institution 
< 10 years 
10-19 years 
20-29 years 
> 29 years 
 
32 (57.1%) 
15 (26.8%) 
5 (8.9%) 
4 (7.1%) 
 
32 (57.1%) 
15 (26.8%) 
5 (8.9%) 
4 (7.1%) 
 
79 (56.8%) 
43 (30.9%) 
11 (7.9%) 
6 (4.3%) 
 
 
 
0.497 
Number of years 
managing diabetics 
< 10 years 
10-19 years 
20-29 years 
> 30 years 
 
 
35 (62.5%) 
11 (19.6%) 
7 (12.5%) 
3 (5.4%) 
 
 
56 (67.5%) 
14 (16.9%) 
8 (9.6%) 
5 (6.0%) 
 
 
91 (65.5%) 
25 (18.0%) 
15 (10.8%) 
8 (5.8%) 
 
 
0.908 
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5.3.3.2   Self reported familiarity with diabetes management guidelines and diabetes 
management indicators  
 
No significant difference was found between self reported familiarity with guidelines and 
recommendation of blood sugar home monitoring, familiarity of physicians with HbA1c 
test, use HbA1c test for diabetes management, recommendation of eye exam, next 
appointment for healthy type 2 diabetics to be seen by physician, the ability of patients to 
use phone consult with their physicians and recommendation of endocrinologist’s consult 
(P > 0.05, see table 5.14). The significant association was found just between self reported 
familiarity with guidelines and the ability of physicians to use phone consult with the 
endocrinologist (P < 0.05, see table 5.14). 
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Table 5.14: Association between self reported familiarity with guidelines and diabetes 
management indicators 
 
 
 
Variable Familiar with 
guidelines 
No: 56 (40.3%)
Not familiar 
with guidelines 
No: 83 (59.7%) 
Total 
No: 139 
(100%) 
P value
 
 
Recommend BS 
home monitoring 
Yes 
No 
 
 
50 (89.3%) 
6 (10.7%) 
 
 
64 (77.1%) 
19 (22.9%) 
 
 
114 (82.0%) 
25 (18.0%) 
 
 
0.067 
Familiarity with 
HbA1c test 
Yes  
No 
 
 
54 (96.4%) 
2 (3.6%) 
 
 
77 (92.8%) 
6 (7.2%) 
 
 
131 (94.2%) 
8 (5.8%) 
 
 
0.364 
Use HbA1c test in 
diabetes management 
Yes 
No 
 
 
37 (66.1%) 
19 (33.9%) 
 
 
48 (60.0%) 
19 (33.9%) 
 
 
85 (62.5%) 
51 (37.5%) 
 
 
0.472 
Recommend eye 
examination 
Yes 
No 
 
 
52 (92.9%) 
4 (7.1%) 
 
 
68 (82.9%) 
14 (17.1%) 
 
 
120 (87.0%) 
18 (13.0%) 
 
 
0.089 
Appointment for 
healthy diabetic 
Monthly 
Every 3 months 
Every 6 months 
Yearly 
Not regularly 
 
 
21 (37.5%) 
13 (23.2%) 
16 (28.6%) 
3 (5.4%) 
3 (5.4%) 
 
 
21 (25.3%) 
35 (42.2%) 
23 (27.7%) 
3 (3.6%) 
1 (1.2%) 
 
 
42 (30.2%0 
48 (34.5%0 
39 (28.1%) 
6 (4.3%) 
4 (2.9%) 
 
 
 
 
0.117 
Patients can use 
phone for consult 
Yes 
No 
 
 
47 (83.9%) 
9 (16.1%) 
 
 
69 (83.1%) 
14 (16.9%) 
 
 
116 (83.5%) 
23 (16.5%) 
 
 
0.901 
Recommend 
endocrinologist’s 
consult 
Yes 
No 
 
 
25 (44.6%) 
31 (55.4%) 
 
 
37 (44.6%) 
46 (55.4%) 
 
 
62 (44.6%) 
77 (55.4%) 
 
 
 
0.994 
Physician can use 
phone to consult with 
endocrinologist 
Yes 
No 
 
 
 
30 (53.6%) 
26 (46.4%) 
 
 
 
26 (31.3%) 
57 (68.7%) 
 
 
 
56 (40.3%) 
83 (59.7%) 
 
 
 
0.009 
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5.3.3.3 Self reported familiarity with diabetes management guidelines and diabetes 
follow up criteria 
 
No significant association was observed between self reported familiarity with guidelines 
and all follow up criteria (P > 0.05, see table 5.15) 
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Table 5.15: Association between self reported familiarity with diabetes management 
guidelines and patients follow up criteria 
 
 
 
Variable Familiar with 
guidelines 
No: 56 (40.3%) 
Not familiar 
with guidelines 
No: 83 (59.7%) 
Total 
No: 139 
(100%) 
P value 
 
 
FBS 
Weekly 
Monthly 
Every 3 months 
Every 6 months 
Not necessary 
 
20 (35.7%) 
27 (48.2%) 
8 (14.3%) 
1 (1.8%) 
0 (.0%) 
 
33 (39.8%) 
36 (43.4%) 
8 (9.6%) 
0 (.0%) 
6 (7.2%) 
 
53 (38.1%) 
63 (45.3%) 
16 (11.5%) 
1 (0.7%) 
6 (4.3%) 
 
 
 
0.166 
Blood pressure 
Weekly 
Monthly 
Every 3 months 
Every 6 months 
Not necessary 
 
24 (42.9%) 
25 (44.6%) 
5 (8.9%) 
1 (1.8%) 
1 (1.8%) 
 
35 (42.2%) 
35 (42.2%) 
5 (6.0%) 
2 (2.4%) 
6 (7.2%) 
 
59 (42.4%) 
60 (43.2%) 
10 (7.2%0 
3 (2.2%) 
7 (5.0%0 
 
 
0.650 
Lipid profile 
Weekly 
Monthly 
Every 3 months 
Every 6 months 
Yearly 
Not necessary 
 
0 (.0%0 
3 (5.4%0 
14 (25.0%) 
33 (58.9%) 
4 (7.1%) 
2 (3.6%) 
 
1 (1.2%) 
3 (3.6%) 
24 (28.9%) 
35 (42.2%) 
9 (10.8%) 
11 (13.3%) 
 
1 (0.7%) 
6 (4.3%) 
38 (27.3%) 
68 (48.9%) 
13 (9.4%)  
13 (9.4%) 
 
 
 
0.231 
Microalbumin 
Weekly 
Monthly 
Every 3 months 
Every 6 months 
Yearly 
Not necessary 
 
0 (.0%) 
5 (8.9%) 
9 (16.1%) 
28 (50.0%) 
9 (16.1%) 
5 (8.9%) 
 
1 (1.2%) 
6 (7.2%) 
19 (22.9%) 
26 (31.3%) 
11 (13.3%) 
20 (24.1%) 
 
1 (0.7%) 
11 (7.9%) 
28 (20.1%) 
54 (38.8%) 
20 (14.4%) 
25 (18.0%) 
 
 
 
0.108 
Eye examination 
Weekly 
Monthly 
Every 3 months 
Every 6 months 
Yearly 
Not necessary 
 
 
0 (.0%) 
1 (1.8%) 
27 (48.2%) 
22 (39.3%) 
6 (10.7%) 
 
 
1 (1.2%) 
5 (6.0%) 
31 (37.3%) 
27 (32.5%) 
19 (22.9%) 
 
 
1 (0.7%) 
6 (4.3%) 
58 (41.7%) 
49 (35.3%) 
25 (18.0%) 
 
 
 
0.108 
BMI 
Weekly 
Monthly 
Every 3 months 
Every 6 months 
Yearly 
Not necessary 
 
0 (.0%) 
4 (7.1%) 
6 (10.7%) 
22 (39.3%) 
9 (16.1%) 
15 (26.8%) 
 
1 (1.2%) 
8 (9.6%) 
9 (10.8%) 
15 (18.1%) 
12 (14.5%) 
38 (45.8%) 
 
1 (0.7%) 
12 (8.6%) 
15 (10.8%) 
37 (26.6%) 
21 (15.1%) 
53 (38.1%) 
 
 
 
 
0.081 
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Table  5.15…. continues 
 
 
 
 
5.3.3.4.   Self reported familiarity with diabetes management guidelines and   
availability of team work in the institution 
 
Statistically significant difference was observed between self reported familiarity with 
guidelines and presence of podiatrist, nutritionist in the work place, significant association 
was noted with tools of health education like presence of posters and brochures and 
personal health education (P < 0.05), very significant difference was found between 
familiarity with guidelines and presence of group health education in the work place (P = 
0, see table 5.16). No significant association was observed between familiarity with 
guidelines and presence of nephrologist, endocrinologist and ophthalmologist (P > 0.05). 
 
Variable Familiar with 
guidelines 
No: 56 
(40.3%) 
Not familiar 
with guidelines 
No: 83 (59.7%) 
Total 
No: 139 
(100%) 
P value
 
 
Creatinin 
Weekly 
Monthly 
Every 3 months 
Every 6 months 
Yearly 
Not necessary 
 
2 (3.6%) 
15 (26.8%) 
29 (51.8%) 
9 (16.1%) 
1 (1.8%) 
0 (.0%) 
 
6 (7.2%) 
18 (21.7%) 
36 (43.4%) 
15 (18.1%) 
7 (8.4%) 
1 (1.2%) 
 
8 (5.8%) 
33 (23.7%) 
65 (46.8%) 
24 (17.3%) 
8 (5.8%0 
1 (0.7%) 
 
 
 
 
0.420 
Foot inspection 
Weekly 
Monthly 
Every 3 months 
Every 6 months 
Yearly 
Not necessary 
 
4 (7.1%) 
27 (48.2%) 
11 (19.6%) 
11 (19.6%) 
0 (.0%) 
3 (5.4%) 
 
3 (3.6%) 
43 (51.8%) 
14 (16.9%) 
13 (15.7%) 
3 (3.6%) 
7 (8.4%) 
 
7 (5.0%) 
70 (50.4%) 
25 (18.0%) 
24 (17.3%) 
3 (2.2%) 
10 (7.2%) 
 
 
 
0.575 
ECG 
Weekly 
Monthly 
Every 3 months 
Every 6 months 
Yearly 
Not necessary 
 
0 (.0%) 
1 (1.8%) 
5 (8.9%) 
28 (50.0%) 
12 (21.4%) 
10 (17.9%) 
 
2 (2.4%) 
6 (7.2%) 
6 (7.2%) 
28 (33.7%) 
21 (25.3%) 
20 (24.1%) 
 
2 (1.4%) 
7 (5.0%) 
11 (7.9%) 
56 (40.3%) 
33 (23.7%) 
30 (21.6%) 
 
 
 
0.265 
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Table 5.16: Association between self reported familiarity with diabetes management 
guidelines and availability of team work in the institution 
 
 
 
 
 
 
 
 
 
Variable Familiar with 
guidelines 
No: 56 
(40.3%) 
Not familiar 
with guidelines 
No: 83 (59.7%) 
Total 
No: 139 
(100%) 
P value
 
 
Podiatrist 
Yes 
No 
11 (19.6%) 
45 (80.4%) 
3 (3.6%) 
80 (96.4%) 
14 (10.1%) 
125 (89.9%) 
 
0.002 
Nephrologist 
Yes 
No 
12 (21.4%) 
44 (78.6%) 
27 (32.5%) 
56 (67.5%) 
39 (28.1%) 
100 (71.9%) 
 
0.153 
Endocrinologist 
Yes 
No 
2 (3.6%) 
54 (96.4%) 
3 (3.6%) 
80 (96.4%) 
5 (3.6%) 
134 (96.4%) 
 
0.989 
Ophthalmologist 
Yes 
No 
13 (23.2%) 
43 (76.8%) 
25 (30.1%) 
58 (69.9%) 
38 (27.3%) 
101 (72.7%) 
 
0.370 
Nutritionist 
Yes 
No 
25 (44.6%) 
31 (55.4%) 
23 (27.7%) 
60 (72.3%) 
48 (34.5%) 
91 (65.5%0 
 
0.039 
Brochures, posters 
Yes 
No  
48 (34.5%) 
91 (65.5%) 
55 (66.3%) 
28 (33.7%) 
103 (74.1%) 
36 (25.9%) 
 
0.010 
Personal health 
education 
Yes 
No 
45 (80.4%) 
11 (19.6%) 
47 (56.6%) 
36 (43.4%) 
92 (66.2%) 
47 (33.8%) 
 
 
0.004 
Group health 
education 
Yes 
No 
27 (48.2%) 
29 (51.8%) 
16 (19.3%) 
67 (80.7%) 
43 (30.9%) 
96 (69.1%) 
 
0.000 
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5.3.3.5.    Self reported familiarity with diabetes management guidelines and clinical 
exam for type 2 diabetics in the clinic  
 
In table 5.17 we can note that no statistically significant association between familiarity 
with guidelines and clinical exam, requiring results of blood sugar, measuring blood 
pressure in supine position, Phondoscopy, feet inspection, mouth inspection and 
neurological exam (P > 0.05). 
 
Table 5.17: Association between self reported familiarity with diabetes management 
guidelines and clinical exam in the clinic 
 
 
 
 
 
 
 
Variable Familiar with 
guidelines 
No: 56 
(40.3%) 
Not familiar 
with guidelines 
No: 83 (59.7%) 
Total 
No: 139 
(100%) 
P value
 
 
Results of home BS 
Yes 
No 
46 (88.5%) 
6 (11.5%) 
54 (84.4%) 
10 (15.6%) 
100 (86.2%) 
16 (13.8%) 
 
0.526 
Check BP 
Yes 
No 
45 (86.5%) 
7 (13.5%) 
49 (77.8%) 
14 (22.2%) 
94 (81.7%) 
21 (18.3%) 
 
0.226 
Phondoscopy 
Yes 
No 
14 (26.9%) 
38 (73.1%) 
11 (17.2%) 
53 (82.8%) 
25 (21.6%) 
91 (78.4%) 
 
0.205 
Foot inspection 
Yes 
No 
43 (82.7%) 
9 (17.3%) 
55 (85.9%) 
9 (14.1%) 
98 (84.5%) 
18 (15.5%) 
 
0.631 
Mouth inspection 
Yes 
No 
98 (84.5%) 
18 (15.5%) 
49 (76.6%) 
15 (23.4%) 
92 (79.3%) 
24 (20.7%) 
 
0.418 
Neurological exam 
Yes 
No 
35 (67.3%) 
17 (32.7%) 
33 (51.6%) 
31 (48.4%) 
68 (58.6%) 
48 (41.4%) 
 
0.087 
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5.3.3.6.   Association between self reported familiarity with diabetes management 
guidelines and clinical exam for type 2 diabetic patients in gynecological clinic 
 
No significant association was observed between self reported familiarity with diabetes 
management guidelines and clinical exam in gynecological clinic (P > 0.05, see table 
5.18). 
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Table 5.18: Association between self reported familiarity with diabetes guidelines and 
diabetic patients clinical exam in gynecological clinic 
 
 
 
 
 
 
 
 
Variable Familiar with 
guidelines 
No: 56 (40.3%)
Not familiar 
with guidelines 
No: 83 (59.7%) 
Total 
No: 139 
(100%) 
P value
 
 
Check BP 
Yes 
No 
4 (100.0%) 
0 (0.0%) 
14 (73.7%) 
5 (26.3%) 
18 (78.3%) 
5 (21.7%) 
 
0.246 
Phondoscopy 
Yes 
No 
0 (0.0%) 
4 (100.0%) 
2 (10.5%) 
17 (89.5%) 
2 (8.7%) 
21 (91.3%) 
 
0.497 
Foot inspection 
Yes 
No 
4 (100.0%) 
0 (0.0%) 
4 (100.0%) 
0 (0.0%) 
18 (78.3%) 
5 (21.7%) 
 
0.246 
Mouth inspection 
Yes 
No 
2 (50.0%) 
2 (50.0%) 
12 (63.2%) 
7 (36.8%) 
14 (60.9%) 
9 (39.1%) 
 
0.624 
Neurological exam 
Yes 
No 
2 (50.0%) 
2 (50.0%) 
2 (50.0%) 
2 (50.0%) 
10 (43.5%) 
13 (56.5%) 
 
0.772 
Refer for specialist 
consult 
Yes 
No 
4 (100.0%) 
0 (0.0%) 
17 (89.5%) 
2 (10.5%) 
21 (91.3%) 
2 (8.7%) 
 
 
0.497 
Change previous 
treatment for pregnant 
Yes 
No 
0 (0.0%) 
4 (100.0%) 
1 (5.3%) 
18 (94.7%) 
1 (4.3%) 
22 (95.7%) 
 
 
0.369 
Change tablet 
treatment to insulin 
Yes 
No 
3 (75.0%) 
1 (25.0%) 
7 (36.8%) 
12 (63.2%) 
10 (43.5%) 
13 (56.5%) 
 
 
0.162 
Refer to diabetician 
Yes 
No 
3 (75.0%) 
1 (25.0%) 
17 (89.5%) 
2 (10.5%) 
20 (87.0%) 
3 (13.0%) 
 
0.435 
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5.3.3.7.   Self reported familiarity with diabetes management guidelines and 
adherence to guidelines 
 
High statistically significant association was observed between self reported familiarity 
with guidelines and presence of a copy of the guidelines, undergo training on the 
guidelines use, adherence to the guidelines and applicability of the guidelines in the work 
place (P = 0.000, see table 5.16). No significant difference was found with guidelines 
developer (P > 0.05, see table 5.19). 
 
Table 5.19: Association between self reported familiarity with diabetes management 
guidelines and adherence to guidelines 
 
 
 
 
Variable Familiar with 
guidelines 
No: 56 (40.3%)
Not familiar 
with guidelines
No: 83 (59.7%)
Total 
No: 139 
(100%) 
P value
 
 
Copy of guidelines 
Yes 
No 
 
29 (51.8%) 
27 (48.2%) 
 
0 (0.0%) 
16 (100.0%) 
 
29 (40.3%) 
43 (59.7%) 
 
 
0.000 
Training on guidelines 
Yes 
No 
 
32 (57.1%) 
24 (42.9%) 
 
3 (3.8%) 
77 (96.3%) 
 
35 (25.7%) 
101 (74.3%) 
 
 
0.000 
Adherence to guidelines 
Always 
Mostly 
Rare 
Never 
 
13 (23.2%) 
26 (46.4%)  
15 (26.8%) 
2 (3.6%0 
 
1 (2.4%) 
3 (7.3%0 
5 (12.2%) 
32 (78.0%) 
 
14 (14.4%) 
29 (29.9%) 
20 (20.6%) 
34 (35.1%) 
 
 
 
0.000 
Applicability of 
guidelines 
Widely applicable 
Partially applicable 
No applicable 
 
 
11 (19.6%) 
40 (71.4%) 
5 (8.9%) 
 
 
0 (0.0%) 
10 (45.5%) 
12 (54.5%) 
 
 
11 (14.1%) 
50 (64.1%) 
17 (21.8%) 
 
 
0.000 
Guidelines developer 
MOH 
UNRWA 
WHO 
PMRS 
ADA 
Germany 
Medical literature 
 
24 (44.4%) 
5 (9.3%) 
17 (31.5%) 
4 (7.4%) 
2 (3.7%) 
1 (1.9%) 
1 (1.9%) 
 
6 (75.0%) 
0 (0.0%) 
2 (25.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
30 (48.4%) 
5 (8.1%) 
19 (30.6%) 
4 (6.5%) 
2 (3.2%) 
1 (1.6%) 
1 (1.6%) 
 
 
 
0.762 
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5.3.3.8.   Self reported familiarity with diabetes management guidelines and 
problematic factors for adherence the guidelines 
 
Table 5.17 present very high significant association between self reported familiarity with 
guidelines and problematic factors for adherence like, unavailability of the guidelines, 
unclearness of the guidelines (P =0, see table 5.20), very high significant difference was 
observed with physicians have no time to follow guidelines and lack of supervisors support 
(P = 0.01, see table 5.20). No significant association was found with Patients 
uncooperativity, Patients financial capacity, Patients noninterest, Physicians not trained on 
guidelines, No feedback from specialists and Unavailability of all lab tests (P > 0.05, see 
table 5.20) 
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Table 5.20: Association between self reported familiarity with diabetes management 
guidelines and problematic factors for adherence the guidelines 
 
 
 
 
 
 
 
 
 
 
Variable Familiar with 
guidelines 
No: 56 
(40.3%) 
Not familiar 
with 
guidelines 
No: 83 
(59.7%) 
Total 
No: 139 
(100%) 
P value
 
 
Unavailability 
Never 
Rarely 
Usually 
Mostly 
 
24 (43.6%) 
13 (23.6%) 
8 (14.5%) 
10 (18.2%) 
 
4 (5.7%) 
1 (1.4%) 
10 (14.3%) 
55 (78.6%) 
 
28 (22.4%) 
14 (11.2%) 
18 (14.4%) 
65 (52.0%) 
 
 
0.000 
Unclearness 
Never 
Rarely 
Usually 
Mostly 
 
24 (43.6%) 
21 (38.2%) 
7 (12.7%) 
3 (5.5%) 
 
1 (4.2%) 
6 (25.0%) 
10 (41.7%) 
7 (29.2%) 
 
25 (31.6%) 
27 (34.2%) 
17 (21.5%) 
10 (12.7%) 
 
 
0.000 
Patients 
uncooperativity 
Never 
Rarely 
Usually 
Mostly 
 
 
5 (9.1%) 
13 (23.6%) 
21 (38.2%) 
16 (29.1%) 
 
 
0 (0.0%) 
3 (10.3%) 
11 (37.9%) 
15 (51.7%) 
 
 
5 (6.0%) 
16 (19.0%) 
32 (38.1%) 
31 (36.9%) 
 
 
 
0.071 
Patients financial 
capacity 
Never 
Rarely 
Usually 
Mostly 
 
 
5 (9.3%) 
15 (27.8%) 
16 (29.6%) 
18 (33.3%) 
 
 
1 (3.4%) 
4 (13.8%) 
6 (20.7%) 
18 (62.1%) 
 
 
6 (7.2%) 
19 (22.9%) 
22 (26.5%) 
36 (43.4%) 
 
 
 
0.084 
Patients noninterest 
Never 
Rarely 
Usually 
Mostly 
 
6 (10.9%) 
16 (29.1%) 
20 (36.4%) 
13 (23.6%) 
 
1 (3.4%) 
4 (13.8%) 
12 (41.4%) 
12 (41.4%) 
 
7 (8.3%) 
20 (23.8%) 
32 (38.1%) 
25 (29.8%) 
 
 
0.153 
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Table 5.20: …continues 
 
 
 
 
 
 
 
 
 
 
Variable Familiar with 
guidelines 
No: 56 
(40.3%) 
Not familiar 
with 
guidelines 
No: 83 
(59.7%) 
Total 
No: 139 
(100%) 
P value
 
 
No time for adherence 
the guidelines 
Never 
Rarely 
Usually 
Mostly 
 
 
13 (24.1%) 
15 (27.8%) 
21 (38.9%) 
5 (9.3%) 
 
 
2 (8.0%) 
9 (36.0%) 
5 (20.0%) 
9 (36.0%) 
 
 
15 (19.0%) 
24 (30.4%) 
26 (32.9%) 
14 (17.7%) 
 
 
0.01 
Physicians not trained  
Never 
Rarely 
Usually 
Mostly 
 
23 (42.6%) 
6 (11.1%) 
7 (13.0%) 
18 (33.3%) 
 
6 (18.2%) 
3 (9.1%) 
8 (24.2%) 
16 (48.5%0 
 
29 (33.3%) 
9 (10.3%) 
15 (17.2%) 
34 (39.1%) 
 
 
0.091 
No supervisors 
support 
Never 
Rarely 
Usually 
Mostly 
12 (22.2%) 
7 (13.0%) 
12 (22.2%) 
23 (42.6%) 
2 (5.1%) 
2 (5.1%) 
6 (15.4%) 
29 (74.4%) 
 
14 (15.1%) 
9 (9.7%) 
18 (19.4%) 
52 (55.9%) 
 
0.015 
No feedback from 
specialists 
Never 
Rarely 
Usually 
Mostly 
 
 
10 (18.9%) 
12 (22.6%) 
18 (34.0%) 
13 (24.5%) 
 
 
3 (12.0%) 
6 (24.0%) 
6 (24.0%) 
10 (40.0%) 
 
 
13 (16.7%) 
18 (23.1%) 
24 (30.8%) 
23 (29.5%) 
 
 
 
0.490 
Unavailability of all 
lab tests 
Never 
Rarely 
Usually 
Mostly 
 
 
8 (14.8%) 
22 (40.7%) 
12 (22.2) 
12 (22.2%) 
 
 
2 (7.7%) 
7 (26.9%) 
4 (15.4%) 
13 (50.0%) 
 
 
10 (12.5%) 
29 (36.3%) 
16 (20.0%) 
25 (31.3%) 
 
 
 
0.095 
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Chapter six.   Discussion and Conclusion 
 Introduction 
 
The distinguishing feature of this study is that is the first to identify the determinants of 
type 2 diabetes complications management in Palestine. This study provides a baseline for 
further studies to improve diabetes complications' management. 
 
According the patient’s medical files, the study was performed in primary health care 
clinics (PHC) that are supervised by the MOH, UNRWA and PMRS in Jenin and Tubas 
districts. 
 
6.1 Summary of study findings 
 
A sample of 800 patient files were included in this study.  These files were randomly 
selected from 16 primary health care centers and from each center 50 medical files were 
selected. The 19 PHC centers were distributed as follows: 9 medical centers operated by 
the MOH; 4 centers by the UNRWA and 3 were operated by the PMRS. 
 
In this study, type 2 diabetes was more prevalent in the age group 40-59 years with a mean 
age 58.8 (SD ± 11.4).  More than half of the patients were followed by MOH clinics. Two 
third of study population had a positive family history of diabetes and 39.3% of patients 
were obese. 
 
Results showed the frequency of follow up tests for type 2 diabetes patients by PHC 
centers. In 17.6% of patients' medical files, included a HbA1c test for the last three 
months. 
 
In describing the complications among the study population as reported by medical files, 
micro-vascular complications was found to be common among the study population over 
60 years old. 
 
The association of socio-demographic, follow up tests and risk factors with diabetes 
complications was also investigated. Significant association was found between 
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retinopathy and health provider, age, educational level, lipid profile testing, diabetes family 
history and history of coronary artery disease. Nephropathy was significantly associated 
with health provider, age group, gender, kidney function test, urine for microalbumin 
testing and history of coronary artery disease. Significant association was found between 
neuropathy and health provider, age, gender, FBS, HbA1c, ECG, diabetes family history, 
history of hypertension and obesity. 
 
The multiple regression models were done for diabetes complications that included all 
significant variables in the univariate analysis.  For the retinopathy model age, low 
educational level, lipid profile testing and history of coronary artery disease were shown a 
significant estimated risk for retinopathy in the model. In  the neuropathy model, age, 
gender, FBS, HbA1c, ECG monitoring and history of hypertension and diabetes were a 
significant risk factor for neuropathy. Age, gender, KFT, urine for microalbumin 
monitoring, history of dislepedimia and coronary artery disease were also shown as risk 
factors for nephropathy. 
 
In the coming sections the study results will be discussed and compared to the present 
literature and study conceptual model in details. 
 
6.2 Socio-demographic factors associations with diabetes complication 
management. 
 
In the study conceptual model and study first objective, socio-demographic factors; i.e. 
age, gender….etc were included as a group of variables that might have an association with 
diabetes complications management.  Each of these complications will be discussed 
separately in the coming sections. 
 
6.2.1 Retinopathy 
 
The prevalence of retinopathy in all age groups was 26.8%. Retinopathy was higher in age 
groups 40-59 and 60-79 years. The mean age of the study population with retinopathy was 
63.55 ± 10.38 years. The mean duration of diabetes for patients with retinopathy was 15.5 
years. The majority of retinopathy patients was diagnosed at MOH PHC centers (78.5%). 
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Strong significant association was found between development of retinopathy with age (P= 
0.000), and educational level of patients (P= 0.013). No association was found between the 
presence of retinopathy with the job category (worker or not worker), gender, marital 
status and place of residency (P >0.05). Multiple regression analysis showed that the risk to 
develop retinopathy increased by the age (3.5 folds) within those patients between 80-99 
years compared to those between 20-39 years, (OR=3.556,95% CI=0.826 - 15.310; 
P=0.000) 
 
Several studies have shown age as a risk factor for having retinopathy among diabetic 
patients.  In Oman was higher in age groups 50-59 and 60-69 (Khandekar et al., 2003). In 
Iran the prevalence of retinopathy was higher 37% (Javadi et al., 2009). The strong 
positive association with duration is frequently reported  (Goldberg, 1972; Kahn, 1975), 
prevalence of retinopathy rose with age (Draper, 1968). In our study the prevalence of 
retinopathy decreased by the duration of diabetes. Most of this study sample was old 
people.  As known, the pattern of frequency of retinopathy is largely determined by age at 
diagnosis of diabetes, therefore, the longer the duration of diabetes before retinopathy 
becomes common. Goldberg (1972) stated that "ageing makes the retinal vasculature more 
vulnerable to the diabetes process whatever it may be, and makes the older patients more 
likely than his younger counterpart to develop retinopathy within a given period of time.’’ 
 
Education is also a powerful and unique predictor of health outcomes.  Lower levels of 
education are associated with poor health, and higher levels of education are associated 
with better health (Al-khdoor, 2007).This study showed that 88.1% of patients did not 
finish high school, they were either illiterates or did not finish 12 years of basic education. 
Significant association was found between retinopathy and educational level (P=0.013). 
Multiple regression showed that the risk to develop retinopathy among illiterates (4.3 
folds) higher those who finished university (OR=0.231, 95% CI=0.051 - 1.049). 
 
In China, no significant association between retinopathy and educational level was seen 
(Chen et al., 1992). In the United States of America, retinopathy was weakly associated 
with lower education level (Moniques, 2000). In Sweden, a study showed that the group in 
poor metabolic control was characterized by a lower education level (Dick larsson, 1999). 
In this study, retinopathy was significantly associated with educational level. (P 
value=0.013; OR=0.171, 95% CI=0.040-0.7410).  These results contradict some studies 
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around the world.  A potential explanation of our results is that the more the patient was 
educated the better awareness he/she had about the importance of metabolic control and 
regular ophthalmological exam. 
 
6.2.2 Nephropathy 
 
The prevalence of nephropathy among study population was 20,5% . majority of patients 
(89.6%) were diagnosed at MOH centers, 9.8% at UNRWA and 0.6% at PMRS. 
Nephropathy was higher in age group 60-79 years (59.1%). The mean age with 
nephropathy was 58 ± 7.89 years Our results showed a small difference in male and female 
in the overall prevalence of diabetic nephropathy (47% vs. 53%). A significant difference 
was found between nephropathy with the health provider institution (P= 0.000), age 
category (P=0.000) and gender (P=0.001), but no association was found between the 
presence of neuropathy with the job category (worker or not worker), educational level, 
marital status and place of residency (P >0.05). The risk to develop nephropathy also 
increased by the age (15 folds) within those patients between 60-79 years compared to 
those between 20-39 (OR=15.356, 95% CI=1.971 - 119.656). logistic regression showed 
that males have a higher risk than females to develop nephropathy (1.6 folds), (OR=1.629, 
95% CI=1.101-2.412). 
 
In Egypt multivariate logistic regression analysis revealed that diabetic patients over 49 
years of age, were more likely to develop chronic diabetic complications (M.El-Shazly et 
al., 2009). Poor glycemic control, hypertriglyceridemia, and longer duration of diabetes 
were independently associated with prevalent microalbuminuria and macroalbuminuria 
(Bessie et al., 2005). Our results showed age and duration of diabetes are significantly 
associated with development of nephropathy The risk to develop nephropathy increased by 
the age (15 folds) within those patients between 60-79 years compared to those between 
20-39 (OR=15.356, 95% CI=1.971 - 119.656). Duration of diabetes has significant 
contribution for the development microalbuminuria by prolonged exposure to 
hyperglycemia-induced advanced glycosylation end products accumulations (Jungmann et 
al., 2001).  
 
Male gender has been associated with the development of nephropathy in diabetes in many 
studies. Gall et al., in a prospective observational study involving 176 patients with type-2 
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diabetes, found that males had a 2.6 times greater risk of developing incipient or overt 
nephropathy. In Mexico, female gender associated significantly with reduced nephropathy 
(Dante Amato, 2005). Male sex (OR 2.6 (95% CI 1.2-5.4); P<0.02) (Mari-Anne gall, 
1997). In Canada, female sex appears to be protective (Amrit et al., 2007). Our findings are 
consistent with the previous studies.   There was a strong association with gender and 
logistic regression showed that males have a higher risk than females in 1.6 folds (OR, 
1.624, 95% CI, 1.10-2.41; P, 0.001). Several studies explained the dominance of male 
gender in developing diabetic nephropathy.  Sex-determining region Y-box 2 (SOX2) 
genetic polymorphism has gender-specific effects on DN, and also implies that 
transcription factors in pluripotency mechanisms may be involved in the pathogenesis of 
diabetes and DN (Gu et al., 2009). Sex hormones may mediate the effects of gender on 
chronic renal disease, through alterations in the renin-angiotensin system, reduction in 
mesangial collagen synthesis, the modification of collagen degradation, and upregulation 
of nitric oxide synthesis (Seliger et al., 2001). Nitric oxide (NO) availability in the renal 
circulation is greater in female than in male patients with type 2 diabetes that is associated 
with reduced levels of oxidative stress in females. The role of this gender-related difference 
in renal endothelial function for the initiation and progression of diabetic nephropathy 
(Markus et al., 2010) 
 
6.2.3 Neuropathy 
 
The prevalence of neuropathy in all age groups was 38.4%. neuropathy was higher in age 
group 40-59 and 60-79 (42% and 54.4%). The mean age of study population with 
neuropathy was 61.25 ± 10.08 years. The mean duration of diabetes for those with 
neuropathy was 13.68 ± 7.69 years. Our results showed a difference in prevalence of 
diabetic neuropathy among males and females (41% and 59%). 87.6% of patients were 
diagnosed with neuropathy at MOH clinics, 9.8% at UNRWA and 2.6% at PMRS. A 
significant association was found with health provider institution (P=0.000) , age  category 
(P= 0.000) and gender (P=0.026). No significant association was found between 
neuropathy and jab category, marital status, place of residence and educational level (P > 
0.05).  The risk to develop neuropathy also increased by the age (5 folds) within those 
patients between 60-79 years compared to those between 20-39 (OR=5.889, 95% CI=1.924 
- 18.026). Males have a higher risk to develop neuropathy than females in 1.178 folds 
(OR=1.178, 95% CI=0.807 - 1.720). 
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Age and duration of diabetes are listed as risk factors for developing neuropathy by many 
literatures. In UK, a cross-sectional multicentre study was performed to establish the 
prevalence of peripheral neuropathy in Type 2 (non-insulin-dependent) diabetic patients it 
was 32.1 % . It increases with both age and duration of diabetes, until it is present in more 
than 50% of Type 2 diabetic patients aged over 60 years (Young et al., 1992). 
The prevalence of diabetic neuropathy across Europe was 28 %.Significant correlations 
were observed between the presence of diabetic peripheral neuropathy with age (p < 0.05), 
duration of diabetes (p < 0.001) (Tesfaye et al., 1996). Age significantly 
independent predictors for first foot ulceration (P 0.01). (Caroline et al., 1998) 
Prevalence of diabetic neuropathy in our study was higher than previous studies (38.4%). 
Neuropathy was higher in age group 60-79 years, it is similar to study in UK. Strong 
significant association was found in our study between age, duration of diabetes and 
neuropathy (P=0.000) 
 
A lot of researches around the world confirm the role of gender in developing neuropathy. 
In Iran statistically significant relationships were found between neuropathy and age, 
gender, quality of diabetes control and duration of disease (P values in the order: 0.04, 
0.04, < 0.001 and 0.005). More attention must be paid to elderly male diabetic patients 
with poor diabetes control (Fargol et al., 2005). The presence of clinical neuropathy 
correlated with greater age, longer duration of IDDM, and male gender. The somatic and 
autonomic test results confirm the relationship between age, diabetes duration, and male 
gender and diabetic neuropathy. These results support an effect of age and gender on the 
development of diabetic complications (DCCT, 1988). In New York this study 
demonstrates that the males in the study population developed neuropathy earlier than did 
the females (Aaberg  et al., 2008). Our findings showed that male gender has a higher risk 
to develop neuropathy and significant difference was detected between gender and 
neuropathy (P=0.026). Males have a higher risk to develop neuropathy in 1.4 folds than 
females (OR=1.397, 95% CI=1.040 - 1.875). 
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6.3 follow up at personal level 
 
The data extracted from patients medical files showed that 33,1% of study population had 
their fasting blood sugar test once in the last month, 17,6% did HbA1c test before three 
months, 81,6% of study population tested their lipid profile (cholesterol and triglyceride) 
once in the last year, ophthalmologist’s report was found in the 45,6% of files of study 
population for the last year and electrocardiogram (ECG) was done for 43,6% of study 
population at least once as base line. 
 
6.3.1 Retinopathy 
 
A significant difference was found between the frequency of retinopathy with lipid profile 
test (P=0.049). No association was found between the presence of retinopathy with FBS, 
HbA1c, and ophthalmologist visit  (P >0.05). 
 
As recommended by the WHO guidelines for patients with type 2 diabetes mellitus follow 
up criteria for retinopathy, patients should be screened for retinopathy soon after diagnosis 
and subsequent examinations should be done on a yearly basis.  A structured eye 
surveillance should be at one year interval. (WHO, 2006) 
 
In Austria, nearly half of people with diabetes in Melbourne are not receiving adequate 
screening or follow up for diabetic retinopathy, despite universal health care. People with 
diabetes were not significantly more likely to have visited an optometrist than people 
without diabetes (P=0.51) (Catherine et al., 1998). In Germany 80% of diabetic patients to 
have had an examination of the retina by an ophthalmologist. (Mühlhauser et al., 1998). 
Regular screening for diabetic retinopathy and more aggressive management of modifiable 
risk factors could reduce the numbers of people who develop vision-threatening 
retinopathy. HbA1c testing is associated with retinopathy (Robyn et al., 2003). 
 
In this study, 33,1% of study population had their fasting blood sugar test once in the last 
month, 17,6% did HbA1c test before three months, 81,6% of study population tested their 
lipid profile (cholesterol and triglyceride) once in the last year. 45.6% of our sample visited 
the ophthalmologist in the last year 
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Our results showed that, association was not significant with ophthalmologist visit 
(P=0.06), because almost of our sample are old agers and with low educational level, so 
they are not aware about the importance of regular eye exam. The service is not available 
at health provider institutions and patients must do fundus exam at private centers and the 
cost may be a real barrier for our people.  From the physicians study results, almost of the 
physicians (87%) recommend their patients for regular eye exam.  However, we found 
reports from eye doctors only in 45.6% of the patients medical files.  A potential 
explanation is that patients did not really did the eye examination due to its cost at the 
private sector or they did the eye examination but did not put their results in their files. 
Patients may check their eyes, but the reports are not inserted in files. 
 
Another interesting finding with retinopathy is that no significant association was found 
between having retinopathy and the HbA1c level at the (OR=1.021, 95% CI=0.675-1.544, 
P=0.921). A possible explanation could be, that the HbA1C testing also can be done out 
the health care service itself (whether the MOH, UNRWA or PMRS) since this service is 
not provided and should be done at the private sector.  Therefore, these results might be 
inaccurate since 17,6% did HbA1c test before three months ,and just 62% of our 
physicians use the test in management of diabetes. Another reason that, HbA1c test is not 
included in UNRWA technical instruction, so no one HbA1c test we found in medical files 
at UNRWA PHC centers. 
 
Adherence to lipid testing recommendations by primary care physicians for elderly patients 
with diabetes has much room for improvement (Massing et al., 2003). more effort is 
needed to ensure that CAD patients with diabetes receive aggressive lipid management 
(Massing et al., 2003). In our study, a significant association was found between lipid 
profile yearly testing and retinopathy (P=0.049), logistic regression showed that patients 
who did not check their lipid profile yearly, they also have an increase estimated risk (1.7 
folds) compared to those who regularly check their serum lipids. If patients did not check 
their serum lipids, so lipids level may increase and this will develop several health 
problems like hypertension and hypertension will lead to retinopathy. 
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6.3.2 Nephropathy 
 
In this study, kidney function test was done for 70,5% of study population, urine for 
Microalbumin was repeated for just 15,6% for the last year of study population. 
 
Type 2 diabetes mellitus should have their urinary albumin excretion measured at least 
once a year until the age of 70. Follow up should also include regular assessment of 
HbA1c, blood pressure, serum creatinin and serum lipids (WHO, 2006).The likelihood of 
success in preventing and reducing the consequences of diabetic kidney disease will 
depend on the availability of resources to monitor patients continuously (WHO, 1994). 
HbA1c levels were not associated with morbidity and mortality in cardiovascular disease or 
development of renal insufficiency. (Diabetes Research and Clinical Practice, 2009) 
In Germany, hemoglobin A1C, dyslipidaemia are risk factors for nephropathy (Raile et al., 
2008). 
 
Our results showed that HbA1c testing is not associated significantly with diagnosis of 
nephropathy (P=0.431). HbA1c test in MOH clinics not available all the time, so patients 
need to do it at private laboratories. UNRWA guidelines not require HbA1c for 
management. 
 
The study conducted in Nigeria,  shows that microalbuminuria is prevalent amongst 
diabetic patients. In Austria, Due to the obvious hazards of nephropathy, it is 
recommended that diabetic patients optimize glucose control, blood pressure control and 
perform annual kidney function tests to prevent unprecedented health complications and 
death could result from nephropathy (Maduka, 2009). Albumin execration rate should be 
assessed at an early stage in patients being evaluated for diabetic nephropathy (Jerums et 
al., 2009). In Spain Early intervention to maintain strict blood pressure control and to 
prevent the development of microalbuminuria is mandatory and will constitute the primary 
aim of intervention in patients with diabetes and also in prediabetes (Ruilope et al., 2009). 
In UK, use of urinary albumin measurement as the front-line test for proteinuria detection 
offers the best chance of improving the sensitivity, quality and consistency of approach to 
the early detection and management of CKD (Lamb, 2009). In our study strong significant 
association was found between annually urine for microalbumin, creatinin testing and 
nephropathy. 93.6% of physicians  recommend kidney function testing for their patients. 
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70.5% of medical files present kidney function tests for the last year. Of our study 
population more than 80% of physicians reported that they recommend urine for 
microalbumin test to these patients, but only 15.65% of medical files presented this test for 
the last year. 
 
6.3.3 neuropathy 
 
In this study, 33,1% of patients had their fasting blood sugar test once in the last month, 
17,6% did HbA1c test before three months, 81,6% of study population tested their lipid 
profile (cholesterol and triglyceride) once in the last year, ophthalmologist’s report was 
found in the 45,6% of files of study population for the last year and electrocardiogram 
(ECG) was done for 43,6% of study population at least once as base line. 
Large scale studies have shown that glycemic control is beneficial in reducing the 
frequency of progression of neuropathy (WHO, 2006). good control of blood glucose 
levels can substantially reduce diabetes complications (UKPDS, 1998). In UK, apart from 
tight blood glucose control, no other treatments have been shown to retard the progression 
of diabetic peripheral neuropathy (DPN). The Eurodiab baseline DPN study found a 
prevalence of 28% for DPN, with glycemic control and duration of diabetes being major 
determinants (Tesfaye et al., 2009). The control of glycosylated hemoglobin (HbA(1c)) 
levels is crucial to the successful treatment of patients with diabetes mellitus (T2DM). 
Glycemic control is a cornerstone for reducing end-organ disease, and HbA(1c) is the 
benchmark for defining glucose control over long durations. The author reviews available 
information from published clinical trials regarding the benefits of tight glycemic control 
in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). He notes that 
published data support the use of tight glucose control for reducing risks of retinopathy, 
nephropathy, and neuropathy in both patients with T1DM and patients with T2DM 
(Spellman, 2009). In Taiwan, blood pressure and fasting glucose level were related to 
somatic neuropathy whereas only systolic blood pressure was correlated with autonomic 
neuropathy. In a univariate analysis, age, renal insufficiency, HbA1c and fasting glucose 
level were significantly associated with somatic neuropathy whereas only systolic blood 
pressure was statistically significantly associated with autonomic neuropathy. In a 
multivariate analysis, systolic blood pressure and fasting glucose level were positively 
associated with somatic neuropathy and systolic blood pressure remained statistically 
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significant for autonomic neuropathy (Hsu et al., 2009). In India, Cardiac autonomic 
neuropathy predisposes patients with diabetes mellitus to silent myocardial infarction 
(SMI). Twenty four hour ambulatory ECG monitoring provides useful diagnostic 
information in early detection and evaluation of SMI in asymptomatic diabetic patients. 
Incidence of SMI was significantly higher in patients with autonomic neuropathy 12/30 
(40%) compared to those without 3/30 (10%) p < 0.001. (Jalal et al., 1999). 
Our results are similar to previous studies around the world. We found a significant 
association between development of neuropathy and FBS (P=0.016), HbA1c (P=0.012) 
and ECG monitoring (P=0.000). More than two thirds of providers state that they 
recommend hemoglobin Alc testing to their patients, but only one quarter (17.6%) of the 
patients medical files confirm this recommendation. Of those physicians who do 
recommend hemoglobin Alc testing to their patients, but only one third of them (35.3%) 
recommend repeat it every three months. Nearly all providers (95.7%) recommend fasting 
glucose monitoring, but fewer than the third (33.1%) of medical files report that they 
actually perform it. Of those physicians who do recommend fasting glucose monitoring, 
less than one half (45.3%) recommend check it even once a month. 43.6% of patients were 
evaluated by ECG since they diagnosed with diabetes. Of our physicians 23.7% perform 
ECG testing to these controlled diabetics. 
6.4   Physicians compliance with diabetes management guidelines 
In this part we will discuss the compliance of physicians with guidelines in general, but not 
separately for the various health care providers.  The number of physicians who are 
included in this study was  6 physicians working at the UNRWA and 8 are from the 
PMRS.  
 
For diabetic patients follow up, WHO recommends fasting and postprandial glucose on 
monthly basis, quarterly HbA1c, yearly chemistry panel, fasting lipid profile, urinalysis 
(including microscopy and urine microalbumin screening).  Also, thyroid stimulating 
hormone should be measured for diabetes type 1 and  type 2,  ECG for adults at baseline, 
and then as clinically indicated, to refer to patients to the ophthalmologist for annual retinal 
screening, or more often as indicated (WHO, 2006) 
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In our study, table 6.1 shows that FBS in the last month was done for 33.1% of patients, 
17.6% of population were tested for HbA1c, lipid profile was performed for the last year 
for 81.6% of diabetics, 70.5% of medical files present kidney function tests for the last 
year, ECG was done only for 43.6% of patients, 45.6% of patients medical files showed 
that their physicians ever sent them for eye examinations. 
 
Table 6.1: comparison between WHO follow up recommendations and our study 
findings  
WHO recommendations physicians 
who 
recommend 
test 
Physicians who 
recommend test 
according to 
guidelines 
Study 
data 
FBS monthly for all patient 95.7% 45.3% 33.1% 
HbA1c quarterly for all 61.2% 35.3% 17.6% 
Lipid profile yearly for all 90.6% 9.4% 81.6% 
Kidney function tests yearly for all 93.6% 17.3% 70.5% 
Urine for microalbumin yearly 82% 14.4% 15.65% 
ECG base line for all 78.4% 23.7% 34.6% 
Ophthalmologist visit yearly for all 86.3% 30.2% 45.6% 
 
In United States only half of patients with diabetes undergo an appropriate examination 
every year (Sinclair et al., 2004).  In Saudi Arabia, it was shown the presence of a gap 
between recommendations of the international guidelines and the actual practices (Al-Elq 
Ah, 2009). In US, Before any intervention, rates of adherence to guidelines were low (15% 
for foot exams, 20% for HbA(1c) measurement, 23% for eye exam referrals, 33% for urine 
protein screening, 44% for lipid profiles, 73% for home glucose monitoring, and 78% for 
blood pressure measurements). One year after development of local consensus guidelines 
and feedback of baseline performance, significant improvements were seen in blood 
pressure measurements (71 vs. 83%; P = 0.002), foot exams (19 vs. 42%; P < 0.001), 
HbA(1c) measurements (26 vs. 37%; P = 0.012), and PCP eye exams (38 vs. 46%; P = 
0.043); a trend toward improvement was seen in referral to eye specialists (25 vs. 33%; P = 
0.059) (Kirkman, 2002). Only 53% patients had HbA1c measurements done in the 
previous year; these persons had a significantly longer duration of diabetes that those who 
did not have their HbA1c measured. Eighty-seven percent of patients had optimal or good 
plasma glucose levels. Compliance with CDA guidelines by physicians was poor; 
physicians were doing about half the recommended checks and procedures (Worrall et al., 
1997). In Estonia, Blood pressure, serum creatinin, eye examination and checking patients' 
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ability to manage their diabetes were the best-followed items while glycosylated 
hemoglobin and weight reduction were the most poorly followed (Anneli et al., 2006). 
Among diabetic patients, regular HbA1c control was reported for 65%, yearly fundoscopy 
for 62%, yearly feet examination for 65%, yearly microalbuminuria control for 49%, 
regular blood pressure control for 96%, and yearly lipid profile for 89%. Regular screening 
of microangiopathic complications was reported for only 33% of diabetic patients. (Patrick 
et al.,2007) In our study, comparing between self-reported physician advice to patients on 
fasting glucose testing and files-reported physician advice is noteworthy (Table 6.1). 
Nearly all providers (95.7%) recommend fasting glucose monitoring, but fewer than the 
third (33.1%) of medical files report that they actually perform it. Of those physicians who 
do recommend fasting glucose monitoring, less than one half (45.3%) recommend check it 
even once a month.  
 
These actually low percentages which indicated in table 6.1, and this lack of compliance 
could be explained by the lack of knowledge of the guidelines by our physicians. 40.3% of 
physicians are familiar with a guidelines for management of type 2 diabetic patients. 
 
In US, the recommendations of ADA include annual comprehensive foot examinations, 
yearly ophthalmologic screening for retinopathy, and urine analysis for microalbuminuria. 
Compliance with practice guidelines by primary care physicians has historically been poor. 
Mechanisms such as the use of patient problem lists and diabetic flow sheets can serve as 
reminders to physicians and can facilitate closer adherence to practice guidelines (Zoorob 
et al., 1997). In Budapest, Microalbuminuria is a sensitive but relatively late marker of 
diabetic kidney disease. Still, screening of diabetic patients for microalbuminuria is of 
great importance since there is no other screening test capable of diagnosing diabetic 
nephropathy at an earlier stage. Compliance with therapeutic guidelines outlined in 
milestone clinical studies of the last years may significantly decrease morbidity, the 
progression of, and the mortality associated with diabetic kidney disease (De chattel et al., 
1997). In Toronto, microalbuminuria screening meets the fundamental some of the burden 
on our health care system. The Canadian Diabetes Association practice guideline regarding 
microalbuminuria screening is an important contribution to the management of patients 
with diabetes. In conscientiously applying the guideline, physicians may be able to prevent 
progressive renal disease, and ultimately renal failure, in many patients with diabetes 
(Sheldon et al., 2002). All individuals with diabetes mellitus should be screened yearly 
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with a spot urine albumin to creatinin ratio to identify those who are at increased risk for 
the development of complications of diabetes mellitus, including nephropathy, retinopathy, 
and cardiovascular disease ( Bennett et al., 2009). 
 
In Palestine, more than two thirds of providers state that they recommend hemoglobin Alc 
testing to their patients, but only one quarter (17.6%) of the patients medical files confirm 
this recommendation. Of those physicians who do recommend hemoglobin Alc testing to 
their patients, but only one third of them (35.3%) recommend repeat it every three months. 
physicians who stated that they did not use the test said that they do not know what is 
HbA1c test (n = 4), and the test is not necessary (n = 14). 
 
The reason for these discrepancies, that majority of physicians are not trained in using the 
guidelines. 25.2% of physicians said that they undergo special training to use the 
guidelines. 
 
Similar discrepancies between physicians' and patients' medical files expectations of care 
were noted for eye examinations of patients with diabetes. More than 86% of providers 
stated that they recommend eye examinations to these patients. Only 45.6% of patients 
medical files showed that their physicians ever sent them for eye examinations, although 
one third 30.2% of physicians said that they recommend eye specialist visit for their 
healthy diabetics once yearly. 
 
Lack of knowledge of guidelines is standing behind this incompliance, because lack of 
knowledge leads to incompliance, just 10% of physicians always adhere the guidelines. 
25.9% of physicians have phondoscope at their work place, and more than two third of 
physicians (69.1%) believe that they need training in using phondoscope. 
 
More than 90% of physicians stated that they recommend lipid profile testing for their 
patients, but we found the lipid profile for the last year in 81.6% of medical files. Just 9.4% 
of physicians ordered lipid profile testing once yearly for their health diabetic. 93.6% of 
physicians told us that they recommend kidney function testing for their patients. 70.5% of 
medical files present kidney function tests for the last year. Only 17.3% of physicians 
recommend repeat kidney function testing for their controlled diabetics once yearly. Of our 
population study more than 80% of physicians reported that they recommend urine for 
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microalbumin test to these patients, but only 15.65% of medical files presented this test for 
the last year. Only 14.4% of physicians know that they should repeat microalbumin testing 
for healthy diabetics at last once yearly. More than two third of physicians (78.4%) stated 
that they recommend electrocardiography (ECG) for their patients. We found ECG in only 
43.6% of patients medical files. Of our physicians 23.7% perform ECG testing to these 
controlled diabetics (Table 6.1). 
 
As revealed by patients’ medical files in this study, the physicians did not undertake 
diabetic management activities recommended by their organizations or WHO 
recommendations. The reasons for this lack of compliance with guidelines could be 
explained by lack of knowledge of the guidelines, lack of training in using these 
guidelines, lack of supervision, lack of belief in the value of the guidelines, and, possibly, 
poor recall of physician advice by patients. 40.3% of physicians are familiar with a 
guidelines for management of type 2 diabetic patients, 20.9% of study population have a 
copy of the guidelines in the work place and 25.2% of physicians said that they undergo 
special training to use the guidelines, just 10% of physicians always adhere the guidelines. 
High statistically significant association was observed between self reported familiarity 
with guidelines and presence of a copy of the guidelines, undergo training on the 
guidelines use, adherence to the guidelines and applicability of the guidelines in the work 
place (P = 0.000). 
  
Summary: 
 
The compliance of our physicians with diabetes management guidelines is low, because 
the majority of them are not familiar with these guidelines and a lot of those who are 
familiar with guidelines are not trained in using these guidelines, which leads to poor 
follow up of our patients which leads to miss diagnosing diabetes complication as earlier as 
possible to prevent their deterioration. 
 
6.5 Health care system's follow up 
 
World health organization (WHO) recommend referral of diabetes patients to different 
kinds of specialists for follow up, WHO emphasize on multi disciplinary team for care 
about diabetics. Health care system should include, diabetes educator, to evaluate patient’s 
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ability to perform self-monitoring of blood glucose and his/her ability to interpret the data, 
dietician, foot-care specialist, ophthalmologist for annual retinal screening, or more often 
as indicated, nephrologists, neurologist, and cardiologist, if needed. The use of 
multidisciplinary mini clinics for diabetes care has the potential to improve clinical 
outcome. These provide team care by a physician, nurse, dietician, chiropodist and health 
educator that will improve treatment and help establish a referral  system for diabetic 
complications. (WHO, 2006) 
 
In our study, according to the availability of different kinds of specialists in the work place, 
just 3.6% of physicians have endocrinologist in their work place, 10.15 have podiatrist, 
27.3% have ophthalmologist, 28.1% have nephrologist, 34.5% of study population have 
nutritionist in their institutions. The services for diabetes diagnosis and follow up and it is 
availability by health care providers are presented previously(see chapter 4, page, 50, 
annex 5). 
  
Of our study population 74.1% of physicians have brushers and posters about diabetes in 
their work place, 30.9% of physicians conducted group health education for diabetic 
patients, 66.2% of physicians performed individual health education. Two third (59.7%) of 
our physicians could not call endocrinologist for consult. The majority (39.6%) of our 
physicians believe that healthy diabetic should be seen by doctor every six months. 
Statistically significant difference was observed between self reported familiarity with 
guidelines and presence of podiatrist (P=0.002), nutritionist in the work place (P=0.039), 
presence of tools of health education like posters and brochures (P=0.010), personal health 
education (P=0.004), and group health education (P=0.000). 
 
In Australia, a one-time, advanced diabetes education program teaching intensive insulin 
self-management with an empowerment style can lead to sustained improvement in patient 
outcomes and reduce use of hospital services for people with Type 2 diabetes on insulin 
(Lowe et al., 2009). In United states, only by teamwork between primary care physician 
and ophthalmologist can blindness from diabetic retinopathy be reduced (Sinclair et al., 
2004). A multifaceted approach to improving diabetes management has led to improved 
performance in clinical measures related to diabetes care that have been shown to reduce 
the risk of patients with diabetes developing diabetes- related complications. All 
components of the diabetes management continuum of care, including primary care 
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physicians, specialists, office staff, patients, diabetes educators, and others, were involved 
in the care improvement activities. The percentage of patients with at least one annual 
HbA1c test increased from 78.5% in 1998 to 90.5% in 2002. During the same time period, 
the percentage of patients whose most recent HbA1c was less than 7.0 increased from 
33.5% to 52.8%, average HbA1c decreased from 8.1 to 7.3, and the percentage of patients 
whose most recent HbA1c was greater than 9.5 decreased from 34.6% to 21.4%. The 
percentage of patients who had an LDL cholesterol screening test within the prior 2 years 
increased from 65.9% in 1998 to 91.7% in 2002. During the same time period, the 
percentage of patients whose most recent LDL cholesterol was less than 130 mg/dL 
increased from 39.9% to 69.8%. The percentage of diabetes patients who had an annual 
eye exam increased from 52% in 1998 to 62% in 2002 (Larsen et al., 2003). In Mexico, 
multidisciplinary team (family practitioner, social worker, dietician, and physical trainer) 
show improvements in the lifestyle and dietary habits of patients with overweight or 
obesity, diabetes, or hypertension (Cueto-Manzano et al., 2009). Modest relationships were 
noted between visit duration and quality of care. Providing counseling or screening 
required additional physician time (Chen et al., 2009). subjects with more frequent visits to 
a multidisciplinary diabetes clinic had lower HbA1C levels during the 3 years of this study 
(Francine et al., 1998). In table 6.2 we can summarize the explanation for discrepancies 
between what physicians recommend and what we actually found in the files.  
Table 6.2: Physicians recommendations and health care system feasibilities 
Comments on health care system Test physicians who 
recommend test 
Study 
results 
HCS in MOH, UNRWA and PMRS 
recommend stable diabetics to visit the 
clinic minimum every 3 months, 
therefore patients could not do FBS 
monthly. 
 
 
FBS 
 
 
95.7% 
 
 
33.1%  
UNRWA not recommend test at all. In 
MOH not always is available, so patients 
do it in private lab. In PMRS patients can 
do it once per year for free. (MOH 
24.7%, UNRWA 0.0%, PMRS 20%).  
 
 
HbA1c 
 
 
61.2% 
 
 
17.6%  
Test recommended and available in all 
organizations for free, so high number of 
patients who did the test (MOH 81.3%, 
UNRWA 95%, PMRS 64.7%) 
 
 
Lipids 
 
 
90.6% 
 
 
81.6% 
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Summary: 
 
Quality of care of diabetic patients can be influenced by health care system (Lobo, 2003). 
Palestinian health care system in general is a mixture, and that is clearly noted in diabetes 
health services, different kinds of health providers with different kinds of guidelines and 
different feasibilities. No one of our three health providers (MOH, UNRWA and PMRS) 
can offer all health services to diabetes patients, absence of multidisciplinary team (no 
endocrinologist, no nephrologist, no ophthalmologist,…ets), no one of health providers has 
all necessary lab tests for diabetics for better follow up, the appointment system which give 
the patient chance to be seen by GP every three months or six months, all of that can lead 
to mismanagement of diabetes complications. Team approach and guidelines give us a 
structured care approach to prevention and treatment. Structured care approach improves 
outcomes (CDA, 2003). 
Test recommended and available all the 
time in MOH and UNRWA for free, 
patients pay for this service at PMRS 
(MOH 78%, UNRWA 98%, PMRS 
11.3%)  
 
KFT 
 
93.6% 
 
70.5%  
 
 
Test not available in all health providers, 
therefore, patients should do this 
expensive test out the clinics. (MOH 
23.1%, UNRWA 9%, PMRS 2%) 
 
 
 
Microalbumin 
 
 
 
82% 
 
 
 
15.65% 
In MOH PHC centers internist is 
available and he can do ECG testing for 
diabetics, majority of ECG sheets 
(68.5%) we found in MOH patients’ files. 
PMRS and UNRWA have only GPs, 
12% of patients both institutions have 
ECG report in their fails.  
 
 
 
ECG 
 
 
 
78.4% 
 
 
 
34.6%  
Our three health providers are not offer 
eye care service for their client. MOH 
give patients yearly special form, by 
which he can check their eyes at private 
sector for some exemption, 50% of MOH 
patients have report in their files. 
UNRWA refer their patients to Sant 
Johns hospital in Toulkarem or Jerusalem 
for free. 70.5% of UNRWA clients have 
checked their eyes. 2% from PMRS have 
a report. 
 
 
 
 
Eye care 
 
 
 
 
86.3% 
 
 
 
 
45.6%  
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6.6  Conclusion: 
 
This study described, for the first time in Palestine, the determinants of type 2 diabetes 
complications management, we identified in this study factors affecting type 2 diabetes 
complications. Diabetic patients medical files in this study reported to have 38.4% 
neuropathy, 26.8% retinopathy, 20.5% nephropathy, 12.1% diabetic foot, 9.5% heart 
attack, 2.4% hypoglycemic crises, 1.1% organ amputation and 0.1% erectile dysfunction. 
We discussed in this study the most prevalent diabetic complications (neuropathy, 
retinopathy and nephropathy). From socio-demographic factors, we found that retinopathy 
was affected by age and educational level. A significant difference was observed between 
retinopathy with age and educational level. Logistic regression showed that the risk to 
develop retinopathy increased by age and the education is a preventive factor. Patients with 
previous coronary artery diseases have a double risk to develop retinopathy. Retinopathy 
was significantly associated with lipid profile testing. 
 
We observed high significant association between nephropathy with age, gender, previous 
coronary artery diseases and annual screening for microalbumin and serum creatinin. 
Multiple regression analysis showed that males have a higher risk to develop nephropathy. 
 
Neuropathy was significantly associated with age, gender, FBS, HbA1c and ECG 
monitoring. Male gender has a greater risk to develop neuropathy. 
 
Lack of physicians compliance with national or WHO guidelines due to lack of knowledge, 
lack of training on use guidelines and lack of supervision on true implementation of these 
guidelines, lead to a lot of discrepancies between what physician reported and what done. 
 
Palestinian health care system is a mixture, and not offered to the patients all health 
services (multidisciplinary team, education, lab test…ets), which need for better follow up 
to prevent or delay or early diagnosing diabetes complications. 
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6.7 Recommendations 
 
The most important issue in diabetes management is to develop strategies which help us to 
prevent or postpone diabetes complications. Therefore, the following are the general  
recommendation at the national level: 
1) There is a need for an awareness program that is development targeting the patients 
who should be aware about the importance of their compliance with the physicians' 
instructions and requests for doing some testing as follow up to control their 
diabetes condition and prevent unnecessary complications.  
2) To work in modifying the health provision for diabetic patients in cooperation 
between all health care providers according to the patients needs. 
3) To have a national advocacy for applying the diabetes guidelines by all health care 
providers, in particular by those working in the private sector. 
4) To have an action plan for having a well trained specialized physicians in diabetes 
care.  
5) From research point of view, to conduct a national study in which the private sector 
will be involved and to assess the diabetic patients needs regarding their health 
care.  
 
Recommendations for the MOH :  
1) To conduct training sessions for all GPs at the PHC centers on diabetes 
management guidelines, the main care provider for diabetes management,. 
2) To provide health education and nutrition clinic service at each diabetes clinic.  
3) To introduce the necessary lab tests, such as: LDL, HDL, urine for microalbumin 
and HbA1c test at the MOH laboratories.   
4) To provide an ophthalmology and podiatristology consultations services in Jenin 
and Tubas districts, and whenever is needed.  
5) To set up monitoring and surveillance plans for the "proper" diabetes management.  
6) To modify patients' files to include more information regarding patients' condition 
such as method of follow up like referral for eye examination, date of diagnosis of 
complications, etc…  
7) To make other types of treatments and medications available at their pharmacies.  
8) To coordinate with the other health care providers to have a unified national plan 
for controlling diabetes complications.   
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Recommendations for the PMRS: 
1) To adopt the local national guidelines, and conduct training for GPs and other 
specialists on these guidelines. 
2) To train the health workers and nurses on diabetes management, since they are in 
direct contact with those patients. 
3) To  provide ophthalmology and podiatristology consultations at the PHC centers.   
4) To provide health educator and nutrition services at each diabetes clinic.  
5) To introduce the necessary lab tests, such as: LDL, HDL, urine for microalbumin 
and HbA1c test at the PMRS laboratories with exemption for diabetics. 
1) To modify patients' files to include more information regarding patients' condition 
such as method of follow up like referral for eye examination, date of diagnosis of 
complications, etc…  
 
Recommendations for the UNRWA: 
1) To adopt HbA1c test to be done quarterly for diabetic patients monitoring 
2) To modify the policy in the monthly FBS and RBS testing and consultations.  
3) To add urine testing for microalbumin in the laboratory testing for these patients.   
4) Registration of the date of diagnosis for each complication in the files 
5) To  provide internist and neurologist consultations for the diabetic patients at their 
clinics. 
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 اﺳﺘﻤﺎرة ﺧﺎﺻﺔ ﺑﺎﻷﻃﺒﺎء
 
 
 أﺧﻲ\ أﺧﺘﻲ اﻟﻤﺸﺎرك\ة: ﻋﻨﺪ اﻻﺟﺎﺑﺔ ﻋﻠﻰ أﺳﺌﻠﺔ اﻻﺳﺘﺒﻴﺎن اﻟﺮﺟﺎء وﺿﻊ رﻗﻢ اﻟﺠﻮاب اﻟﺼﺤﻴﺢ ﻓﻲ اﻟﻤﺮﺑﻊ
 
  (7555749950ﻟﻼﺳﺘﻔﺴﺎر ﻋﻦ أي ﺳﺆال ﻳﻤﻜﻨﻚ اﻻﺗﺼﺎل ﻋﻠﻰ رﻗﻢ )
 
  _____________اﻟﻌﺎﺋﻠﺔ___________اﻟﺜﺎﻧﻲ_________اﻻﺳﻢ اﻷول(: ا رﻏﺒﺖإذ)اﻻﺳﻢ اﻟﺜﻼﺛﻲ .1
 
      .2   _________________________(:إذا رﻏﺒﺖ)رﻗﻢ اﻟﻬﺎﺗﻒ أو اﻟﺠﻮال 
    
  :اﻟﺠﻨﺲ.3 ذآﺮ.1  أﻧﺜﻰ.2
 
   (ﺳﻨﻮات)_____________________:اﻟﻌﻤﺮ.4
 
   _____________(:ﺑﻜﺎﻟﻮرﻳﻮس)ﺳﻨﺔ اﻟﺘﺨﺮج ﻣﻦ اﻟﺠﺎﻣﻌﺔ.5
 
    :ﺑﻠﺪ اﻟﺘﺨﺮج.6  أوروﺑﺎ اﻟﻐﺮﺑﻴﺔ.1  أوروﺑﺎ اﻟﺸﺮﻗﻴﺔ.2
      دول اﻻﺗﺤﺎد اﻟﺴﻮﻓﻴﻴﺘﻲ.3  ﺑﻴﺔدوﻟﺔ ﻋﺮ.4
    ﺣﺪد,ﻏﻴﺮ ذﻟﻚ.5 
 
   :ﻧﻮع اﻟﺘﺨﺼﺺ,إذا آﻨﺖ أﺧﺼﺎﺋﻲ.7 ﻏﺪد ﺻﻤﺎء.1  ﺳﻜﺮي.2  ﺑﺎﻃﻨﻲ.3
   ﻋﻴﻮن.4  آﻠﻰ.5  ﺣﺪد,ﻏﻴﺮ ذﻟﻚ.6
 
   ____________:ﺳﻨﺔ إﻧﻬﺎء اﻟﺘﺨﺼﺺ.8
 
   :ﻣﻜﺎن ﻋﻤﻠﻚ اﻷﺳﺎﺳﻲ.9 ﺻﺤﺔ.1 وآﺎﻟﺔ ﻏﻮث.2  ﺟﻤﻌﻴﺔ أهﻠﻴﺔ.3  ﻗﻄﺎع ﺧﺎص.4
 ,ﻏﻴﺮ ذﻟﻚ.8
 ﺣﺪد
   ﻋﻴﺎدة ﺧﺎﺻﺔ.5 ﻣﺴﺘﺸﻔﻰ ﺣﻜﻮﻣﻲ.6  ﺧﺪﻣﺎت ﻋﺴﻜﺮﻳﺔ.7
 
   (ﺳﻨﻮات)_____________:ﻋﺪد اﻟﺴﻨﻮات اﻟﺘﻲ ﻋﻤﻠﺘﻬﺎ ﻓﻲ ﺗﻠﻚ اﻟﻤﺆﺳﺴﺔ أو اﻟﻌﻴﺎدة.01
 
   :ﻣﻜﺎن ﻋﻤﻠﻚ اﻟﺜﺎﻧﻮي.11 وآﺎﻟﺔ ﻏﻮث.1 ﺟﻤﻌﻴﺔ أهﻠﻴﺔ.2  ﻗﻄﺎع ﺧﺎص.3
   ﻋﻴﺎدة ﺧﺎﺻﺔ.4 ﻻ ﻳﻮﺟﺪ.5  ﺣﺪد, ﻏﻴﺮ ذﻟﻚ.6
 
   ﺎن ﻋﻤﻠﻚ ﻣﺮﺿﻰ ﺳﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ؟ هﻞ ﻳﺮاﺟﻌﻚ ﻓﻲ ﻣﻜ.21  ﻧﻌﻢ.1  ﻻ.2
 
   (ﺳﻨﻮات)____________:ﻋﺪد اﻟﺴﻨﻮات اﻟﺘﻲ ﺗﻌﺎﻣﻠﺖ ﻓﻴﻬﺎ ﻣﻊ ﻣﺮﺿﻰ اﻟﺴﻜﺮي.31
 
   (ﺗﻘﺮﻳﺒﺎ)____________آﻢ ﻣﺮﻳﺾ ﺳﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ ﻳﺮاﺟﻌﻚ ﺷﻬﺮﻳﺎ؟.41
 
51.ﺧﺎص ﺑﺄﻃﺒﺎء اﻟﻘﻄﺎع اﻟﺨﺎص,ﻣﺎ هﻲ ﻧﺴﺒﺔ اﻟﻤﺮﺿﻰ اﻟﺬﻳﻦ ﻳﺮاﺟﻌﻮﻧﻚ و ﻓﻲ ﻧﻔﺲ اﻟﻮﻗﺖ ﻳﺮاﺟﻌﻮن ﻋﻴﺎدات 
  %________________(ﺗﻘﺮﻳﺒﺎ)اﻟﺼﺤﺔ أو اﻟﻮآﺎﻟﺔ ؟
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   هﻞ ﺗﻨﺼﺢ ﻣﺮﺿﺎك ﺑﻔﺤﺺ اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم ﻓﻲ اﻟﻤﻨﺰل؟.61  ﻧﻌﻢ.1  ﻻ.2
 
   ﻣﺮة ﻳﻮﻣﻴﺎ.1
  ﻣﺮﺗﻴﻦ ﻳﻮﻣﻴﺎ.2
  آﻢ ﻣﺮة ﺗﻨﺼﺤﻬﻢ ﺑﻌﻤﻞ اﻟﻔﺤﺺ؟,إذا آﺎن اﻟﺠﻮاب ﻧﻌﻢ. 71
  )dellortnoc tneitap eht fi(
    ﻳﻮم ﺑﻌﺪ ﻳﻮم.3
    اﺳﺒﻮﻋﻴﺎ.4
    ﺮﻳﺎﺷﻬ.5
    ﻏﻴﺮ ذﻟﻚ.6
    ﻟﻢ اﺣﺪد ﻟﻬﻢ. 7
    ﻻ داﻋﻲ.8
 
 
  )c1AbH( هﻞ ﺗﻌﺮف ﻣﺎ هﻮ ﻓﺤﺺ اﻟﺴﻜﺮ اﻟﺘﺮاآﻤﻲ؟.81 ﻧﻌﻢ.1  ﻻ.2
 
   هﻞ ﺗﺴﺘﺨﺪم هﺬا اﻟﻔﺤﺺ ﻟﺘﻘﻴﻴﻢ ﻣﺮﺿﺎك اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ داﺋﻤﺎ؟.91  ﻧﻌﻢ.1  ﻻ.2
 
  ﺷﻬﺮﻳﺎ.1
آﻞ ﺛﻼث ﺷﻬﻮر.2
  ﻣﺎ هﻲ اﻟﻔﺘﺮة اﻟﺘﻲ ﺗﻄﻠﺐ ﻓﻴﻬﺎ ﻣﻦ ﻣﺮﺿﺎك إﻋﺎدة اﻟﻔﺤﺺ؟.02
    )dellortnoc tneitap eht fi(      
   آﻞ ﺳﺖ ﺷﻬﻮر.3
   ﺳﻨﻮﻳﺎ.4
   آﻞ ﺳﻨﺘﻴﻦ.5
   ﻻ اﻃﻠﺒﻪ ﺑﺘﺎﺗﺎ.6
   ﺣﺪد,ﻏﻴﺮ ذﻟﻚ.7
 
   (ﺗﻘﺮﻳﺒﺎ%)_________ﻣﺎ هﻲ ﻧﺴﺒﺔ اﻟﻤﺮﺿﻰ ﻣﻦ ﻣﺠﻤﻮع ﻣﺮﺿﺎك اﻟﺬﻳﻦ ﻃﻠﺒﺖ ﻣﻨﻬﻢ إﺟﺮاء اﻟﻔﺤﺺ؟.12
 
   ﻓﻤﺎ هﻮ اﻟﺴﺒﺐ؟,ﺗﺴﺘﺨﺪم هﺬا اﻟﻔﺤﺺإذا آﻨﺖ ﻻ .22 ﻻ أﻋﺮف ﻣﺎ هﻴﺔ هﺬا اﻟﻔﺤﺺ.1
   ﺑﺴﺒﺐ ﺗﻜﻠﻔﺘﻪ اﻟﻌﺎﻟﻴﺔ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﻤﺮﻳﺾ.2
   ﻏﻴﺮ ﺿﺮوري.3
   ﺣﺪد,ﻏﻴﺮ ذﻟﻚ.4
 
   هﻞ ﺗﻘﻮم ﺑﺘﺤﻮﻳﻞ ﻣﺮﺿﺎك اﻟﺴﻜﺮي  ﻟﻴﻔﺤﺼﻮا ﻋﻴﻮﻧﻬﻢ ﻋﻨﺪ أﺧﺼﺎﺋﻲ اﻟﻌﻴﻮن؟.32  ﻧﻌﻢ.1  ﻻ.2
 
   ﺷﻬﺮﻳﺎ.1
   آﻞ ﺛﻼث ﺷﻬﻮر.2
  آﻞ ﺳﺖ ﺷﻬﻮر.3
  ﺧﻼل اي ﻓﺘﺮة ﻳﺠﺐ ﻋﻠﻴﻬﻢ ﻓﺤﺺ ﻋﻴﻮﻧﻬﻢ؟,إذا آﺎن اﻟﺠﻮاب ﻧﻌﻢ.42
  (ﺎل ﻻ ﻳﻮﺟﺪ ﻣﻀﺎﻋﻔﺎت ﻓﻲ ﻋﻴﻮن اﻟﻤﺮﻳﺾﻓﻲ ﺣ)
 
    ﺳﻨﻮﻳﺎ.4
    آﻞ ﺳﻨﺘﻴﻦ.5
    ﺣﺴﺐ اﻣﻜﺎﻧﻴﺘﻬﻢ. 6
 
   هﻞ  ﺗﺤﺼﻞ ﻣﻦ اﻟﻤﺮﻳﺾ ﻋﻞ ﺗﻘﺮﻳﺮ ﻣﻦ أﺧﺼﺎﺋﻲ اﻟﻌﻴﻮن؟.52  ﻧﻌﻢ.1  ﻻ.2
 
   ﻣﻮﺟﻮد ﻋﻨﺪك ﻓﻲ اﻟﻌﻴﺎدة؟( ﻓﻮﻧﺪوﺳﻜﻮﺑﻲ)هﻞ ﺟﻬﺎز ﻓﺤﺺ اﻟﻌﻴﻦ.62  ﻧﻌﻢ.1  ﻻ.2
 
   هﻞ ﺗﺸﻌﺮ ﺑﺎﻟﺤﺎﺟﺔ ﻟﻠﺘﻤﺮﻳﻦ ﻋﻠﻰ اﺳﺘﺨﺪام ﺟﻬﺎز اﻟﻔﻮﻧﺪوﺳﻜﻮﺑﻲ؟.72  ﻧﻌﻢ.1  ﻻ.2
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اﻟﺮﺟﺎء ﺿﻊ رﻗﻢ )ﻣﺎ هﻲ ﻋﺪد اﻟﻤﺮات اﻟﺘﻲ ﺗﺠﺮي ﻓﻴﻬﺎ اﻟﻔﺤﻮﺻﺎت اﻟﺘﺎﻟﻴﺔ ﻟﻤﺮﺿﻰ اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ؟.82       
(                اﻻﺟﺎﺑﺔ اﻟﺼﺤﻴﺤﺔ  ﺑﺎﻟﻤﺮﺑﻊ
ﻻ أﻗﻮم .6
 ﺑﺬﻟﻚ
آﻞ ﺳﺖ .4  ﺳﻨﻮﻳﺎ.5
 ﺷﻬﻮر
 ﺛﻼث آﻞ.3
ﺷﻬﻮر
  اﺳﺒﻮﻋﻴﺎ.1 ﺷﻬﺮﻳﺎ.2
  ﻓﺤﺺ اﻟﺴﻜﺮ.1   
  ﻓﺤﺺ اﻟﻀﻐﻂ.2   
  ﻓﺤﺺ اﻟﺪهﻮن.3   
  ﺑﺮوﺗﻴﻦ ﻓﻲ اﻟﺒﻮل.4   
 )airunimublaorciM(
  ﻓﺤﺺ اﻟﺸﺒﻜﻴﺔ.5   
 )IMB(ﻣﺆﺷﺮ آﺘﻠﺔ اﻟﺠﺴﻢ.6   
  اﻟﻜﺮﻳﺎﺗﻨﻴﻦ.7   
  ﻓﺤﺺ اﻻﻗﺪام.8   
  ﺗﺨﻄﻴﻂ ﻗﻠﺐ.9   
 
ﻣﺎ هﻲ اﻟﻔﺘﺮة اﻟﺘﻲ ﻳﺠﺐ ﻋﻠﻰ ﻣﺮﻳﺾ اﻟﺴﻜﺮي ﻣﻦ اﻟﻨﻮع ,ﺣﺴﺐ وﺟﻬﺔ ﻧﻈﺮك.92  ﺷﻬﺮﻳﺎ.1
ﺳﺮﻳﺮﻳﺎ  ﻣﻦ ﻗﺒﻞ اﻟﻄﺒﻴﺐ؟ أن ﻳﻔﺤﺺ )dellortnoC( اﻟﺜﺎﻧﻲ اﻟﻤﺴﻴﻄﺮ ﻋﻠﻴﻪ
 
    آﻞ ﺛﻼث ﺷﻬﻮر.2
    آﻞ ﺳﺖ ﺷﻬﻮر.3
    ﺳﻨﻮﻳﺎ.4
    ﺣﺪد,ﻏﻴﺮ ذﻟﻚ.5
 
؟(dellortnoC)ﻣﺘﻰ ﻳﺮاﺟﻌﻚ ﻣﺮﻳﺾ اﻟﺴﻜﺮي اﻟﻤﺴﻴﻄﺮ ﻋﻠﻴﻪ.03  آﻞ ﺷﻬﺮ.1
  آﻞ ﺛﻼث ﺷﻬﻮر.2
  آﻞ ﺳﺖ ﺷﻬﻮر.3
  آﻞ ﺳﻨﺔ ﻣﺮة.4
  ﻏﻴﺮ ذﻟﻚ.5
 
هﻞ ﻳﺴﺘﻄﻴﻊ اﻟﻤﺮﻳﺾ اﻻﺗﺼﺎل ﺑﻚ ﻟﻼﺳﺘﺸﺎرة ﻓﻲ أي وﻗﺖ؟.13 ﻧﻌﻢ.1  ﻻ.2
 
؟ﻋﺎدةهﻞ ﺗﺤﻮل ﻣﺮﺿﺎك ﻷﺧﺼﺎﺋﻲ اﻟﻐﺪد .23  ﻧﻌﻢ.1  ﻻ.2
 
.33  ﻟﻤﺎذا؟,إذا آﺎن اﻟﺠﻮاب ﻻ  ﻻ ﻳﻮﺟﺪ.1  ﻻ داﻋﻲ.2
 
ﻣﺎ هﻲ اﻟﻤﺴﺎﻓﺔ اﻟﺘﻲ ﻳﺒﻌﺪهﺎ ﻋﻨﻚ أﺧﺼﺎﺋﻲ اﻟﻐﺪد؟.43  ﻓﻲ ﻧﻔﺲ اﻟﺒﻨﺎﻳﺔ.1
  ﻓﻲ ﻧﻔﺲ اﻟﻤﺪﻳﻨﺔ.2
  ﻓﻲ ﻣﺪﻳﻨﺔ أﺧﺮى.3
 
هﻞ ﻋﻨﺪك اﻹﻣﻜﺎﻧﻴﺔ ﻟﻼﺗﺼﺎل ﺑﺎﺧﺼﺎﺋﻲ ﻏﺪد ﻣﻦ اﺟﻞ اﻻﺳﺘﺸﺎرة؟.53  ﻧﻌﻢ.1  ﻻ.2
 
  :هﻞ ﻳﻮﺟﺪ اﻟﺘﺎﻟﻴﺔ, (ﻣﺆﺳﺴﺔ أو ﻋﻴﺎدة ﺧﺎﺻﺔ)ﻓﻲ ﻣﻜﺎن ﻋﻤﻠﻚ . 63
   (ﻤﺮض ﻣﺪربﻃﺒﻴﺐ أو ﻣ)أﺧﺼﺎﺋﻲ ﻗﺪم .1  ﻧﻌﻢ.1  ﻻ.2
   أﺧﺼﺎﺋﻲ آﻠﻰ.2  ﻧﻌﻢ.1  ﻻ.2
   أﺧﺼﺎﺋﻲ ﻏﺪد.3  ﻧﻌﻢ.1  ﻻ.2
   أﺧﺼﺎﺋﻲ ﻋﻴﻮن.4  ﻧﻌﻢ.1  ﻻ.2
   أﺧﺼﺎﺋﻲ ﺗﻐﺬﻳﺔ.5  ﻧﻌﻢ.1  ﻻ.2
   هﻞ ﻳﺘﻮﻓﺮ ﻓﻲ ﻣﻜﺎن ﻋﻤﻠﻚ ﻧﺸﺮات أو ﺑﻮﺳﺘﺮات ﻋﻦ ﻣﺮض اﻟﺴﻜﺮي؟.6  ﻧﻌﻢ.1  ﻻ.2
   هﻞ ﻳﺘﻢ ﻓﻲ ﻣﻜﺎن ﻋﻤﻠﻚ ﺗﺜﻘﻴﻒ ﻓﺮدي ﻟﻠﻤﺮﺿﻰ؟.7  ﻧﻌﻢ.1  ﻻ.2
   ﻞ ﻳﺘﻢ ﻓﻲ ﻣﻜﺎن ﻋﻤﻠﻚ ﺗﺜﻘﻴﻒ ﺟﻤﺎﻋﻲ ﻟﻠﻤﺮﺿﻰ؟ه.8  ﻧﻌﻢ.1  ﻻ.2
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 اﻷﺳﺌﻠﺔ اﻟﺘﺎﻟﻴﺔ ﻳﺴﺘﻄﻴﻊ اﻹﺟﺎﺑﺔ ﻋﻠﻴﻬﺎ ﺟﻤﻴﻊ اﻷﻃﺒﺎء ﺑﺎﺳﺘﺜﻨﺎء أﻃﺒﺎء اﻷﻣﺮاض اﻟﻨﺴﺎﺋﻴﺔ:
 
  إذا ﺣﻀﺮ اﻟﻤﺮﻳﺾ ﻟﻌﻴﺎدﺗﻚ ﺑﻌﺪ أآﺜﺮ ﻣﻦ ﺷﻬﺮ ﻣﻦ زﻳﺎرﺗﻪ اﻟﺴﺎﺑﻘﺔ و ﺣﺴﺐ ﻣﻮﻋﺪ ﺣﺪدﺗﻪ ﻟﻪ؟.73
  ﺟﺮاهﺎ ﻟﻨﻔﺴﻪ  ﻓﻲ اﻟﻤﻨﺰل؟هﻞ ﺗﻄﻠﺐ ﻣﻨﻪ ﻧﺘﺎﺋﺞ ﻓﺤﺺ اﻟﺴﻜﺮ اﻟﺘﻲ .1  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﻘﻮم ﺑﻘﻴﺎس اﻟﻀﻐﻂ ﻟﻪ وهﻮ ﻣﺴﺘﻠﻖ؟. 2  ﻧﻌﻢ.1  ﻻ.2
  ﻟﻠﻤﺮﻳﺾ؟( ﻓﻮﻧﺪوﺳﻜﻮﺑﻲ)هﻞ ﺗﻘﻮم ﺑﻔﺤﺺ اﻟﺸﺒﻜﻴﺔ .3  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﻘﻮم ﺑﻔﺤﺺ ﻗﺪﻣﻴﻪ؟.4  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﻘﻮم ﺑﻔﺤﺺ ﻓﻢ اﻟﻤﺮﻳﺾ؟.5  ﻧﻌﻢ.1  ﻻ.2
  (اﺣﺴﺎس,ﻗﻮة,ﻣﻨﻌﻜﺴﺎت)هﻞ ﺗﻘﻮم ﺑﺎﻟﻔﺤﺺ اﻟﻌﺼﺒﻲ ﻟﻠﻤﺮﻳﺾ.6  ﻧﻌﻢ.1  ﻻ.2
 
 
 اﻷﺳﺌﻠﺔ اﻟﺘﺎﻟﻴﺔ ﺧﺎﺻﺔ ﻓﻘﻂ ﺑﺄﻃﺒﺎء اﻷﻣﺮاض اﻟﻨﺴﺎﺋﻴﺔ:
 
  :اذاﺣﻀﺮت ﻟﻌﻴﺎدﺗﻚ ﻣﺮﻳﻀﺔ ﺳﻜﺮي  ﻣﻦ اﻟﻨﻮع اﻟﺜﺎﻧﻲ.83
  هﻞ ﺗﺴﺄﻟﻬﺎ ﻋﻦ ﻧﺘﺎﺋﺞ ﻓﺤﺺ اﻟﺴﻜﺮ ﻟﺪﻳﻬﺎ؟.1  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﻘﻴﺲ ﻟﻬﺎ اﻟﻀﻐﻂ و هﻲ ﻣﺴﺘﻠﻘﻴﺔ؟.2  ﻧﻌﻢ.1  ﻻ.2
   هﻞ ﺗﻘﻴﺲ هﺎ اﻟﻮزن؟.3  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﻘﻮم ﺑﻔﺤﺺ أﻗﺪام اﻟﻤﺮﻳﻀﺔ؟.4  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﻘﻮم ﺑﻔﺤﺺ اﻟﺸﺒﻜﻴﺔ؟.5  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﻘﻮم ﺑﻔﺤﺺ ﻓﻢ اﻟﻤﺮﻳﻀﺔ؟.6  ﻧﻌﻢ.1  ﻻ.2
  (إﺣﺴﺎس,ﻗﻮة,ﻣﻨﻌﻜﺴﺎت)هﻞ ﺗﻘﻮم ﺑﺎﻟﻔﺤﺺ اﻟﻌﺼﺒﻲ ﻟﻠﻤﺮﻳﻀﺔ.7  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﺤﻮﻟﻬﺎ ﻟﻠﻄﺒﻴﺐ اﻟﻤﺨﺘﺺ ﻗﺒﻞ إﻋﻄﺎﺋﻬﺎ أي ﻋﻼج؟.8  ﻧﻌﻢ.1  ﻻ.2
 
  ﻚ ﺳﻴﺪة ﺣﺎﻣﻞ وهﻲ ﺑﺎﻷﺻﻞ ﻣﺮﻳﻀﺔ ﺳﻜﺮي ﻧﻮع ﺛﺎﻧﻲ؟إذا ﺣﻀﺮت ﻟﻌﻴﺎدﺗ.93
  ؟( ﺣﺒﻮب ﺳﻜﺮي)هﻞ ﺗﺒﻘﻴﻬﺎ ﻋﻠﻰ ﻋﻼﺟﻬﺎ اﻟﺴﺎﺑﻖ .1  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﻘﻮم أﻧﺖ ﺑﺘﻐﻴﻴﺮ اﻟﺤﺒﻮب ﻻﻧﺴﻮﻟﻴﻦ؟.2  ﻧﻌﻢ.1  ﻻ.2
  هﻞ ﺗﻘﻮم ﺑﺘﺤﻮﻳﻠﻬﺎ ﻟﻠﻤﺘﺨﺼﺺ ﺑﺤﻤﻞ اﻟﺴﻜﺮي؟.3  ﻧﻌﻢ.1  ﻻ.3
 
 اﻷﺳﺌﻠﺔ اﻟﺘﺎﻟﻴﺔ هﻲ ﻟﺠﻤﻴﻊ اﻷﻃﺒﺎء ﺑﺪون اﺳﺘﺜﻨﺎء:
 
  ﻟﻌﻼج ﻣﺮض اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ؟)senilediuG(دﻟﻴﻞ  ﻋﻠﻰ هﻞ أﻧﺖ ﻣﻄﻠﻊ.04  ﻧﻌﻢ.1  ﻻ.2
 
   هﻞ ﺗﻤﻠﻚ ﻧﺴﺨﺔ ﻣﻦ هﺬا اﻟﺪﻟﻴﻞ  ﻓﻲ ﻣﻜﺎن ﻋﻤﻠﻚ؟, إذا آﺎن اﻟﺠﻮاب ﻧﻌﻢ.14  ﻧﻌﻢ.1  ﻻ.2
 
   هﻞ ﺗﻠﻘﻴﺖ ﺗﺪرﻳﺐ ﻋﻠﻰ اﺳﺘﺨﺪام دﻟﻴﻞ ﻟﻌﻼج ﻣﺮﺿﻰ اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ؟.24  ﻧﻌﻢ.1  ﻻ.2
 
هﻞ ﺗﻠﺘﺰم ﺑﺈرﺷﺎدات ذﻟﻚ اﻟﺪﻟﻴﻞ ﻓﻲ .34 داﺋﻤﺎ.1 ﻏﺎﻟﺒﺎ.2  اﻧﺎدر.3  ﻣﻄﻠﻘﺎ.4
 ﻋﻼج ﻣﺮﺿﻰ اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ؟
 
 
آﻴﻒ ﺗﻘﻴﻢ اﺳﺘﺨﺪام هﺬا اﻟﺪﻟﻴﻞ ﻓﻲ ﻋﻼج ﻣﺮﺿﻰ .44 ﻣﻄﺒﻘﺔ ﺟﺪا.1  ﻣﻄﺒﻘﺔ ﺟﺰﺋﻴﺎ.2  ﻏﻴﺮ ﻣﻄﺒﻘﺔ.2
 اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ ﻓﻲ ﻣﻜﺎن ﻋﻤﻠﻚ أو ﻣﺆﺳﺴﺘﻚ؟
 
 
ﻣﻨﻈﻤﺔ .3
 اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ
   ﻣﻦ هﻲ اﻟﺠﻬﺔ اﻟﺘﻲ وﺿﻌﺖ هﺬا اﻟﺪﻟﻴﻞ؟.54  زارة اﻟﺼﺤﺔو.1  وآﺎﻟﺔ اﻟﻐﻮث.2
, ﺟﻬﺔ أﺧﺮى.5 
 اذآﺮهﺎ
    اﻹﻏﺎﺛﺔ اﻟﻄﺒﻴﺔ4
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آﻴﻒ ﺗﻘﻴﻢ اﻟﻤﻌﻴﻘﺎت اﻟﺘﺎﻟﻴﺔ ﻟﻼﻟﺘﺰام ﺑﺪﻟﻴﻞ اﻹرﺷﺎدات اﻟﺨﺎص ﺑﻌﻼج ﻣﺮﺿﻰ اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ؟.64          
  إﻃﻼﻗﺎ.1  ﻧﺎدرا.2  ﻋﺎدة.3  ﻏﺎﻟﺒﺎ.4
  داتﻋﺪم ﺗﻮﻓﺮ دﻟﻴﻞ ﻟﻺرﺷﺎ.1   
  ﻋﺪم وﺿﻮح ﺗﻠﻚ اﻹرﺷﺎدات.2   
  ﻋﺪم ﺗﻌﺎون اﻟﻤﺮﺿﻰ.3   
  اﻹﻣﻜﺎﻧﻴﺎت اﻟﻤﺎدﻳﺔ ﻟﻠﻤﺮﺿﻰ.4   
  ﻋﺪم اهﺘﻤﺎم اﻟﻤﺮﺿﻰ.5   
  ﻻ ﻳﻮﺟﺪ وﻗﺖ آﺎﻓﻲ ﻋﻨﺪ اﻟﻄﺒﻴﺐ ﻟﺘﺘﺒﻊ اﻹرﺷﺎدات.6   
  ﻋﺪم ﺗﺪرﻳﺒﻲ ﻋﻠﻰ اﺳﺘﺨﺪام دﻟﻴﻞ اﻹرﺷﺎدات.7   
  ﻦ ﺗﻌﻤﻴﻢ اﻟﺪﻟﻴﻞﻻ ﻳﻮﺟﺪ دﻋﻢ ﻣﻦ ﻗﺒﻞ اﻟﻤﺴﺌﻮﻟﻴﻦ ﻋ.8   
  ﻋﺪم وﺟﻮد ﺗﻐﺬﻳﺔ راﺟﻌﺔ ﻣﻦ ﻗﺒﻞ اﻷﺧﺼﺎﺋﻴﻴﻦ.9   
ﻋﺪم وﺟﻮد إﻣﻜﺎﻧﻴﺎت ﻹﺟﺮاء ﺟﻤﻴﻊ اﻟﻔﺤﻮﺻﺎت اﻟﻼزﻣﺔ .01   
 ﻟﻠﻤﺮﺿﻰ
  اذآﺮهﺎ, أﺧﺮى. 11   
 
 
 
 
 
  :هﻞ ﺗﻮد ﺑﺎﺿﺎﻓﺔ ﻣﻼﺣﻈﺎت اﺧﺮى
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  ﻣﺨﻴﻢ.3ﻣﺪﻳﻨﺔ                  .2ﻗﺮﻳﺔ                 .1:          ﻣﻜﺎن اﻹﻗﺎﻣﺔ.01
 
  ﺳﻠﺒﻲ.2اﻳﺠﺎﺑﻲ               .1:               ﺗﺎرﻳﺦ ﻋﺎﺋﻠﻲ ﻟﻤﺮض اﻟﺴﻜﺮي.11
     
  اﻟﺴﻤﻨﺔ.4أﻣﺮاض ﺷﺮاﻳﻴﻦ اﻟﻘﻠﺐ      .3(        دﺳﻠﺒﻴﺪﻳﻤﻴﺎ)ﺧﻠﻞ ﻓﻲ اﻟﺪهﻮن. 2ﺿﻐﻂ        .1:  أﻣﺮاض ﻣﺰﻣﻨﺔ أﺧﺮى.21
 
  ﻻ.2ﻧﻌﻢ           .1هﻞ ﻳﻮﺟﺪ ﻓﺤﺺ ﻟﻨﺴﺒﺔ اﻟﺴﻜﺮ ﺧﻼل اﻟﺸﻬﺮ اﻟﻤﺎﺿﻲ؟                 .31
 
  ﻻ.2          ﻧﻌﻢ .1هﻞ ﻳﻮﺟﺪ ﻓﺤﺺ ﺳﻜﺮي ﺗﺮاآﻤﻲ ﺧﻼل اﻟﺜﻼث ﺷﻬﻮر اﻟﻤﺎﺿﻴﺔ؟    .41
 
  ﻻ.2ﻧﻌﻢ           .1هﻞ ﻳﻮﺟﺪ ﻓﺤﺺ ﺷﺎﻣﻞ ﻟﻠﺪهﻮن ﺧﻼل اﻟﻌﺎم اﻟﻤﺎﺿﻲ؟                 .51
 
  ﻻ.2ﻧﻌﻢ           .1هﻞ ﻳﻮﺟﺪ ﻓﺤﺺ وﻇﻴﻔﺔ اﻟﻜﻠﻰ ﺧﻼل اﻟﻌﺎم اﻟﻤﺎﺿﻲ؟                  .61
 
  ﻻ.2      ﻧﻌﻢ     .1هﻞ ﻳﻮﺟﺪ ﻓﺤﺺ ﺑﻮل ﻟﻠﻤﺎﻳﻜﺮوأﻟﺒﻮﻣﻴﻦ ﺧﻼل اﻟﻌﺎم اﻟﻤﺎﺿﻲ؟        .71
 
  ﻻ.2ﻧﻌﻢ           .1هﻞ ﻳﻮﺟﺪ ﺗﻘﺮﻳﺮ ﻣﻦ ﻃﺒﻴﺐ اﻟﻌﻴﻮن ﺧﻼل اﻟﻌﺎم اﻟﻤﺎﺿﻲ؟             .81
 
  ﻻ.2ﻧﻌﻢ           .1هﻞ ﻳﻮﺟﺪ ﺗﺨﻄﻴﻂ ﻗﻠﺐ و ﻟﻮ ﻣﺮة واﺣﺪة ﻋﻨﺪ ﻓﺘﺢ اﻟﻤﻠﻒ؟             .91
 
  ﺣﻤﻴﺔ ﻓﻘﻂ.4ﻧﺴﻮﻟﻴﻦ                    ا.3ﺣﺒﻮب و اﻧﺴﻮﻟﻴﻦ                 .2ﺣﺒﻮب               .1:  ﻧﻈﺎم اﻟﻌﻼج.02
 
  ﻻ.2ﻧﻌﻢ         .1.   هﻞ ﻳﻮﺟﺪ ﻋﻨﺪ اﻟﻤﺮﻳﺾ ﺟﻬﺎز ﻟﻔﺤﺺ اﻟﺴﻜﺮ ﻓﻲ اﻟﺒﻴﺖ.12
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  :  وﺟﻮد اﻟﻤﻀﺎﻋﻔﺎت.22
 
  اﻹﺻﺎﺑﺔ ﺑﻨﻮﺑﺔ ﻗﻠﺒﻴﺔ.5   (          رﺗﻴﻨﻮﺑﺎﺛﻲ)اﻋﺘﻼل ﻓﻲ اﻟﺸﺒﻜﻴﺔ .1
  ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم.6(                ﻧﻴﻮروﺑﺎﺛﻲ)اﻋﺘﻼل ﻋﺼﺒﻲ .2
  هﺒﻮط اﻟﺴﻜﺮ.7(                   ﻧﻔﺮوﺑﺎﺛﻲ)اﻋﺘﻼل آﻠﻮي .3
 ﺑﺘﺮ أﻋﻀﺎء ﺑﺴﺒﺐ اﻟﺴﻜﺮي.8            ﻗﺪم ﺳﻜﺮﻳﺔ                         .4
  ﺿﻌﻒ ﺟﻨﺴﻲ. 9              
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
861 
 )3( xidneppA
 
                      
  
 اﺳﺘﻤﺎرة ﺧﺎﺻﺔ ﺑﺎﻟﻤﺮآﺰ اﻟﺼﺤﻲ
 
 
  _____________________________________________________:آﺰاﺳﻢ اﻟﻤﺮ.1
 
  ____________________________________________________:ﺗﺒﻌﻴﺔ اﻟﻤﺮآﺰ.2
 
  ___________________________________________:اﻟﺨﺪﻣﺎت اﻟﺘﻲ ﻳﻘﺪﻣﻬﺎ اﻟﻤﺮآﺰ.3
 
  _______________________________:ياﻟﻔﺤﻮﺻﺎت اﻟﻤﺨﺒﺮﻳﺔ اﻟﻤﺘﻮﻓﺮة ﻟﻤﺮﺿﻰ اﻟﺴﻜﺮ.4
 ______________________________________________________________
 
  ____________________________________________________:ﻋﺪد اﻟﻤﻮﻇﻔﻴﻦ.5
 
  ___________________________________________________:ﻋﺪد اﻟﺘﻤﺮﻳﺾ.6
 
  ل.2ﻧﻌﻢ       .1      هﻞ ﺗﻠﻘﻰ اﻟﺘﻤﺮﻳﺾ ﺗﺪرﻳﺐ ﺧﺎص ﺑﺎﻟﺴﻜﺮي؟ .7
 ا
  ﻻ.2ﻧﻌﻢ       .1هﻞ ﻳﻮﺟﺪ أﺧﺼﺎﺋﻲ ﺗﻐﺬﻳﺔ ﻟﻤﺮﺿﻰ اﻟﺴﻜﺮي؟       .8
 
  آﻴﻒ ﻳﺤﺼﻞ ﻣﺮﺿﻰ اﻟﺴﻜﺮي ﻋﺎدة ﻋﻠﻰ اﺳﺘﺸﺎرة أﺧﺼﺎﺋﻲ اﻟﺘﻐﺬﻳﺔ ﻓﻲ هﺬا اﻟﻤﺮآﺰ؟, إذا اﻟﺠﻮاب ﻧﻌﻢ.9
 
  ﺣﺪد,ﻏﻴﺮ ذﻟﻚ.6  ﻻ ﻳﻮﺟﺪ ﺟﺪول زﻣﻨﻲ  .5آﻞ ﺳﻨﺔ    .4آﻞ ﺳﺖ ﺷﻬﻮر    .3آﻞ ﺛﻼث ﺷﻬﻮر    .2  زﻳﺎرة  آﻞ .1
 
  ﻻ.2ﻧﻌﻢ     .1هﻞ ﺗﻠﻘﻰ ﻃﺒﻴﺐ اﻟﻤﺮآﺰ ﺗﺪرﻳﺐ ﺧﺎص ﺑﺈدارة  ﻣﺮﺿﻰ اﻟﺴﻜﺮي؟     .01
 
  ﻻ.2ﻧﻌﻢ      .1هﻞ ﻳﻮﺟﺪ ﻣﺜﻘﻒ ﺻﺤﻲ؟     .11
 
  آﻴﻒ ﺗﺠﺮي ﻋﺎدة ﻋﻤﻠﻴﺔ اﻟﺘﺜﻘﻴﻒ اﻟﺼﺤﻲ ﻟﻤﺮﺿﻰ اﻟﺴﻜﺮي ﻓﻲ اﻟﻤﺮآﺰ؟, إذا اﻟﺠﻮاب ﻧﻌﻢ.21
 
  ﺣﺪد,ﻏﻴﺮ ذﻟﻚ. ﻻ ﻳﻮﺟﺪ ﺟﺪول زﻣﻨﻲ   .5آﻞ ﺳﺖ ﺷﻬﻮر   .4 آﻞ ﺛﻼث ﺷﻬﻮر   . 3 ﺷﻬﺮﻳﺎ    .2ﻓﻲ آﻞ ﻋﻴﺎدة   .1
 
  ______________________________:ﻋﺪد ﻣﺮﺿﻰ اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ.31
 
  ________________________:ﻋﺪد زﻳﺎرات ﻃﺒﻴﺐ اﻟﺴﻜﺮي ﻟﻠﻤﺮآﺰ ﺷﻬﺮﻳﺎ.41
 
  __________________________________:ﻋﺪد اﻟﻌﻴﺎدات اﻟﻌﺎﻣﺔ ﺷﻬﺮﻳﺎ.51
 
  ___________________________________:ات اﻻﺧﺘﺼﺎصﻋﺪد ﻋﻴﺎد.61
 
 ﻻ.2     ﻧﻌﻢ    .1؟         )c1AbH(هﻞ ﻳﺠﺮي اﻟﻤﺨﺘﺒﺮ ﻓﺤﺺ.71
  
  ﻻ.2      ﻧﻌﻢ    .1هﻞ ﻳﻮﺟﺪ ﺗﺼﻮﻳﺮ أﺷﻌﺔ؟                          .81
 
 
961 
 
 
ﻋﺪد اﻟﻤﺮﺿﻰ 
 اﻟﻤﻔﺤﻮﺻﻴﻦ ﺷﻬﺮﻳﺎ
ﻋﺪد اﻟﺰﻳﺎرات 
ﺷﻬﺮﻳﺎ
91  ﺘﺼﺎﺻﺎت اﻟﺘﺎﻟﻴﺔ؟هﻞ ﺗﺘﻮﻓﺮ أي ﻣﻦ اﻻﺧ ﻧﻌﻢ.1 ﻻ.2
  ﻃﺒﻴﺐ ﻋﻴﻮن.1 
  ﻃﺒﻴﺐ آﻠﻰ.2 
  ﻃﺒﻴﺐ ﺑﺎﻃﻨﻲ.3 
  ﻃﺒﻴﺐ ﻏﺪد.4 
  ﻃﺒﻴﺐ ﺳﻜﺮي.5 
 
 
  ﻃﺒﻴﺐ ﺧﺎص ﺑﻤﺮﺿﻰ اﻟﺴﻜﺮي.2ﻃﺒﻴﺐ اﻟﻌﻴﺎدة          .1ﻣﻦ ﻳﻘﻮم ﺑﻤﺘﺎﺑﻌﺔ ﻣﺮﺿﻰ اﻟﺴﻜﺮي ﻓﻲ اﻟﻤﺮآﺰ؟        .02
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  اﻟﻌﺎﻣﺔ اﻟﺼﺤﺔ آﻠﻴﺔ  / اﻟﻘﺪس ﻌﺔﺟﺎﻣ
  اﻟﻌﺎﻣﺔ اﻟﺼﺤﺔ ﻟﻤﺎﺟﺴﺘﻴﺮ آﻤﺘﻄﻠﺐ ﺑﺤﺚ
  ﺳﻤﺎرة إﻳﺎد: اﻟﻄﺎﻟﺐ اﺳﻢ
 
, ﻧﻮﻋﻴﻦ أهﻤﻬﺎ,  ﻋﺪة أﻧﻮاعإﻟﻰ اﻟﻤﺮض ﻳﻘﺴﻢ ﺣﻴﺚ, ﻓﻠﺴﻄﻴﻦ ﻓﻲ اﻟﻤﻨﺘﺸﺮة اﻷﻣﺮاض أآﺜﺮ ﻣﻦ اﻟﺴﻜﺮي ﻣﺮض ﻳﻌﺘﺒﺮ
 ﻧﺎﺗﺞ هﻮ و اﻟﻤﺮض ﻣﻦ اﻟﺜﺎﻧﻲ ﻨﻮعاﻟ هﻮ و اﻟﻜﺒﺎر ﻳﺼﻴﺐ ﻧﻮع و, اﻷول اﻟﻨﻮع ﻋﻠﻴﻪ ﻳﻄﻠﻖ اﻟﺸﺒﺎب و اﻷﻃﻔﺎل ﻳﺼﻴﺐ ﻧﻮع
 ﻳﺆدي ﻣﻤﺎ ﻟﻼﻧﺴﻮﻟﻴﻦ اﻟﺠﺴﻢ ﺧﻼﻳﺎ ﺣﺴﺎﺳﻴﺔ ﻓﻲ ﺧﻠﻞ أو اﻟﺪم ﻓﻲ اﻟﺴﻜﺮ ﻧﺴﺒﺔ ﻳﻨﻈﻢ اﻟﺬي اﻻﻧﺴﻮﻟﻴﻦ إﻓﺮاز ﻓﻲ ﻘﺺﻧ ﻋﻦ 
 و اﻟﺒﺼﺮ آﻀﻌﻒ اﻟﻤﺮض هﺬا ﻣﻀﺎﻋﻔﺎت و أﻋﺮاض ﻇﻬﻮر إﻟﻰ ﺑﺪورﻩ ﻳﺆدي ﻣﻤﺎ اﻟﺪم ﻓﻲ اﻟﺴﻜﺮ ﻧﺴﺒﺔ ارﺗﻔﺎع إﻟﻰ
  .اﻷﻋﺼﺎب و اﻟﻜﻠﻰ ﻓﻲ ﻣﺸﺎآﻞ
 
و   ﺟﻨﻴﻦ ﺘﻲﻣﺤﺎﻓﻈ ﻓﻲ اﻟﺜﺎﻧﻲ اﻟﻨﻮع اﻟﺴﻜﺮي ﻣﺮض ﻣﻀﺎﻋﻔﺎت إدارة ﻓﻲ اﻟﻤﺆﺛﺮة اﻟﻌﻮاﻣﻞ ﻣﻌﺮﻓﺔ إﻟﻰ اﻟﺒﺤﺚ هﺬا ﺪفﻳﻬ
 اﻟﺼﺤﺔ ﻟﻮزارة اﻟﺘﺎﺑﻌﺔ اﻷوﻟﻴﺔ اﻟﺮﻋﺎﻳﺔ ﻣﺮاآﺰ ﻓﻲ اﻟﺜﺎﻧﻲ اﻟﻨﻮع اﻟﺴﻜﺮي ﻣﺮﺿﻰ ﻣﻊ اﻟﻌﺎﻣﻠﻴﻦ اﻷﻃﺒﺎء ﺧﻼل ﻣﻦ ﻃﻮﺑﺎس
 هﺬا ﻣﻀﺎﻋﻔﺎت اﻧﺘﺸﺎر ﻣﻦ اﻟﺤﺪ و اﻟﻮﻗﺎﻳﺔ ﻋﻠﻰ اﻟﻌﻤﻞ اﺟﻞ ﻣﻦ اﻟﺨﺎص اﻟﻘﻄﺎع و اﻟﻄﺒﻴﺔ اﻹﻏﺎﺛﺔ و اﻟﻐﻮث وآﺎﻟﺔ و
 ﻳﺘﻌﺎﻣﻠﻮا اﻟﺬﻳﻦ اﻷﻃﺒﺎء ﺟﻤﻴﻊ ﻣﻘﺎﺑﻠﺔ ﺳﻴﺘﻢ ﻟﺬا. ﻋﻨﻪ اﻟﻨﺎﺗﺠﺔ اﻟﻮﻓﻴﺎت ﻧﺴﺒﺔ ﺗﻘﻠﻴﻞ ﺑﺎﻟﺘﺎﻟﻲ و اﻟﻤﺮﺿﻰ هﺆﻻء ﻋﻨﺪ اﻟﻤﺮض
  .اﺳﺘﺜﻨﺎء دون  و ﻃﻮﺑﺎسﺟﻨﻴﻦ ﺘﻲﻣﺤﺎﻓﻈ ﻓﻲ اﻟﺜﺎﻧﻲ اﻟﻨﻮع اﻟﺴﻜﺮي ﻣﺮﺿﻰ ﻣﻊ
 و , اﻻﺳﺘﺒﻴﺎن أﺳﺌﻠﺔ ﻋﻠﻰ اﻹﺟﺎﺑﺔ ﻣﻨﻜﻢ ﻧﺮﺟﻮ ﻟﺬا, اﻟﺪراﺳﺔ ﺑﺄهﺪاف ﺧﺎﺻﺔ ﺳﺌﻠﺔأ ﻋﻠﻰ ﻳﺤﺘﻮي اﺳﺘﺒﻴﺎن ﺑﺘﺠﻬﻴﺰ ﻗﻤﻨﺎ ﻟﻘﺪ
 اﻟﺘﻌﻠﻴﻤﺎت ﺣﺴﺐ ﻋﻠﻴﻬﺎ اﻹﺟﺎﺑﺔ و ﺑﺘﻤﻌﻦ ﻓﻘﺮة آﻞ ﺑﻘﺮاءة و ﺗﺎﻣﺔ ﺑﻤﻮﺿﻮﻋﻴﺔ اﻷﺳﺌﻠﺔ آﺎﻓﺔ إﺟﺎﺑﺔ ﺣﻀﺮﺗﻜﻢ ﻣﻦ ﺁﻣﻠﻴﻦ
 ﻟﻜﻢ ﻧﻀﻤﻦ و, ﻓﻘﻂ ﻟﻌﻠﻤﻲا اﻟﺒﺤﺚ ﻷﻏﺮاض ﺳﺘﺴﺘﻌﻤﻞ اﻻﺳﺘﺒﻴﺎن ﻓﻲ اﻟﻮاردة اﻟﻤﻌﻠﻮﻣﺎت إن ﻋﻠﻤﺎ, ﻗﺒﻞ آﻞ ﺳﺆال اﻟﻮاردة
 هﺬﻩ أهﺪاف ﻹﺗﻤﺎم اﻟﻤﺸﺎرآﺔ ﻋﻠﻰ ﺑﺎﻟﻤﻮاﻓﻘﺔ اﻟﺘﻮﻗﻴﻊ ﻣﻨﻜﻢ ﻧﺮﺟﻮ ﻟﺬا. ﺑﻬﺎ ﺳﺘﺪﻟﻮن اﻟﺘﻲ اﻟﻤﻌﻠﻮﻣﺎت ﻓﻲ اﻟﺘﺎﻣﺔ اﻟﺴﺮﻳﺔ
  .اﻟﺪراﺳﺔ
 
  ﺗﻌﺎوﻧﻜﻢ ﺣﺴﻦ ﻟﻜﻢ ﺷﺎآﺮﻳﻦ
 
  ﺳﻤﺎرة إﻳﺎد: اﻟﺒﺎﺣﺚ
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 وﺟﻮد إن و, اﻟﺪراﺳﺔ هﺬﻩ ﻓﻲ ﺔاﻟﻤﺸﺎرآ ﻗﺮرت ﻋﻠﻴﻪ و اﻻﺳﺘﺒﻴﺎن هﺬا ﻓﻲ اﻟﻮاردة اﻟﺘﻌﻠﻴﻤﺎت ﺟﻤﻴﻊ ﺑﺪراﺳﺔ ﻗﻤﺖ ﺪﻘﻟ
  .اﻟﺪراﺳﺔ هﺬﻩ  ﻓﻲ ﻟﻠﻤﺸﺎرآﺔ ﻗﺒﻮﻟﻲ ﻋﻠﻰ دﻟﻴﻞ هﻮ ﺗﻮﻗﻴﻌﻲ و اﺳﻤﻲ
 
  __________________:اﻟﺘﺎرﻳﺦ
 
  __________________:اﻟﺴﺎﻋﺔ
 
  :اﻟﺘﻮﻗﻴﻊ:                                                                    اﻟﻤﺸﺎرك اﺳﻢ
 
      :اﻟﺘﻮﻗﻴﻊ                                                        ﺳﻤﺎرة إﻳﺎد: اﻟﺒﺎﺣﺚ اﺳﻢ
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Appendix (5) 
 
Variable MOH UNRWA PMRS 
 PHC centers 9 (56.3%) 4 (25%) 3 (18.7) 
Health Services 1.mother health 
2.family planning 
3.GP 
4.Well Baby 
5.dental health in 2 
centers 
6.school health 
In 2 centers 
7.internal medicine  
8.diabetes clinic 
9.medicines 
10.laboratory 
11.chronic diseases 
1.mother health 
2.family planning 
3.GP 
4.dental health in 1 
center 
5.school health in 1 
center 
6.medicines 
7.laboratory 
8. chronic diseases 
1.mother health 
2.family planning 
3.GP 
4.Well Baby 
5.dental health in 1 
center 
6. school health 
7.psychological 
health 
8.medicines 
9.laboratory 
10. chronic diseases 
Lab tests 1.CBC in 4 centers 
2.FBS 
3.HbA1c in 2 
centers 
4.lipid profile 
5.KFT 
6.urina analysis 
7.liver function 
1.CBC 
2.FBS 
3.lipid profile 
4.KFT 
5.urina analysis 
6. liver function in 1 
center 
1.CBC 
2.FBS 
3.HbA1c 
4.lipid profile 
5.KFT 
6.urina analysis 
7. liver function 
Mean of 
employees 
 
9.2 15.7 8.3 
Mean of nurses 
 
2.1 5 4 
Nurses get 
training on 
diabetes care 
Yes in 2 centers Yes in 3 centers Yes  
Availability of 
nutritionist 
Yes in central clinic No No 
GP get training 
on diabetes 
management 
Yes in 3 centers Yes yes 
Availability of 
health educator 
 
Available in central 
clinic 
Available in 1 center  Not available 
Number of 
diabetics 
registered 
 
5464 
 
1269 
 
628 
Number of 
diabetes clinics 
per month 
Twice monthly 
except central clinic 
daily 
8 times per month 
except the camp clinic 
daily 
4 times per monthly 
GP clinic per 
month 
22 (daily) 8 except the camp 
clinic 26 (daily) 
26 (daily) 
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Availability of 
XR machine 
No No No 
Availability of 
ophthalmologist 
 
No No No 
Nephrologist 
 
No No No 
Internist 
 
Yes No No 
Endocrinologist 
 
No No No 
Diabetician 
 
Yes No No 
Physician 
responsible for 
diabetics 
Diabetician GP GP 
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Appendix (6) 
 
Components of the clinic visit by WHO: 
 
Each patient visit to the health care facility should cover the following items. 
• Medical history, including: 
? Symptoms of hyperglycemia or hypoglycemia 
? Results of prior HbA1c and home blood glucose records 
? Meal patterns including frequency and content, and any change in weight 
? Lifestyle and psychosocial elements 
? Any acute complications such as infection, hypoglycemia or ketoacidosis 
? Any chronic complications related to vision, kidney, nerve, or the 
cardiovascular system 
? Any associated cardiovascular risk factors such as a positive family history 
? hypertension, dislepedimia 
? Review of all medications; ask if the patient is taking aspirin 
 
• Physical examination, including: 
? Height and weight 
? Vital signs, including blood pressure supine and sitting 
? Fundoscopic examination, looking for any signs of retinopathy 
? Oral examination, including gums 
? Cardiovascular including evaluation for pulses and bruits 
? Abdominal exam, assess liver size 
? Foot examination, for deformities 
? Neurological examination: light, touch, vibration sense, reflexes, motor 
strength. 
 
• Diagnostic studies, including: 
? Fasting and 2-hour postprandial glucose, if feasible 
? Quarterly HbA1c 
? Yearly chemistry panel, fasting lipid profile, urinalysis (including 
microscopy and          urine Microalbumin screening) 
? Thyroid stimulating hormone for type 1 and for type 2, as indicated 
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? ECG in adults at baseline, and then as clinically indicated. 
 
Quick guide of MOH just mention the medical history and full physical examination 
without details, but according to the laboratory test it provides us with which test should 
the patient perform in diabetic clinic: 
• Fasting plasma glucose. 
• HbA1c Q 3-6 months. 
• Fasting lipid profile (14 hours). 
• Ophthalmologic examination. 
• Serum Creatinin in adults; and in children if proteinuria is present. 
• Urinalysis: glucose, ketones, protein, sediment. 
• Test for microalbuminuria (quantitative). 
• Urine culture if sediment is abnormal or symptoms are present. 
• Thyroid-stimulating hormone (TSH) in all diabetes type 1 patients. 
• Electrocardiogram (ECG) in adults. 
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Appendix (7)           
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